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This year marks the 126th anniversary of the discovery, by Robert Koch, of 
Mycobacterium tuberculosis, the infectious agent of the disease we now call TB. The 
word 'consumption" conjures images of bygone eras, but the word 'tuberculosis' is 
synonymous with immense present-day mortality and suffering, largely in developing 
countries, where HIV and TB coinfection form a lethal combination. More than one-third 
of the world's population is infected with tubercle bacilli. One in every ten of these 
individuals will develop TB at some point in their life time, and this year around 1.7 
million people will die of the disease. 
Fifty years ago it seemed as though TB would soon be consigned to the pages of 
history. The development of the antibiotic streptomycin allowed, for the first time, those 
with TB to be cured. And for a short while the disease seemed on the ebb. Today, 
however, TB remains as much of a threat as it was in the pre-antibiotic era. Poor 
adherence to TB control programs, the consequent emergence of drug resistance, and the 
widespread prevalence of HIV has caused resurgence in the incidence of the disease, 
which threatens to escalate further out of control. New drugs, better vaccines and new 
diagnostics are desperately needed to turn the tide of infection. Although progress toward 
developing more effective vaccines for TB has been modest, the recent identification and 
development of several new drugs offers real hope that new antibiotics could shorten the 
current six-month treatment time and reduce the emergence of drug resistance. This is a 
remarkable achievement in today's climate of languishing investment in development of 
new antimicrobials. 
To overcome the problem of drug resistance in M. tuberculosis, one of the 
challenges in search of new antimycobacterial agents, focus has now shifted to 
development of compounds from natural sources. By boosting host immunologic 
responsiveness, these compounds may be particularly useful in the treatment of drug-
resistant tuberculosis. We studied the incorporation of such compounds, like neem 
extract, as the herbal component in management of tuberculosis. 
The interaction of microbes with monocytes is likely to have an enormous impact 
on the initiation of the immune response against a pathogen. The initial interaction of 
mononuclear phagocytes with M. tuberculosis gives rise to a cytokine profile dominated 
by TNF-a. It is well established that both phagocytic and non-phagocytic interaction of 
M. tuberculosis bacilli with mononuclear phagocytes as well as mycobacterial protein 
and non-protein components can induce this pro-inflammatory cytokine. In the early 
stages of infection, TNF-a secreted by macrophages is one of the pivotal pro-
inflammatory cytokines responsible for disease localization and granuloma formation. 
Paradoxically, in the more advanced and chronic stage of mycobacterial diseases, TNF-a 
has been shown to be responsible for disease severity and pathogenesis. Antigen 85B is 
one of the many M tuberculosis products that induce production of TNF-a. Along with 
the other two proteins in the M. tuberculosis 85 complex (85A and 85C), 85B is 
abundantly secreted b>' M. tuberculosis. 
Proteins of the antigen 85 complex (Ag85A, Ag85B and Ag85C) are major 
secretory proteins of actively replicating M. tuberculosis. They share high sequence 
homology at the nucleotide and protein level both with each other and with Ag85 from 
other mycobacterial species. Ag85 complex proteins are mycoiyltransferases. As such, 
they play an essential role in the final stages of mycobacterial cell wall synthesis, since 
inhibitors of this activity inhibit both the transfer and the deposition of mycolates into the 
mycobacterial cell wall and cell growth. Ag85 proteins bind to plasma and cellular 
fibronectins. high-molecular-weight glycoproteins found in plasma and tissues that play 
important roles in cell motility and adhesion, development, phagocytic function, wound 
healing, and inflammation. The pathophysiology of Ag85 proteins in patients with 
tuberculosis is complex. 
In the present study initial characterization of sera and monocytes of patients with 
active tuberculosis and MDR-TB to evaluate the expression of TNF-a and 
M. tuberculosis 85B. Direct binding ELISA on microtitre plates coated with protein 
antigens of H37RV bacilli sonicate showed remarkable reactivity against antibodies found 
in sera of tuberculosis patients and MDR-TB patients, as evidenced by high antibody litre 
i.e. >I.'12800. Simiilarly, an appreciable reactivity was observed with tuberculosis sera 
and MDR-TB sera against secreted culture filtrate protein antigens with an antibody titre 
> 1:6400, whereas no reactivity was observed with normal human sera in either case. 
M tuberculosis infection gives rise to a cytokine profile that is dominated by 
TNF-a. In our study also, estimation by ELISA showed an appreciable magnitude of 
soluble TNF-a in sera of tuberculosis patients. Furthermore, M. tuberculosis 85B is a 
predominant protein produced during human M. tuberculosis infection; however its role 
in tuberculosis pathogenesis is not clear and warrants further investigation. The presence 
of circulating M. tuberculosis 85B antigen in sera of tuberculosis patients, either in the 
free form or complexed with fibronectin has been well established. We also found an 
appreciably elevated level of antigen 85B in sera of tuberculosis patients and MDR-TB 
patients. 
After characterizing sera, an attempt was made to characterize monocytes from 
tuberculosis patients with respect to TNF-a and 85B. Monocytes from tuberculosis 
patients were subjected to TNF-a and 85B mRNA evaluation by real-time RT-PCR and 
revealed appreciably high basal levels of both mRNA expressions. TNF-a and 85B 
proteins were also found to be significantly elevated in supernatants of monocyte cultures 
of tuberculosis patients as well as MDR-TB patients. 
Being an intracellular pathogen and despite of encountering a robust immune 
response, M. tuberculosis successfully survives and persists in its human host, of the 
various M. tuberculosis genes shown to be up regulated after M. tuberculosis infection of 
human mononuclear cells, the 85B gene was expressed most frequently. Antigen 85B is a 
mycolyl transferase involved in cell wall biosynthesis shown to catalyse the formation of 
trehalose dimycolate which enhances the host inflammatory response. Thus, in the 
present study, we investigated the early regulation of M tuberculosis 85B gene by neem 
extract in M. tuberculosis cultures. 
Real-time RT-PCR data showed that neem extract down regulated the expression 
of 85B mRNA in M. tuberculosis (H37RV) cultures in a dose-dependent manner, without 
any significant effect on the expression of the housekeeping gene of M tuberculosis, i.e., 
16S rRNA. An appreciable suppression of 85B mRNA by -1.7, 2.4, and 3 logs (p<O.OOI 
for all) were recorded with 600, 800 and 1000 jug/ml of neem extract, respectively. From 
our data it is evident that the concentrations of neem extract that have been employed in 
this study do not affect M. tuberculosis growth, but on the contrary, it appreciably 
downregulates the M. tuberculosis 85B gene expression. 
The effect of neem extract on expression of A/, tuberculosis antigen 85 complex 
(30/31 kDa) in M. tuberculosis sonic extract as revealed by gradient SDS-PAGE was also 
found to be dose-dependent. Neem extract concentrations of 600-1000 \xglm\ prosed to 
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be a potent inhibitors of antigen 85 complex protein expression. In supernatants obtained 
from 14 days M tuberculosis cultures receiving various doses of neem extract, the 
secretion of antigen 85 complex was found to be dose-dependent. Neem extract 
decreased the specificity of TB-antibodies and MDR-TB antibodies for M tuberculosis 
protein antigens as revealed by immunoassays for sonic extract and culture filtrate protein 
antigens of M tuberculosis co-cultured with neem extract against TB-antibodies MDR-TB 
antibodies. 
Interestingly, antigen 85B is immunodominant and potently induces TNF-a when 
complexed to fibronectin in mononuclear phagocytes. Therefore, the role of M. 
tuberculosis 85B in intracellular infection may be the maintenance of an inflammatory 
response. Through sustaining TNF-a activity, the abundant release of M. tuberculosis 
85B in situ may contribute to the pathogenesis of M tuberculosis infection. The 
expression of 85B in M. tuberculosis-'mfected monocytes correlates positively with both 
the amount of secreted TNF-a and subsequent intracellular mycobacterial growth. 
In our experiments involving in-vitro M. tuberculosis infection of human 
monocytes, no effect on host housekeeping genes such as the R18 gene (18S rRNA) was 
observed as revealeo by quantitative real-time RT-PCR data. Also, the kinetics (0-120 
hours) of expression of TNF-a and M tuberculosis 85B mRNA in M. tuberculosis-
infected monocytes by real-time RT-PCR and ELISA was investigated. The levels of 
TNF-a mRNA cooy numbers in infected monocytes at various time intervals were 
recorded as 2.1 logs, 6.3 logs (p<O.OOI), 10.3 logs (p<0.001), 4.6 logs (p<0.001) and 1.9 
logs (p<0.05). after 0, 4, 24, 72 and 120 hours of M tuberculosis infection, respectively. 
The concentration of soluble TNF-a secreted in supernatants of infected monocyte 
cultures at various time interval was also observed as 28.44. 59.68 (p<0.001), 96.78 
(p<0.001), 188.23 (p<0.001). 105.78 (p<0.00!). 60.55 (p<0.001), and 11.23 (p<0.001) 
pg/mi after 0. 4, 12, 24, 48, 72 and 120 hours of M. tuberculosis infection respectively. 
The data revealed that the expression of TNF-a mRNA in infected monocytes as well as 
secreted TNF-a in culture supernatants was time-dependent, maximal at 24 hours of 
infection, followed by a substantial decrease at the remaining time intervals of infection. 
Furthermore, 16S rRNA expression in M. tuberculosis-'mfecied monocytes was 
observed to linearly increase with time. Also the expression of M. tuberculosis 858 
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niRNA was found to continue to increase up to 120 hours of infection. The ratio of 
85B:16S was also increased with increasing time periods of infection and correlated with 
85B mRNA levels at various time periods. The 85B:16S ratio recorded at various time 
interval was 0.0013, 0.0018 (p<0.05), 0.0822 (p<0.001), 0.3234 (p<0.001), and 0.7866 
(p<0.001), after 0, 4, 24, 72 and 120 hours of infection, respectively. In the supernatants 
of infected monocyte cultures the expression of secreted antigen 85 complex increased 
with time. Furthermore, the M. tuberculosis-infected monocytes exhibited a linear time-
dependent decrease in GPx activity in comparison to control monocytes. 
Cellular activation, and thereby induction of TNF-a, is mediated via NF-KB. It has 
been well documented that TNF-a induced nuclear translocation of NF-KB was inhibited 
in SN50 peptide-treated human monocytic cell lines as demonstrated in EMSA. Thus, we 
employed SN50, an inhibitor of NF-KB, to assess the role of NF-KB in activation of gene 
expression in M. tuberculosis-infected monocytes. Our results clearly show that the 
increased expression of TNF-a and 85B mRNA in M tuberculosis-infected monocytes is 
mediated mainly via NF-KB. Interestingly, inhibition of reactive oxygen intermediates 
(ROls) and reactive nitrogen intermediates (RNls), reduced expression of TOF-a and M. 
tuberculosis 85B genes in M tuberculosis-infected monocytes. 
The neem tree is considered as the panacea for all diseases and has also been 
hailed as 'heal all', 'divine tree', 'village dispensary' and "nature's drugstore'. All parts 
of the neem tree- leaves, flowers, seeds, fruits, roots and bark have been used 
traditionally for the treatment of inflammation, infections, fever, skin diseases and dental 
disorders. The oil from the neem leaves is recognized to possess antibacterial activity 
against a wide spectrum of Gram-negative and Gram-positive microorganisms, including 
M.tuberculosis and Streptomycin-resistant strains. Neem leaf is known to inhibit Vibrio 
cholerae, Klebsiella pneumoniae, M. tuberculosis and M.pyogenes in vitro. The medicinal 
utilities have been described especially for neem leaf, its constituents have been 
demonstrated to exhibit immunomodulatory, anti-inflammatory, antihyperglycaemic, 
antiulcer, antimalarial, antifungal, antibacterial, antiviral, antioxidant, antimutagenic and 
anticarcinogenic properties.The aqueous extract of neem leaf exerts its immunostimulant 
activity by enhancing both humoral and cell mediated responses. Radical scavenging 
properties of neem leaf have also been reported. Neem leaf has been documented to 
decrease the extent of lipid peroxidation. Aqueous as well as 70 percent ethanolic neem 
leaf extracts significantly reduce N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-
induced lipid peroxidation, by enhancing the activities of glutathione dependent 
antioxidants as well as superoxide dismutase (SOD) and catalase (CAT). 
The aqueous extract is reported to contain several active substances and is known 
to posses anti-inflamn"iatory, and immunomodulatory activities. The immunomodulatory 
activity of the neern-bark extract has also been reported. Anti-inflammatory, 
immunostimulant and antiulcerogenic actions have also been reported in the extracts of 
A. indica. In fact, the study showed neem extract to be more effective than aspirin in 
inhibiting prostaglandins. There have been attributed by several researchers to a strong 
Thl cytokine response, particularly IFN-gamma and TNF. Increases in CDS cells have 
also been reported. Neem has "inhibitory action on a wide spectrum of micro-organisms, 
including Candida albicans, C. tropicalis, gonorrhoeae, the multidrug-resistant 
Staphylococcus aurevs and urinary tract Escherichia coli, Herpes simplex-2 and HIV-1." 
Nimbidin, a major crude principle extracted from neem oil, inhibited nitric oxide 
(NO) and prostaglandin E2 (PGE2) production in lipopolysaccharide (LPS) stimulated 
macrophages following in vitro exposure. Inducible nitric oxide synthase (iNOS) activity 
measured in the presence or absence of nimbidin in cytosolic preparation of macrophages 
cultured with lipopolysaccharide (LPS) for 24 h. Nimbidin is, as such, a general anti-
inflammatory drug and is effective in both acute and chronic states of inflammation. The 
medicinal properties of Azadirchata indica includes a variety of effects like antipyretic, 
anti-malarial, anti-tumour, anti-ulcer, anti-diabetic, anti-fertility as well as effects on the 
central nervous and cardiovascular system. Immunomodulatory properties of different 
neem preparations 5uch as, activation of B cells, T cells and macrophages have been 
reported earlier. Neem kernel oil induces secretion of gamma interferon and tumor 
necrotic factor-alpha. 
Here we investigated the modulatory/suppressive effect of neem extract on the 
expression of TNF-a and M tuberculosis 85B in M. tuherculosis-lnfecied monocytes 
after 24 hours of infection. In the present study, we employed neem extract 
concentrations in between 0-1000 pg/ml, which failed to show any toxic effect on 
monocytes as revealed by MTT assay. Also, no effect was observed on housekeeping 
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genes: R18 (18S rRNA) by quantitative real-time RT-PCR, thereby indicating that neem 
extract did not non-specifically affect human TNF-a transcription in M. tuberculosis-
infected monocytes. Also, the effect of various doses of neem extract employed in the 
present study failed to show any toxic or inhibitory effect on the mycobacterial 
housekeeping gene M. tuberculosis 16S rRNA as revealed by real-time RT-PCR in 
monocytes infected with M. tuberculosis. 
The present study revealed neem extract to down regulate the expression of TNF-
a gene in M. tuberculosis-'mkcted monocytes as well as the secretion of soluble TNF-a 
in culture supernatants in a dose-dependent manner. The results show an appreciable 
suppression in endogenous TNF-a mRNA expression by -0.4 logs, 0.9 logs, 1.7 logs, 2.4 
logs, 3.8 logs, and 4.8 logs (/'<0.00l for all), upon treatment with 100, 200, 400, 600, 
800 and 1000 pg/ml of neem extract, respectively in M. tuberculosis-mfected monocytes. 
Interestingly, in comparison to the inhibitory effects of neem extract with those of 
NAC, SN50 and anti-TNF-a antibody, neem extract was found to be the most potent 
inhibitor of TNF-a and M tuberculosis 85B expression in M luberculosis-inkcitd 
monocytes. Our results indicate that the increased expression of TNF-a and 85B mRNA 
in M. ti/berculosis-irifected monocytes is mediated via activation of NF-KB, as evidenced 
by the suppression of TNF-a mRNA in the presence of SN50, an inhibitor of NF-KB. 
SN50/M, an inactive analogue of SN50 failed to show any such effect. In view of it, our 
data demonstrated that this effect involved inhibition of the NF-KB pathway induced by 
neem extract probably by inhibiting the degradation of IKBO. Since a number of genes 
involved in inflammatory responses are regulated by NF-KB pathway, thus a high 
magnitude downregulation of the NF-KB pathway by neem extract would predictably 
reduce the elaboration of NF-KB-mediated TNF-a mRNA expression and, in turn, 85B 
gene expression. M. tuberculosis-mfected macrophages release lL-12 and IL-18 which 
stimulate the CD4 and CDS T-cells to release IFN-y. IFN-y is crucial for the control of M 
tuberculosis infection. It stimulates phagocytosis of M tuberculosis and also the release 
of TNF-a from macrophages, which is important in granuloma formation and control of 
the extent of infection. TNF-a and IL-ip, along with IFN-y produced by T-lymphocytes, 
can induce NO in macrophages via inducible form of the enzyme nitric oxide synthase 
(iNOS). Mycobacterial cell wall components such as LAM and 19 kDa lipoprotein, along 
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with T-ce!)-derived IFN-y may also induce NO expression.Treatment witli anti-oxidants 
like neem extract and NAC in MTB-infected monocytes exhibited a decrease in level of 
IFN-y. Thus, it appears that down-regulation of sIFN-y levels in culture supernatants of 
MTB-infected monocytes is ameliorated by neem extract. 
Next, in the present study, the inhibitory effect of antibiotics like streptomycin, 
rifampicin and isoniazid in comparison to neem extract were probed. The results 
showed that co-culturing of MTB-infected cells with streptomycin, rifampicin and 
isoniazid down regulated the TNF-a mRNA & MTB 858 expressions in dose dependent 
manner. The IC5ofor l>JF-a mRNA & MTB 85B mRNA suppressions was found to be of 
the order of isoniazid >streptomycin >rifampicin. 
Glutathione directly reacts with ROS, and glutathione peroxidase (GPx) catalyzes 
the removal of hydrogen peroxide. Decrease in GPx activity indicates impairment of 
hydrogen peroxide-neutralizing mechanisms. Here, we observed a decline in GPx activity 
in M. tuberculosis-'mkctsd monocytes. Enhancement of GPx activity in M. tuberculosis-
infected monocyte cultures after addition of NAC, a precursor of the in vivo antioxidant 
glutathione, indicates reversal of impaired neutralizing mechanisms. Surprisingly, here a 
slightly greater augmentation in GPx activity was observed when neem extract was co-
cultured instead of NAC, indicating neem extract to be an effective natural antioxidant 
combating ROS, generated as a consequence of cellular activation in M tuberculosis-
infected monocytes. 
In conclusion, the presence of elevated levels of TNF-a and M. tuberculosis 85B 
in tuberculosis patients is the indication of severity of the disease. The expression of M 
tuberculosis 85B v/as downreguiated by neem extract in a dose-dependent manner in 
H37RV cultures. Furthermore, M tuberculosis infection of monocytes leads to a 
concomitant activation of TNF-a and expression of M. tuberculosis 85B gene. M. 
tuberculosis infection of human monocytes initiates a cascade of events whereby cellular 
activation by TNF-a, RNI, and ROI enhances the expression of M. tuberculosis 85B in 
monocytes. The augmented expression of TNF-a and M. tuberculosis 85B gene in M. 
tuherculosis-\nfec{e6 monocytes by cellular activation and ROS was suppressed by neem 
extract in a dose-dependent manner. The effect of neem extract was mediated by 
suppression of NF-KB. Also, neem extract enhanced the GPx activity, which correlated 
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inversely with the dovvTiregulation of TNF-a and M. tuberculosis 85B in M. tuberculosis-
infected monocytes. Neem extract may prove to be valuable in the containment of M 
tuberculosis and, therefore, be useful as an adjunct in treatment of tuberculosis. These 
observations strengthen the idea that neem extract should be tested in in vivo models to 
evaluate its therapeutic potential in the pathogenesis of tuberculosis. 
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This year marks the 126th anniversary of the discovery, by Robert Koch, of 
Mycobacterium tuberculosis, the infectious agent of the disease we now call TB. The 
word 'consumption' conjures images of bygone eras, but the word 'tuberculosis' is 
synonymous with immense present-day mortality and suffering, largely in developing 
countries, where HIV and TB coinfection form a lethal combination. More than one-third 
of the world's population is infected with tubercle bacilli. One in every ten of these 
individuals will develop TB at some point in their life time, and this year around 1.7 
million people will die of the disease. 
Fifty years ago it seemed as though TB would soon be consigned to the pages of 
history. The development of the antibiotic streptomycin allowed, for the first time, those 
with TB to be cured. And for a short while the disease seemed on the ebb. Today, 
however, TB remains as much of a threat as it was in the pre-antibiotic era. Poor 
adherence tc TB control programs, the consequent emergence of drug resistance, and the 
widespread prevalence of HIV has caused resurgence in the incidence of the disease, 
which threatens to escalate further out of control. New drugs, better vaccines and new 
diagnostics are desperately needed to turn the tide of infection. Although progress toward 
developing more effective vaccines for TB has been modest, the recent identification and 
development of several new drugs offers real hope that new antibiotics could shorten the 
current six-month treatment time and reduce the emergence of drug resistance. This is a 
remarkable achievement in today's climate of languishing investment in development of 
new antimicrobials. 
To overcome the problem of drug resistance in M. tuberculosis, one of the 
challenges in search of new antimycobacterial agents, focus has now shifted to 
development of compounds from natural sources. By boosting host immunologic 
responsiveness, these compounds may be particularly useful in the treatment of drug-
resistant tuberculosis. We studied the incorporation of such compounds, like neem 
extract, as the herbal component in management of tuberculosis. 
The interaction of microbes with monocytes is likely to have an enormous impact 
on the initiation of the immune response against a pathogen. The initial interaction of 
mononuclear phagocytes with M. tuberculosis gives rise to a cytokine profile dominated 
by TNF-a. It is well established that both phagocytic and non-phagocytic interaction of 
M. tuberculosis bacilli with mononuclear phagocytes as well as mycobacterial protein 
and non-proi:ein components can induce this pro-inflammatory cytokine. In the early 
stages of infection, TNF-a secreted by macrophages is one of the pivotal pro-
inflammatory cytokines responsible for disease localization and granuloma formation. 
Paradoxically, in the more advanced and chronic stage of mycobacterial diseases, TNF-a 
has been shewn to be responsible for disease severity and pathogenesis. Antigen 85B is 
one of the many M tuberculosis products that induce production of TNF-a. Along with 
the other two proteins in the M tuberculosis 85 complex (85A and 85C), 85B is 
abundantly secreted by M. tuberculosis. 
Proteins of the antigen 85 complex (Ag85A, Ag85B and Ag85C) are major 
secretory proteins of actively replicating M. tuberculosis. They share high sequence 
homology at the nucleotide and protein level both with each other and with Ag85 from 
other mycobacterial species. Ag85 complex proteins are mycolyltransferases. As such, 
they play an essential role in the final stages of mycobacterial cell wall synthesis, since 
inhibitors of this activity inhibit both the transfer and the deposition of mycolates into the 
mycobacterial cell wall and cell growth. Ag85 proteins bind to plasma and cellular 
fibronectins, high-molecular-weight glycoproteins found in plasma and tissues that play 
important roles in cell motility and adhesion, development, phagocytic function, wound 
healing, and inflammation. The pathophysiology of Ag85 proteins in patients with 
tuberculosis is complex. 
In the present study initial characterization of sera and monocytes of patients with 
active tuberculosis and MDR-TB to evaluate the expression of TNF-a and 
h4. tuberculosis 85B. Direct binding ELISA on microtitre plates coated with protein 
antigens of H37RV bacilli sonicate showed remarkable reactivity against antibodies found 
in sera of tuberculosis patients and MDR-TB patients, as evidenced b}- high antibody titre 
i.e. >1:12800. Similarly, an appreciable reactivity was observed with tuberculosis sera 
and MDR-TB sera against secreted culture filtrate protein antigens with an antibody titre 
>1:6400, whereas no reactivity was observed with normal human sera in either case. 
M. tuberculosis infection gives rise to a cytokine profile that is dominated by 
TNF-a. In our study also, estimation by ELISA showed an appreciable magnitude of 
soluble TNF-a in sera of tuberculosis patients. Furthermore, M tuberculosis 85B is a 
predominant protein produced during human M. tuberculosis infection; however its role 
in tuberculosis pathogenesis is not clear and warrants further investigation. The presence 
of circulating M tuberculosis 85B antigen in sera of tuberculosis patients, either in the 
free form or complexed with fibronectin has been well established. We also found an 
appreciably elevated level of antigen 85B in sera of tuberculosis patients and MDR-TB 
patients. 
After characterizing sera, an attempt was made to characterize monocytes from 
tuberculosis palients with respect to TNF-a and 85B. Monocytes from tuberculosis 
patients were subjected to TNF-a and 85B mRNA evaluation by real-time RT-PCR and 
revealed appreciably high basal levels of both mRNA expressions. TNF-a and 85B 
proteins were also found to be significantly elevated in supernatants of monocyte cultures 
of tuberculosis patients as well as MDR-TB patients. 
Being an intracellular pathogen and despite of encountering a robust immune 
response, M. tuberculosis successfully survives and persists in its human host, of the 
various M. tuberculosis genes shown to be up regulated after M tuberculosis infection of 
human mononuclear cells, the 85B gene was expressed most frequently. Antigen 85B is a 
mycolyl transferase involved in cell wall biosynthesis shown to catalyse the formation of 
trehalose dimycolate which enhances the host inflammatory response. Thus, in the 
present study, we investigated the early regulation of M tuberculosis 85B gene by neem 
extract in M tuberculosis cultures. 
Real-time RT-PCR data showed that neem extract down regulated the expression 
of 85B mRNA in M. tuberculosis (H37RV) cultures in a dose-dependent manner, without 
any significant effect on the expression of the housekeeping gene of M. tuberculosis, i.e., 
16S rRNA. An appreciable suppression of 85B mRNA by -1.7, 2.4, and 3 logs (p<0.001 
for all) were recorded with 600, 800 and 1000 ^g/ml of neem extract, respectively. From 
our data it is evident that the concentrations of neem extract that have been employed in 
this study do not affect M. tuberculosis groulh, but on the contrary, it appreciably 
downregulates the M. tuberculosis 85B gene expression. 
The effect of neem extract on expression of M tuberculosis antigen 85 complex 
(30/31 kDa) in M. tuberculosis sonic extract as revealed by gradient SDS-PAGE was also 
found to be dose-dependent. Neem extract concentrations of 600-1000 |ug/ml proved to 
be a potent inhibitors of antigen 85 complex protein expression. In supematants obtained 
from 14 days M. tuberculosis cultures receiving various doses of neem extract, the 
secretion of antigen 85 complex was found to be dose-dependent. Neem extract 
decreased the specificity of TB-antibodies and MDR-TB antibodies for M. tuberculosis 
protein antigens as revealed by immunoassays for sonic extract and culture filtrate protein 
antigens of M tuberculosis co-cultured with neem extract against TB-antibodies MDR-TB 
antibodies. 
Interestingly, antigen 85B is immunodominant and potently induces TNF-a when 
complexed to fibronectin in mononuclear phagocytes. Therefore, the role of M 
tuberculosis 85B in intracellular infection may be the maintenance of an inflammatory 
response. Through sustaining TNF-a activity, the abundant release of M. tuberculosis 
85B in situ may contribute to the pathogenesis of M. tuberculosis infection. The 
expression of 85B in M. tuberculosis-'mkctQd monocytes correlates positively with both 
the amount of secreted TNF-a and subsequent intracellular mycobacterial growth. 
In our experiments involving in-vitro M. tuberculosis infection of human 
monocytes, no effect on host housekeeping genes such as the RI8 gene (18S rRNA) was 
observed as revealed by quantitative real-time RT-PCR data. Also, the kinetics (0-120 
hours) of expression of T7VF-a and M. tuberculosis 85B mRNA in M. tuberculosis-
infected monocytes by real-time RT-PCR and ELISA was investigated. The levels of 
TNF-a mRNA copy numbers in infected monocytes at various time intervals were 
recorded as 2.1 logs, 6.3 logs (p<0.001), 10.3 logs (p<0.001), 4.6 logs (p<0.001) and 1.9 
logs (p<0.05), after 0, 4, 24, 72 and 120 hours of M tuberculosis infection, respectively. 
The concentration of soluble TTslF-a secreted in supernatants of infected monocyte 
cultures at various time interval was also observed as 28.44. 59.68 (p<0.001), 96.78 
(p<0.001), 188.23 (p<0.001), 105.78 (p<0.001), 60.55 (p<0.00l), and 11.23 (p<0.001) 
pg/ml after C, 4, 12, 24, 48, 72 and 120 hours of M. tuberculosis infection respectively. 
The data revealed that the expression of TNF-a mRNA in infected monocytes as well as 
secreted TNF-a in culture supernatants was time-dependent, maximal at 24 hours of 
infection, followed by a substantial decrease at the remaining time intervals of infection. 
Furthermore, I6S rRNA expression in M. tuberculosis-infected monocytes was 
observed to linearly increase with time. Also the expression of M tuberculosis 858 
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mRNA was found to continue to increase up to 120 hours of infection. The ratio of 
85B:]6S was also increased with increasing time periods of infection and correlated with 
85B mRNA levels at various time periods. The 85B:16S ratio recorded at various time 
interval was 0.0013, 0.0018 (p<0.05), 0.0822 (p<0.001), 0.3234 (p<0.001), and 0.7866 
(p<0.001), after 0. 4, 24, 72 and 120 hours of infection, respectively. In the supernatants 
of infected monocyte cultures the expression of secreted antigen 85 complex increased 
with time. Furthermore, the M. tuberculosis-infected monocytes exhibited a linear time-
dependent decrease in GPx activity in comparison to control monocytes. 
Cellular activation, and thereby induction of TNF-a, is mediated via NF-KB. It has 
been well documented that TNF-a induced nuclear translocation of NF-KB was inhibited 
in SN50 peptide-treated human monocytic cell lines as demonstrated in EMSA. Thus, we 
employed SN50, an inhibitor of NF-KB, to assess the role of NF-KB in activation of gene 
expression in M. tuberculosis-infected monocytes. Our results clearly show that the 
increased expression of TNF-a and 85B mRNA in M. tuberculosis-'mfected monocytes is 
mediated ma::nly via NF-KB. Interestingly, inhibition of reactive oxygen intermediates 
(ROIs) and reactive nitrogen intermediates (RNIs), reduced expression of TNF-a and M 
tuberculosis 85B genes in M tuberculosis-'mfected monocytes. 
The neem tree is considered as the panacea for all diseases and has also been 
hailed as 'heal all', 'divine tree', 'village dispensary' and 'nature's drugstore'. All parts 
of the neem tree- leaves, flowers, seeds, fruits, roots and bark have been used 
traditionally for the treatment of inflammation, infections, fever, skin diseases and dental 
disorders. The oil from the neem leaves is recognized to possess antibacterial activity 
against a wide spectrum of Gram-negative and Gram-positive microorganisms, including 
M.tuherculosis and Streptomycin-resistant strains. Neem leaf is known to inhibit Vibrio 
cholerae. Klebsiella pneumoniae, M.tuberculosis and M.pyogenes in vitro. The medicinal 
utilities have been described especially for neem leaf, its constituents have been 
demonstrated to exhibit immunomodulatory, anli-inflammatory, antihyperglycaemic, 
antiulcer, antimalarial, antifungal, antibacterial, antiviral, antioxidant, antimutagenic and 
anticarcinogenic properties.The aqueous extract of neem leaf exerts its immunostimulant 
activity by enhancing both humoral and cell mediated responses. Radical scavenging 
properties of neem leaf have also been reported. Neem leaf has been documented to 
decrease the extent of lipid peroxidation. Aqueous as well as 70 percent ethanolic neem 
leaf extracts significantly reduce N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-
induced lipid peroxidation, by enhancing the activities of glutathione dependent 
antioxidants as well as superoxide dismutase (SOD) and catalase (CAT). 
The aqueous extract is reported to contain several active substances and is known 
to posses anti-inflammatory, and immunomodulatory activities. The immunomodulatory 
activity of the neem-bark extract has also been reported. Anti-inflammatory, 
immunostimulant and antiulcerogenic actions have also been reported in the extracts of 
A. indica. In fact, the study showed neem extract to be more effective than aspirin in 
inhibiting prostaglandins. There have been attributed by several researchers to a strong 
Thl cytokine response, particularly IFN-gamma and TNF. Increases in CDS cells have 
also been reported. Neem has "inhibitory action on a wide spectrum of micro-organisms, 
including Candida albicans, C. tropicalis, gonorrhoeae, the multidrug-resistant 
Staphylococcus aureus and urinary tract Escherichia coli, Herpes simplex-2 and HIV-1." 
Nimbidin, a major crude principle extracted from neem oil, inhibited nitric oxide 
(NO) and prostaglandin E2 (PGE2) production in lipopolysaccharide (LPS) stimulated 
macrophages following in vitro exposure. Inducible nitric oxide synthase (iNOS) activity 
measured in the presence or absence of nimbidin in cytosolic preparation of macrophages 
cultured with lipopolysaccharide (LPS) for 24 h. Nimbidin is, as such, a general anti-
inflammatory drug and is effective in both acute and chronic states of inflammation. The 
medicinal properties of Azadirchata indica includes a variety of effects like antipyretic, 
anti-malarial, anti-tumour, anti-ulcer, anti-diabetic, anti-fertility as well as effects on the 
central nervous and cardiovascular system. Immunomodulatory properties of different 
neem preparations such as. activation of B cells, T cells and macrophages have been 
reported earlier. Neem kernel oil induces secretion of gamma interferon and tumor 
necrotic factor-alpha. 
Here we investigated the modulatory/suppressive effect of neem extract on the 
expression of TNF-a and M tuberculosis 85B in M. /uberculosis-'wfected monocytes 
after 24 hours of infection. In the present stud}', we employed neem extract 
concentrations in between 0-1000 )ig/ml, which failed to show any toxic effect on 
monocytes as revealed by MTT assay. Also, no effect was observed on housekeeping 
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genes: R18 ( 8S rRNA) by quantitative real-time RT-PCR, thereby indicating that neem 
extract did not non-specifically affect human TNF-a transcription in M. tuberculosis-
infected monocytes. Also, the effect of various doses of neem extract employed in the 
present study failed to show any toxic or inhibitory effect on the mycobacterial 
housekeeping gene M. tuberculosis I6S rRNA as revealed by real-time RT-PCR in 
monocytes infected with M tuberculosis. 
The present study revealed neem extract to down regulate the expression of TNF-
a gene in M tuberculosis-infected monocytes as well as the secretion of soluble TNF-a 
in culture supematants in a dose-dependent manner. The results show an appreciable 
suppression in endogenous TNF-a mRNA expression by -0.4 logs, 0.9 logs, 1.7 logs, 2.4 
logs, 3.8 logs, and 4.8 logs (/'<0.00l for all), upon treatment with 100, 200, 400, 600, 
800 and 1000 |ig/ml of neem extract, respectively in M. tuberculosis-infected monocytes. 
Interestingly, in comparison to the inhibitory effects of neem extract with those of 
NAC, SN50 and anti-TNF-a antibody, neem extract was found to be the most potent 
inhibitor of TNF-a and M. tuberculosis 85B expression in M. tuberculosis-Infected 
monocytes. Our results indicate that the increased expression of TNF-a and 85B mRNA 
in M tuberculosis-infected monocytes is mediated via activation of NF-KB, as evidenced 
by the suppression of TNF-a mRNA in the presence of SN50, an inhibitor of NF-KB. 
SN50/M, an inactive analogue of SN50 failed to show any such effect. In view of it. our 
data demonstrated that this effect involved inhibition of the NF-KB pathway induced by 
neem extract probably by inhibiting the degradation of iKBa. Since a number of genes 
involved in inflammatory responses are regulated by NF-KB pathway, thus a high 
magnitude downregulation of the NF-KB pathway by neem extract w-ould predictably 
reduce the elaboration of NF-KB-mediated TNF-a mRNA expression and, in turn, 85B 
gene expression. M. tuberculosis-infected macrophages release IL-12 and IL-18 which 
stimulate the CD4 and CDS T-cells to release IFN-y. IFN-y is crucial for the control of M 
tuberculosis infection. It stimulates phagocytosis of M tuberculosis and also the release 
of TNF-a from macrophages, which is important in granuloma formation and control of 
the extent of infection. TNF-a and IL-ip, along with IFN-y produced by T-lymphocytes, 
can induce NO in macrophages via inducible form of the enzyme nitric oxide synthase 
(iNOS). Myccbacterial cell wall components such as LAM and 19 kDa lipoprotein, along 
VII 
with T-cell-derived IFN-y may also induce NO expression.Treatment with anti-oxidants 
like neem extract and NAC in MTB-infected monocytes exhibited a decrease in level of 
IFN-y. Thus, it appears that down-regulation of sIFN-y levels in culture supernatants of 
MTB-infected monocytes is ameliorated by neem extract. 
Next, in the present study, the inhibitory effect of antibiotics like streptomycin, 
rifampicin and isoniazid in comparison to neem extract were probed. The results 
showed that co-cuituring of MTB-infected cells with streptomycin, rifampicin and 
isoniazid down regulated the TNF-a mRNA & MTB 85B expressions in dose dependent 
manner. The IC50 for TNF-a mRNA & MTB 85B mRNA suppressions was found to be of 
the order of isoniazid >streptomycin >rifampicin. 
Glutathione directly reacts with ROS, and glutathione peroxidase (GPx) catalyzes 
the removal of hydrogen peroxide. Decrease in GPx activity indicates impairment of 
hydrogen peroxide-neutralizing mechanisms. Here, we observed a decline in GPx activity 
in M. tubercidosis-'mfQCied monocytes. Enhancement of GPx activity in M. tuberculosis-
infected monocyte cultures after addition of NAC, a precursor of the in vivo antioxidant 
glutathione, indicates reversal of impaired neutralizing mechanisms. Surprisingly, here a 
slightly greater augmentation in GPx activity was observed when neem extract was co-
cultured instead of NAC, indicating neem extract to be an effective natural antioxidant 
combating ROS, generated as a consequence of cellular activation in M. tuberculosis-
infected monocytes. 
In conclusion, the presence of elevated levels of TNF-a and M tuberculosis 85B 
in tuberculosis patients is the indication of severity of the disease. The expression of M 
tuberadosis 85B was downregulated by neem extract in a dose-dependent manner in 
H37RV cultures. Furthermore, M. tuberculosis infection of monocytes leads to a 
concomitant activation of TNF-a and expression of M. tuberculosis 85B gene. M. 
tuberculosis nfection of human monocytes initiates a cascade of events whereby cellular 
activation by TNF-a, RNI, and ROI enhances the expression of M tuberculosis 85B in 
monocytes. The augmented expression of TNF-a and M. tuberculosis 85B gene in M 
tuberculosis-mftcitd monocytes by cellular activation and ROS was suppressed by neem 
extract in a dose-dependent manner. The effect of neem extract was mediated by 
suppression of NF-KB. Also, neem extract enhanced the GPx activity, which correlated 
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inversely with the downregulation of TNF-a and M. tuberculosis 85B in M tuberculosis-
infected monocytes. Neem extract may prove to be valuable in the containment of M 
tuberculosis and, therefore, be useful as an adjunct in treatment of tuberculosis. These 
observations strengthen the idea that neem extract should be tested in in vivo models to 
evaluate its therapeutic potential in the pathogenesis of tuberculosis. 
LIST OF FIGURES: 
Page No. 
Figure 1 A: Schematic diagram of the Cell wall structure of 21 
mycobacteria. 
Figure IB: Schematic diagram of Mycobacterium tuberculosis cell 21 
envelope. 
Figure!: TNF-a signalling pathways. 29 
Figure 3: NF-kB Activation Pathways. 31 
Figure4A: Chemical Structure of Streptomycin (C2iH39N70i2). 37 
Figure 4B: Chemical Structure of Rifampicin (C43H58N4O12). 37 
Figure 4C: Chemical Structure of isoniazid (C6H7N3O). 37 
Figure 5: Picture of Neem. 40 
Figure 6A: Gradient SDS-PAGE 6-15% of MTCF. 70 
Figure6B: Gradient SDS-PAGE 6-15% of Purified MTCF. 71 
Figure 6C: Gradient SDS-PAGE 6-15% of MTSE. 72 
Figure?: Dose response effect of Neem extract (0-1000 |ig/ml) on 73 
the secreted Ag 858 protein in 14 days culture upernatants 
of Mycobacterium tuberculosis H37RV. 
Figure 8A: Gradient SDS-PAGE 6-15% of MTCF, co-culture with 74 
varying doses of H2O2 (0-20 nM). 
Figure 8B: Gradient SDS-PAGE 6-15% of MTSE. co-culture with 75 
"b 
varying doses of H2O2 (0-20 nM). 
Figure 9: Dose response effect of H2O2 (0-20 nM) on the secreted 76 
Ag 85B protein in 14 days culture supernatants of 
Mycobacterium tuberculosis H37RV. 
Figure 10: Gradient SDS-PAGE 6-15% of MTCF, co-culture with 77 
varying doses of H2O2 (0-20 nM) and W mM NAC. 
Figure 11: Dose response effect of H2O2 (0-20 nM) and NAC (0-10 79 
mM) on the secreted Ag 858 protein in 14 days culture 
supernatants of Mycobacterium tuberculosis H37RV. 
Figure 12: Gradient SDS-PAGE 6-15% of MTCF, co-culture with 80 
NADPH (lOnM) and NAC (10 mM). 
Figure 13: Dose response effect of NADPH (0- 20 nM) and NAC (0- 81 
10 mM) on the secreted Ag 85B protein. 
Figure 14: Direct binding ELISA for MTCF against antibodies 84 
present in sera from patients with active tuberculosis and 
MDR- TB as well as normal healthy individual. 
Figure 15: Direct binding ELISA of MTSE against antibodies present 85 
in sera from patients with active tuberculosis and MDR-
TB as well as normal healthy individual. 
Figure 16: Direct binding ELISA for MTCF, co-cultured with neem 86 
extract against antibodies present in sera from patients with 
active tuberculosis and MDR- TB as well as normal 
healthy individual. 
Figure 17: Direct binding ELISA for MTSE, co-cultured with neem 87 
extract. 
Figure 18: Inhibition ELISA for MTCF and MTSE either untreated or 88 
co-cultured with 1000 fig/ml Neem extract. 
Figure 19: Inhibition ELISA for MTCF and MTSE either untreated or 89 
co-cultured with 1000 |ug/ml Neem extract. 
Figure 20: Inhibition ELISA for DNA isolated from MTB-infected 90 
monocytes untreated with Neem extract. 
Figure 21: Inhibition ELISA for DNA isolated from MTB-infected 93 
monocytes co-cultured with 1000 ^g/ml Neem extract. 
Figure 22: Inhibition ELISA for protein lysates of MTB infected 94 
MN's against antibodies present in TB and MDR-TB sera 
at 24 hrs culture. 
Figure 23: Inhibition ELISA for protein lysates of MTB infected 95 
MN's co-cultured with neem extract against antibodies 
present in TB and MDR-TB sera at 24 hrs culture. 
Figure 24: Inhibition ELISA for protein lysates of MTB infected 96 
MN's modulated with 10 mM NAC against antibodies 
present in TB and MDR-TB sera at 24 hrs culture. 
.\i 
Figure 25: Inhibition ELISA for protein iysates of MTB infected 97 
MN's co-cultured with 100 i^g/ml SN50 or SN50M against 
antibodies present in TB and MDR-TB sera at 24 hrs 
culture. 
Figure 2:6: inhibition ELISA for protein Iysates of MTB infected 98 
MN's modulated with 2 ng/ml monoclonal anti-TNF-a Ab 
against TB and MDR-TB sera at 24 hrs co-culture. 
Figure 27: Inhibition ELISA for protein Iysates of MTB infected 101 
MN's modulated with 100 ^g/ml Streptomycin against TB 
and MDR-TB sera at 24 hrs co-culture. 
Figure 28: Inhibition ELISA for protein Iysates of MTB infected 102 
MN's modulated with lOO^g/ml Rifampicin against TB 
and MDR-TB sera at 24 hrs co-culture. 
Figure 29: Inhibition ELISA for protein Iysates of MTB infected 103 
MN's modulated with 100(ig/ml Isoniazid against TB and 
MDR-TB sera at 24 hrs co-culture. 
Figure 30: Inhibition ELISA for protein Iysates isolated from MN's of 104 
TB and MDR-TB patients co-cultured with 100 |ig/ml 
Streptomycin against TB and MDR-TB sera at 24 hrs co-
culture. 
Figure 31: Inhibition ELISA for protein iysates isolated from MN's of 105 
TB and MDR-TB patients co-cultured with 100 |ag/ml 
Rifampicin against TB and MDR-TB sera at 24 hrs co-
culture. 
Figure 32: Inhibition ELISA for protein Iysates isolated from MN's of 106 
TB and MDR-TB patients co-cultured with 100 ^g/ml 
Isoniazid against TB and MDR-TB sera at 24 hrs co-
culture. 
Figure 33: Inhibition ELISA for protein Iysates isolated from MN's 107 
modulated with 1000 |ig/ml Neem extract against TB and 
MDR-Tb sera at 24 hrs co-culture. 
Figure 34: Inhibition ELISA for protein Iysates isolated from MN's 108 
co-cultured with 100 ^g/ml NAC against TB and MDR-Tb 
sera at 24 hrs co-culture. 
Figure 35: Real time; Effect of Neem Extract on expression of host 111 
house keeping gene (16S rRNA). 
XII 
Figure 36: Real time: Dose response effect of Neem extract on 85B 112 
mRNA expression in 24hrs in MN's infected with MTB. 
Figure 37: Real time: Dose response effect of Neem extract on 85B to 113 
16S ratio in 24 hr culture of M"N's infected with MTB. 
Figure 38: Dose response effect of neem extract on the expression of 114 
secreted MTB Ag85B in 24 hr culture supernatants of 
MTB-infected human monocytes. 
Figure 39: Dose response effect of Neem extract on the expression of 115 
18S rRNA in Mycobacterium tuberculosis (H37RV). 
Figure 40: Time course kinetics of TNF-a mRNA expression in 116 
human monocytes that were infected in vitro with MTB. 
Figure 41: Time course kinetics of expression of secreted TNF-a in 117 
M tuberculosis-'mfQcied monocytecultures. 
Figure 42: Time course kinetics of expression of mycobacterial 16S 119 
rRNA in M tuherculosis-lnfQCtQd monocytes. 
Figure 43: Time course kinetics of M. tuberculosis 85B mRNA 120 
expression in M. tuberculosis-infected monocytes. 
Figure 44: Time course kinetics of expression of M. tuberculosis 121 
85B:16S ratio in M tuberculosis-lnfecied monocytes. 
Figure 45: Real time: Effect of Neem Extract on expression of host 122 
house keeping gene (18S rRNA). 
Figure 46: Real time: Dose response effect of Neem extract on TNF-a 125 
mRNA expression in 24 hrs in MM's infected with MTB. 
Figure 47: Dose response effect of Neem extract on the expression of 126 
I6S rRNA in MTB infected monocytes. 
Figure 48: Dose response effect of Neem extract on the expression of 127 
85B mRNA in MTB (H37RV) infected monocytes. 
Figure 49: Real time: Expression of intra-monocyte TNF-a mRNA in 128 
MNs untreated and treated with SN50 and SN50/M at 24 
hrs. 
XIII 
FigurefJO: Real time: Expression of intra-monocyte 85B:16S mRNA 129 
in MNs l:lmtb infected untreated and treated with SN50 
and SN50/M at 24 hrs. 
Figure f)l: Dose-response effect of Neem extract on expression of 130 
soluble TNF-a in M. tuberculosix-mfQctQd monocyte 
cultures in 24 hrs. 
Figure 52: Dose response effect of Neem extract on GPx activity in 24 131 
hr cultures of MTB-infected monocytes. 
Figure 53: GPx activity in 24 hr cultures of MTB-infected monocytes 133 
with NAC, SN50, SN50M and neem extract. 
Figure 54: Determination of MDA levels: Human monocytes of 134 
healthy uninfected controls, MTB infected, TB patients 
and MDR-TB patients. 
Figure 55: Determination of MDA levels: Human monocytes of 135 
healthy uninfected controls, MTB infected, TB patients 
and MDR-TB patients with or without NAC. 
Figure 56: Determination of MDA levels: Human monocytes of 137 
healthy uninfected controls, MTB infected, TB patients 
and MDR-TB patients with or without NE. 
Figure 57: ELISA for modulation of expression of sTNF-alpha in 138 
MTB-infected monocyte co-cultured with varying doses of 
NADPH(0-lOnM). 
Figure 58: ELISA for modulation of expression of secreted antigen 139 
85 complex in MTB-infected monocyte co-cultured with 
varying doses of NADPH (0-10 nM). 
Figure 59: ELISA for modulation of GPx activity in MTB-infected 142 
monocyte co-cultured with varying doses of NADPH (0 -
10 nM). 
Figure 60: ELISA for modulation of GPx activity in MTB-infected 143 
monocyte co-cultured with varying doses of streptomycin. 
Figure 61: ELISA for Expression of sTNF-a in MTB-infected 144 
monocyte co-cultured with varying doses of streptomycin. 
Figure 62: ELISA for modulation of Expression of secreted MTB 145 
antigen 85B in MTB-infected monocyte co-cultured with 
XIV 
varying doses of streptomycin. 
Figure 63: ELISA for modulation of GPx activity in MTB-infected 149 
monocyte co-cultured with varying doses of Rifampicin. 
Figure64: ELISA for Expression of sTNF-a in M. tuberculosis- 150 
infected monocytes with Rifampicin. 
Figure 65: ELISA for modulation of Expression of secreted MTB 151 
antigen 85B in M. tuberculosis-'mkcied monocytes with 
Rifampicin. 
Figure 66: ELISA for modulation of GPx activity in MTB-infected 152 
monocyte with Isoniazid. 
Figure 67: ELISA for Expression of sTNF-a in MTB-infected 153 
monocyte with Isoniazid. 
Figure 68: ELISA for modulation of Expression of secreted MTB 154 
antigen 85B in MTB-infected monocyte with Isoniazid. 
Figure 69: Dose respose effect of neem extract (0-1000 |ag/ml) on the 155 
expression of sIFN-y proteins in 24 hr culture supernatants 
of in vitro MTB- infected monocytes. 
Figure 70: Modulatory effects of neem extract (1000 fig/ml) versus 155 
NAC (10 mM) on the expression of sIFN-y proteins in 24 
hr culture supernatants of in vitro MTB- infected human 
monocytes. 
Figure 71: Dose response effect of Neem extract on the expression of 156 
iNOS mRNA and MTB 85B mRNA in MTB-infected 
monocytes. 
Figure 72: Modulation of iNOS mRNA in MTB-infected monocytes 156 
with SNP and a mixture of SNP + Neem extract. 
XV 
LIST OF TABLE 
Page no. 
Table!: Sequences of primers and probes for quantification of 65 
human TNF-a and M. tuberculosis 85B mRNA. 
XVI 
LIST OF ABBREVIATIONS 
ALP 
ATP 
BCG 
BSA 
Cbfa 
cDNA 
DC 
DEPC 
DNA 
dNTP 
DTT 
DOTS 
EDTA 
ELISA 
EMSA 
GM-CSF 
GPx 
GSH : 
GSSH : 
H2O2 : 
ICAM : 
: Alkaline phosphatase 
: Adenosine triphosphate 
: Baciile Calmette-Guerin 
: Bovine serum albumin 
Core binding factor a 
Complementary DNA 
Dendritic cell 
: Diethyl pyrocarbonate 
: Deoxyribonucleic acid 
: Deoxyribonucleotide triphosphate 
: Dithiothretrol 
: Directly Observes Treatment Strategy 
: Ethylene diamine tetra acetic acid 
Enzyme linked immunosorbant assay 
: Electrophoretic mobility shift assay 
: Granulocyte macrophage colony stimulating 
factor 
I Glutathione peroxidase 
Glutathione 
Oxidized GSH 
Hydrogen peroxide 
Intracellular cell adhesion molecule 
XVII 
ICso 
IgG 
IFNy 
IL 
LAM 
LPS 
iNOS 
IKB 
M-CSF 
MHC 
MDR 
Ml 
mM 
MN 
niRNA 
MTCF 
MTSE 
MTT 
NAC 
NFAT 
NFKB 
NO 
NADPH 
Concentration for 50% inhibition 
Immunoglobulin G 
Interferon gamma 
Interleukin 
Lipoarabinomannan 
Lipopolysaccharide 
Inducible nitric oxide synthase 
Inhibitory kappa B 
Macrophage- CSF 
Major histocompatibility factor 
Multidrug-resistant 
Millilitre 
Millimolar 
Monocyte 
Messenger RNA 
Mycobacterium tuberculosis culture filtrate 
Mycobacterium tuberculosis sonic extract 
3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium-
bromide) 
N-acetylcysteine 
Nuclear factor of activated T cells 
Nuclear factor kappa B 
Nitric oxide 
Reduced P-nicotinamide adenine dinucleotide 
phosphate 
XVIII 
NHS 
nM 
NMMA 
NOC-9 
oATP 
PAGE 
PBMC(s) 
PBS 
PMSF 
pNPP 
RANK 
rh 
RN i^ 
RNI 
ROI 
ROS 
RPMI 
rRNA 
RT-PCR 
SDS 
SN50 
SNP 
sTNF-a 
TDM 
TEMED 
Normal human sera 
Nanomolar 
N - monomethyl-L-arginine-monoacetate 
Nonoate-9 
Oxidized ATP 
Polyacrylamide gel electrophoresis 
Peripheral blood mononuclear cell(s) 
Phosphate buffered saline 
Phenylmethylsulphonyl floride 
Para nitro phenyl phosphate 
Receptor activator of NFKB 
Recombinant human 
Ribonucleic acid 
Reactive nitrogen intermediates 
Reactive oxygen intermediates 
Reactive oxygen species 
Roswell Park Memorial Institute 
Ribosomal RNA 
Real-time polymerase chain reaction 
Sodium dodecyl sulphate 
Synthetic polypeptide and an inhibitor of NFKB 
Sodium nitroprusside 
Soluble TNF- a 
Trehalose dimycolate 
N,N,N',N'-tetramethylethylene diamine 
XIX 
TLR 
TMM 
TGF-p 
TNFa 
TNFR 
Tris 
JAg 
Toll-like receptor 
Trehalose monomycolates 
Transforming growth factor beta 
Tumor necrosis factor alpha 
TNF receptor 
TNFR associated protein 
Tartarate resistant acid phosphatase 
Tris (hydroxymethy) aminomethane 
Microgram 
Microlitre 
Micromolar 
XX 
Tuberculosis (TB) is a common and deadly infectious disease. Consumption, 
lupus vulgaris and phthisis are some of the more colorful names for tuberculosis (TB), is 
a bacterial infection caused by a germ called Mycobacterium tiiherciilusis. The bacteria 
usually attack the lungs, but can also affect the central nervous system, the lymphatic 
system, the circulatory system, the genitourinary system, bones, joints and even the skin. 
Epidemiology: 
Tuberculosis (TB) is a high burden disease, especially in developing countries. 
According to the World Health Organization (WHO), in 2006, there were 9.2 million new 
TB cases, 86% being in Asia and Africa. The death toll reached 1.7 million people, 
including 200,000 HIV-infected patients (WHO and Global Tuberculosis Programme. 
2008). Tuberculosis remains a major global health problem that kills up to 2 million 
people annually (Rengarajan et al., 2008). The disease tuberculosis is caused by the 
bacterium Mycobacterium tuberculosis, which is a highly infectious organism transmitted 
via aerosol. M. tuberculosis, the most notorious member of the Mycobacteria, was first 
isolated and cul'.ured by Robert Koch in 1882. Effective drugs to treat and cure the 
disease have been available for more than 50 }'ears, yet every 15 seconds, someone in the 
world dies fron TB. Even more alarming: a person is newly infected with M. 
tuberculosis every second of every day. Left untreated, a person with active TB will 
infect an average of 10 to 15 other people every year (Dye et al.. 2005). 
The WHO estimated 8.9 million new cases of TB in 2004: about 3.9 million cases were 
acid-fast bacilli (.AFB) sputum smear-positive, the most infectious form of the disease. 
The staggering extent of infection by this e.xclusivel}' human pathogen. M. tuberculosis. 
encompasses a total of two billion persons, approximatelv' eight million people develop 
active disease £.nd nearly two million are killed each }ear (Barnes and Cave. 2003; 
Kusner. 2005). Moreover, it was declared a global health emergenc) bv' WHO in 1993 
(WHO, 2002). Global efforts to control TB were reinvigorated in 1991, when a World 
Health Assembly resolution recognized TB as a major global public health problem. Two 
targets for TB control were established as part of this resolution - detection of 70 % of 
new AFB smear-positive cases, and cure of 85 % of such cases b}' the \'ear 2000. Despite 
intensified efforts, these targets were not met; more than 80 % of known cases are 
successfully treated, but only 45 % of cases are detected (WHO, 1993; WHO, 1994; 
WHO, 2006a). Targets were established to measure progress in the implementation of the 
DOTS (directly observed treatment strategy) to combat tuberculosis. 
The recent resurgence in tuberculosis is attributed partly to the AIDS epidemic 
with the emergence of multidrug-resistant strains especially in areas where the WHO-
recommended DOTS has not yet been implemented (Pablos-Mendez et al., 1998; De 
Cock and Chaisso, 1999). Co-infection with the human immunodeficiency virus (HIV) 
and tuberculosis form a lethal combination, each speeding the other's progress. Sub-
Saharan Africa bears the brunt of the HlV-fuelled tuberculosis epidemic (Corbett et al.. 
2002). Based upon DOTS, DOTS-Plus is a comprehensive management strategy under 
development and testing of the DOTS strategy. DOTS-Plus should be implemented in 
selected areas with moderate to high levels of MDR-TB in order to combat an emerging 
epidemic. It is vital that DOTS-Plus pilot projects follow WHO recommendations in 
order to minimize the risk of creating drug resistance to second-line TB drugs (which are 
more toxic and expensive, and less effective, than first-line drugs). More recently, DOTS-
Plus projects have also been approved in Georgia, Honduras, Jordan, Kenya, Kyrgyzstan. 
Lebanon, Nepal, Nicaragua, Romania, and Syria (Gupta et al., 2002; Sharma and Liu, 
2006; WHO, 2002d). 
Clinical manifestations: 
The infectious agent of TB, Mycobacterium tuberculosis, is an alternative 
intracellular pathogen that infects mainly macrophages in the lungs. Even though M. 
tuberculosis can infect several organs, in adults around 85% of cases are pulmonary 
(Pncheco et i.].. 2008), Pulmonary disease is most common clinical manifestation of 
tuberculosis (Shafer and Ediin, 1996). Pulmonary TB has been variousK' described as 
consumption and phthisis, both terms indicating the severe wasting and the coughing of 
blood associated with later stages of the disease (Smith, 2003). The incidence of various 
extrapulmonary forms of tuberculosis varies from countr}' to country, such that on the 
average between 1964 and 1989. 20% of the 20.000 new cases of TB in the United Slates 
were extrapulmonary while 5 to 10% of the approximatel) seven million new cases each 
year in the developing countries were extrapulmonary (Talavera et al., 2001). 
Extrapulmonary tuberculosis accounts for about 20°/1» of disease in HIV-seronegative 
people, but is nore common in HlV-seropositive individuals (Shafer and Edlin, 1996). 
Among people not infected with HIV, extrapulmonary disease, particularly lymphatic 
tuberculosis, is particularly common in women and young children (Rieder. 1999). 
Pleural tuberculosis occurs as a result of either primary progressive M. tuberculosis 
infection or reactivation of latent infection. Unlike other clinical manifestations of 
tuberculosis, pleural disease probably represents an increased, rather than diminished, 
immune response (Frieden et a!., 2003). 
Tuberculosis of the central nervous system (CNS) is a highly devastating form of 
tuberculosis. v\hich. even in the setting of appropriate antitubercular therapy, leads to 
unacceptable levels of morbidity and mortality (Rock et al.. 2008). The involvement of 
tuberculosis of the central nervous system can include inflammation of the meninges, as 
well as space-occup\ing lesions (tuberculomas) of the brain. The clinical manifestations 
are due to the presence of M tuberculosis as well as the inflammatory host immune 
response. Children under 5 years of age and HIV-infected individuals are at increased 
risk of tuberculous meningitis (Berenguer et al.. 1992; Thwaites et al.. 2000). which can 
clinically manifest as chronic meningitis, with headache, fever, and changed mental 
status. Neurological manifestations can include cranial nerve palsies and motor, sensory, 
and cerebellar defects, according to the location of the tuberculomas; seizures can also 
occur. Meningitis is fatal in almost all cases without chemotherapy, and prompt 
identification and treatment is essential to prevent serious neurological sequelae (Frieden 
etal., 200.V). 
Tuberculosis can affect any bone or joint, but the spine (i.e.. Pott"s disease) is the 
most common bon\' structure involved. In the spine, the most common location is the 
thoracic section. Vertebral-body involvement can be followed by disease of an adjacenl 
intervertebral disc (Iseman, 2000). Genitourinary tuberculosis (including involvement of 
the renal and inale and female genital tracts) is uncommon and is difficult to distinguish 
from other infections of the genitourinary tract (Frieden et al.. 2003). In men. 
manifestations include those of prostatitis or prostate enlargement, epididymitis, and 
orchitis, but disease can also present as a painless scrotal mass. Urine analysis may show 
red or white blood cells, or both, with a negative urine culture for bacteria (sterile pyuria). 
In women, genitourinary tuberculosis is an important cause of infertility in areas with 
high tuberculosis incidence (Goldfarb and Saimn, 1996). 
Disseminated tuberculosis is defined as involvement of many organs 
simultaneously and can occur as a result of primary progressive disease or reactivation of 
latent infection. The clinical manifestation of pulmonary involvement is a miliary (millet 
seed) pattern rather than an infiltrate in most cases, but not all patients with disseminated 
disease have pulmonary involvement (Frieden et al., 2003). Mortality is high despite 
chemotherapy and may be related to delays in diagnosis and other commonly present 
underlying medical conditions (Rieder et al., 1990). 
Pathophysiology: 
Tubercu'osis is caused by an acid-fast bacillus, Mycobacterium tuberculosis. TB 
may infect any part of body, but it is usually confined to the lungs due to the high-oxygen 
demand of the organism and route of transmission. Transmission of M. tuberculosis 
consists of aerosolized droplet nuclei, which are produced when an infected person 
coughs, sneeze^, or speaks (Thomason and Warren, 2005). Theses respiratory droplets 
less than 5 microns in size must reach the lung alveoli where the Mycobacterium 
tuberculosis begins to multiply (Williams and Wilkins, 2000). 
The pathogenesis of tuberculosis is complex and its manifestations diverse, 
reflecting a lifetime of dynamic interactions between mycobacterial virulence factors and 
the human immune system (Ellner, 1997; Hingley-Wilson et al., 2003). M tuberculosis is 
an extraordinarily effective human pathogen. Surve\s with PPD (purified protein 
derivative) or positive tuberculin skin tests suggest that one third of the world's 
population is infected with the bacillus (Dye et al., 1999). Primary infection leads to 
active disease in only about 10% of infected individuals, mostly within two years (Styblo. 
1980). In the remaining 90% majority of cases the immune system contains the infection 
and the individual is non-infectious and symptom-free. This clinical latency can persist 
throughout the person's lifetime. Reactivation of latent infection can result when host 
immune responses are perturbed through advanced immunosuppression (eg., AIDS/HIV 
infection, use of steroids, malnutrition, etc.) or advanced age (Flynn and Chan, 2001; 
Tufariello et al., 2003). Reactivation of latent infection contributes substantially to the 
incidence of adult tuberculosis, especially in more developed countries where disease 
prevalence is fairly low (Stead, 1967). Primary tuberculosis usually becomes established 
in the lower portion of the lung where ventilation is greatest (Stead, 1967). M 
tuberculosis exhibits specific cellular tropism for mononuclear phagocytes, i.e., alveolar 
macrophages, monocytes and dendritic cells (Kusner, 2005). M tuberculosis has the 
remarkable capacity to circumvent destruction within one of the most hostile cell types of 
a vertebrate host: the macrophage, where they establish a niche to survive and even 
replicate (Houben et al., 2006). M. tuberculosis infection initiates a cascade of events 
resulting in either successful containment of the infection or progression to active disease 
(Frieden etal.. 2003). 
In brief after being ingested by alveolar macrophages. M. tuberculosis replicates 
and spreads via the lymphatic system to the hilar lymph nodes. The bacterium thus 
utilizes the host cell as a mechanism of transport into the blood stream and deeper tissues. 
Cell-mediated immunity usually develops 2-8 weeks after infection. Activated 
lymphocytes ard macrophages form granulomas that limit further replication and spread 
of the organism (Schluger and Rom, 1998). Although the host response is essential to 
control of infection, the tubercle bacillus participates in the establishment of latency by 
using various strategies to evade elimination by the host. The evasion and interaction of 
pathogenic mycobacteria with the host immune system is discussed in greater detail in 
the following pages. 
,An orchestrated series of innate immune pathways, and T-helper I (Thl)-
dominant adaptive immune pathways are actixated following phagoc}'tosis of the 
bacteria, to cu minate in a granuloma at the initial focus of infection (Salgame. 2005). 
The innate host response is necessary for induction of adaptive immunity to M. 
tuberculosis (C'revel el al.. 2002). 
(A) Non-specific innate host defense and immune-evasion strategies of M 
tuberculosis'. 
M. tuberculosis (Mtb) is a highly successful human pathogen that elicits strong 
innate and adaptive immune responses (Rengarajan et al.. 2008). The first step in the 
innate host defense is cellular uptake of M. tuberculosis, which involves different cellular 
receptors and humoral factors. Toll-like receptors seem to play a crucial role in immune 
recognition of i\4. tuberculosis, which is the next step. The subsequent inflammatory 
response is regulated by production of pro- and anti-inflammatory cytokines and 
chemokines. Effector mechanisms also contribute to innate immunity. Most of the 
mediators at this point are derived from macrophages and dendritic cells. The initial 
response determines the local outgrowth, sometimes dissemination of M tuberculosis or 
containment of infection (Crevel et ai., 2002). Phagocytic ceils also play a key role in 
antigen presentation and the initiation of T cell immunity which follows. 
(1) Phagocytosis of M tuberculosis: 
Macropnages serve as the primary host cell invaded by Mycobacterium 
tuberculosis throughout the course of infection. Phagocytosis proceeds upon the 
interaction of Mtb proteins with innate receptors on the macrophage (Ernst, 1998). M. 
tuberculosis primarily infects macrophages and later dendritic cells and monocyte-
derived macrophages by using multiple phagocytic cell surface receptors to gain entry 
(Aderem and Underhill. 1999). These receptors include the mannose receptors, 
complement receptors and Fc receptors. Endocytosis involves receptor-binding to non-
opsonized M. tuberculosis or recognition of opsonins on the surface of M. tuberculosis 
(Crevel et a!., 2002). The best-characterized receptor for non-opsonin mediated 
phagocNlosis of M tuberculosis is the macrophage mannose receptor, which recognizes 
terminal mannose residues on mycobacteria (Schlesinger et al., 1996). Phagocytosis 
through mannose receptors does not trigger Oi" production (Astarie-Dequeker, 1999) and 
iV/ tuberculosis exerts an anti-inflammator\ signal through this receptor (Nigou el al.. 
2001). M nmerculosis opsonized with complement Victor C3 bind and are taken up 
through complement receptor 1 (CRI). CF<3 and CR4. 
Fc receptors, which facilitate phagocytosis of particles coated with IgG 
antibodies, seem to play little role in tuberculosis (Armstrong and Hart, 1975). However, 
Fc receptor-mediated phagocytosis is direcll}' linked to an inflammatory response 
(binding to CR is not) (Aderem and Underhill, 1999). Distinct routes of entry of .1/. 
tuberculosis may lead to differences in signal transduction, immune activation and 
intracellular survival of M tuberculosis (Crevel et al.. 2002). 
(2) M. tuberculosis recognition by toif-Iike receptors: 
TLRs are believed to represent key receptors for the recognition of mycobacterial 
antigens and activation of macrophages and DCs. The initial interaction of M 
tuberculosis with phagocytes through toll-like receptors (TLRs) can affect induction of 
the adaptive response by inflammatory cytokine production as well as begin the process 
of bacterial containment by induction of antimycobacterial functions (Flynn and Ernst, 
2000). it is partly through this interaction with TLRs that macrophages produce 
inflammatory cytokines and chemokines that serve as signals of infection (Tufariello et 
al., 2003). TLRs mediate the activation of cells of the innate immune system, resulting in 
destruction of invading microbes through the activation of several signalling cascades. 
TLRs are phylogenetically conserved mediators of innate immunity, which are essential 
for microbial recognition on macrophages and dendritic cells (Belvin and Anderson, 
1996; Medzhitov et al., 1997). Activation of TLRs is an important link between innate 
cellular responses and the subsequent activation of adaptive immune defenses against 
microbial pathogens (Salgame, 2005). 
Toll-like receptors, key players in innate immunity, are now known to be 
important for the initiation and coordination of host responses to Mycobacterium 
tuberculosis. The interaction of M. tuberculosis with toll-like receptors triggers 
intracellular signaling cascades that culminate in a proinflammatory response, but can 
also trigger signals that dampen the innate immune response (Eun-K}eong, 2008). TLR-
signalling leads to the nuclear translocation of NF-icB (nuclear factor-icB). NF-KB is a 
transcription :actor involved in the expression of many immune response genes such as 
those encoding the cytokines TNF-a and interleukins (Houben et al., 2006). TLR-
signalling also triggers differentiation of monocytes into macrophages and dendritic cells, 
thereby generating the cellular populations necessary for a potent innate and adaptive 
immune response (Krutzik et al.. 2005). 
Eleven members of the TLR family have been identified so far (Kawai and Akira 2005). 
Members of ihe TLR famil\ are transmembrane proteins containing repeated leucine-rich 
motifs in tiieir extracellular domains, similar to other pattern-recognizing proteins of the 
innate immune system (Crevel et al., 2002). The cytoplasmic domain of TLR is 
homologous to the signalling domain of IL-IR (IL-I receptor) and links to IRAK (IL-IR 
associated kinase), a serine kinase that activates transcription factors like NF-KB to signal 
the production of cytokines (Oddo et al., 1998). Through TLRs M. tuberculosis lysate or 
soluble mycobacterial cell wall-associated lipoproteins induce production of IL-12, a 
strong pro-inflammatory cytokine (Brightbill et al., 1999). Myeloid differentiation protein 
88 (MyD88), a common signalling component that links all TLRs to IRAK (Oddo et al., 
1998), was found to be essential for M tubercidosis-'xnAwcQd macrophage activation 
(Underbill et al.. 1999). From several lines of evidence it has become clear that 
phagocytosis does not lead to immune activation in the absence of functional TLRs 
(Crevel etal., 2002). 
Besides generating cytokine activity, TLR stimulation in macrophages 
upregulates phagocN^osis of bacteria (Doyle et al., 2004) and apoptotic cells (Shiratsuchi 
et al.. 2004). TLRs also appear to regulate fusion events between phagosomes and 
lysosomes (Doyle et al.. 2004). Whether or not pathogenic mycobacteria interfere with 
TLR signalling to block their delivery to phagosomes, eg., through modulation of MAPK 
signalling pathways remains to be established in vivo (Houben et al., 2006). 
(3) Effector mechanisms for killing of M tuberculosis: 
(a) Avoidance of macrophage-mediated killing: 
Macrophages are central to host defense against microbes, but intracellular 
pathogens have evolved to evade their antimicrobial functions (Rengarajan et al., 2005). 
Although macrophages provide an effecti\e initial barrier against infection by bacterial 
pathogens. M. (uherculosis has evolved numerous strategies that allow it to survive and 
set up initial residence within these cells (Zahrt. 2003) after gaining entry via multiple 
cell surface receptors (eg., mannose receptors, complement receptors and Fc receptors). 
Pathogenic mxcobacteria coat themseKes with a serum protein that is recognized by 
complement, thereby avoiding host inflammatory response (Caron and Hall, 1998). M. 
tuberculosis crosses the first line of defense, i.e.. the alveolar barrier by invading the 
alveolar epithelial cell and secondarily, the endothelial layer, or it does so within infected 
macrophages (Bermudez and Sangarib, 2001). M tuberculosis evades the innate 
antimicrobial defenses of macrophages by inhibiting the maturation of its phagosome to a 
bactericidal phagolysosome (Kusner, 2005). 
One of the hallmarks of MTB infection is that once inside macrophages and 
monocytes, Mtb resides within phagosomes that neither acidify nor fuse with lysosomes 
(Armstrong and Hart, 197!; Clemens and Horwitz, 1996; Clemens et al., 2000; Clemens 
et al.. 2002; Russell et al., 2002; Mwandumba et al., 2004) has been considered the 
central feature of tuberculous pathogenesis, providing the organism with a means to 
avoid both the direct antimicrobial activity of the innate immune system as well as 
effective antigen presentation by inhibiting MHC class II dependent antigen presentation 
pathway and elicitation of adaptive immunity (Vergne et al., 2003; Kusner, 2004). Thus, 
the survival mechanisms or pathogenic strategies involved include inhibition of 
phagosome maturation and acidification, modification of the normal phagosomal 
trat^ ficking pathway, and alteration of recruitment or association of various proteins to the 
phagosomal membrane. These are discussed below: 
Inhibition of phagosome maturation and the consequent intracellular survival of 
M. tuberculosis occurs via inhibition of macrophage Ca'^-mediated signal transduction 
through inhibition of macrophage sphingosine kinase (Kusner, 2005). Many lipid 
components of the mycobacterial cell wall have essential roles in the innate ability of 
mycobacteria to block the fusion of the bacterial phagosome to lysosomes (Houben et al., 
2006). Altered phagosomal maturation is associated with alteration in the protein content 
of the vacuole including altered Rab GTPase composition (Clemens et al., 2000). 
exclusion of the vacuolar protein ATPase with consequent lack of acidification (Sturgill-
Koszycki et al.. 1994), and retention of a protein designated TACO (tryptophan aspartate 
rich coat protein) (Ferrari et al., 1999). Whereas some m\cobacterial cell wall lipids, such 
as trehalose mycolates. influence the inflammatory response (Geisel et al., 2005; Rao et 
al., 2005), other components modulate trafficking inside the macrophage. For example, 
the M. tuberculosis Ptdlns-3P analog, glycosylated phosphatidyl inisitol 
lipoarabinomainan (ManLAM). blocks phagosome maturation (Fratti et al., 2003) and 
inhibits the rise in Ca"" concentration in the macrophage cytosol upon phagocytosis of 
mvcobacteria. 
(b) Role of nitric oxide (NO): 
Putative and effective host defense mechanisms by innate immune cells to A/. 
tuberculosis within the phagolysosomes of activated macrophages include the production 
of reactive oxygen (ROI) and reactive nitrogen intermediates (RNl). Catalytic action of 
the respiratory burst by the NADPH-oxidase complex produces ROI such as hydrogen 
peroxide (H2O2), superoxide anion (O2") and hydroxy! radical (OH) (Chan et al., 2001). 
NO is a non-specific, chemically reactive molecule that is important in host defense 
against a wide variety of microbial pathogens. Although controversial, there is a growing 
body of evidence that NO produced by M. tuberculosis-Infected human macrophages and 
epithelial cells is also antimycobacterial against M tuberculosis (Rockett et a!., 1998; 
Jagannath et a I., 1998). Human macrophages produce NO from increased iNOS activity 
(Chan et al., 2001) as in human lung epithelial cells (Robbins et al., 1994). TNF-a and 
IL-ip, along with IFN-y produced by T lymphocytes, can induce NO in macrophages via 
inducible form of the enzyme nitric oxide synthase (iNOS) (Kvvon, 1997). Mycobacterial 
cell wall components such as LAM and 19 kDa lipoprotein, along with T cell-derived 
IFN-y may also induce NO expression (Adams et al., 1993; Brightbill et al.. 1999). 
(c) Apoptosis: 
The process of apoptosis has adapted to function as a defense mechanism against 
intracellular infection (Barber, 2001). As an intracellular microbe, M. tuberculosis 
depends on viable macrophages as niche cells in which to replicate and survive (Kelly et 
al., 2008). Apoptosis of infected phagocytic cells may prevent dissemination of infection 
by reducing \ lability of intracellular M. tuberculosis and limiting its outgrowth (Keane et 
al.. 1997; Placido et al.. 1997). NO ma\ induce such apoptosis (Chan et al.. 2001). TNF-a 
is also required for induction of apoptosis in response to M. tuberculosis infection (Kcane 
et ai., 1997). Another potential mechanism for apoptosis-induced mycobacterial killing is 
that, as with host nuclear fragmentation, mycobacterial DNA may also be destroyed 
during apoptosis (Molloy and Kaplan, 1996). The selective induction of IL-IO by M. 
tuberculosis may lead to decreased TNF-a activity and reduced apoptosis of infected 
cells (Astarie-Dequeker et al., 1999). Human monocyte-derived macrophages infected 
with ;V/. tuberculosis are also partially susceptible to Fas-mediated apoptosis (Oddo et al., 
1998). In addition, increased expression of Fas ligand in infected macropiiages may also 
contribute to decreased macrophage apoptosis (Mustafa et al., 1999). A recent report 
suggested that the newly identified murine ipr gene is important in susceptibility to 
tuberculosis and proposed that macrophage apoptosis in vivo also plays a role in host 
defense against M tuberculosis (Pan et al., 2005). This emphasizes the importance of 
apoptosis in influencing the host response to infection. 
(4) Cytokine production driven by M tuberculosis: 
Cytokines are a group of hormone-like polypeptides that play a variety of 
regulatory roles in host defense against infection (Poveda et al., 1999). Once infection is 
established, a focal nonspecific inflammatory response follows. This response is 
regulated by a network of pro- and anti-inflammatory cytokines and chemokines (Crevel 
et al., 2002), which serve as signals of infection (Means et al., 1999). There are two kinds 
of cytokines, pro-inflammatory and anti-inflammatory. The pro-inflammatory cytokine 
network plays a crucial role in the inflammatory response and the outcome of 
mycobacterial function. This response is antagonized by anti-inflammatory mechanisms. 
In addition some cytokines may inhibit the production or the effects of pro-inflammatory 
cytokines in tuberculosis (Crevel et al., 2002). 
(a) Pro-inflammatory cytokines: 
(i) TNF-a: 
Tumor necrosis factor (TNF) is a prototypic proinflammatory cytokine that 
contributes significantly to the development of immunopathology in various disease 
states (Chakravart) et al., 2008). Stiinulation of monocytes, macrophages and dendritic 
cells with mycobacteria or mycobacterial products induces TNF-a production (Henderson 
et al., 1997; Valone et al., 1988), Tumor necrosis factor (TNF) is a central mediator of 
granuloma formation and control of bacilli spread synergizing with IFNy to hamper M. 
tuberculosis infection (Pacheco et al., 2008), induces macrophage activation and has 
immunoreguiatory properties (Tsenova et al, 1999). However, systemic spillover of 
TNF-a may account for unwanted inflammatory effects like fever and wasting (Crevel et 
a!., 2002). Thus, TNF-a has both adverse and beneficial effects in the human immune 
response (Tufariello et al., 2003). To limit the deleterious effects of TNF-a (Hernandez 
and Rook, 1994; Bekker et al., 2000), systemic production of TNF-a is downregulated 
(Friedland et al., 1995; Takashima et al., 1990). In spite of this, anti-TNF-a therapy in the 
treatment of tjberculosis is associated with an increased risk of developing tuberculosis 
(Keane and Gershon, 2002), mainly due to reactivation of a chronic infection (Keane et 
al., 2001). In addition, TNF-a has an important role in the maintenance of the 
granulomatous response in latent tuberculosis, and in maintaining the organization of the 
granuloma, the integrity of which contributes to the containment of M. tuberculosis 
(Tufariello et al., 2003). In the chronic phase of M. tuberculosis infection, TNF is 
essential for maintaining the structure of the tuberculous granuloma and may regulate the 
granulomatous response by exerting an anti-inflammatory effect through modulation of 
the expression of proinflammatory mediators (Chakravarty et al., 2008). 
(ii) IL-lp: 
Interleukin-ip (IL-IP), a major proinflammatory cytokine, has not been 
implicated in host-Mtb interactions. IL-ip is activated by processing upon assembly of 
the inflammasome, a specialized inflammatory caspase-activating protein complex 
(Master et al. 2008). This pro-inflammatory cytokine is produced mainly by monocytes, 
macrophages and dendritic cells (Dahl et al., 1996; Gerosa et al.. 1999). It is expressed in 
excess (Schauf et al., 1993) and at the site of disease in tuberculosis patients (Bergeron et 
al., 1997). IL-IR antagonist (IL-lRa) is the naturally occurring antagonist of IL-I. It has 
been suggested that an increased IL-lp/lL-lRa ratio protects against a more severe 
presentation of tuberculosis, especially tuberculosis pleuritis (Wilkinson et al.. 1999). 
(iii) IL-6: 
This is an earl\ c}'tokine, which has both pro- and anti-inflammatory properties 
(VanHeyningen et al., 1997) and is produced at the site of infection (Hoheisel et al., 
1998). IL-6 nay be harmful in mycobacterial infections, as it inhibits the production of 
TNF-a and I'^-ip (Schindler et al., 1990). However, other reports indicate a protective 
role for IL-6. which seems related to optimal IFN-y production early in M. tuberculosis 
infection (Ladel et al., 1997a). 
(iv) IL-12: 
12 
lL-12 is produced mainly by pliagocytic cells after phagocytosis of M. 
tuberculosis (Ladei et al., 1997b). It is an important early pro-inflammatory cytokine that 
drives the production of IFN-y from natural killer (NK) cells (Trinchieri, 2003). Thus, IL-
12 is the inducer cytokine and IFN-y is the effector cytokine that mediates protection 
(Ismail et al., 2002) as discussed further. IL-12 is a regulatory cytokine that connects the 
innate and adaptive host response to mycobacteria (Trinchieri, 1995) and which exerts its 
protective effects mainly through the induction of IFN-y (Cooper et al., 1997). In 
tuberculosis, IL-12 has been detected in lung infiltrates (Taha et al., 1997), and in 
granulomas (Fkrgeron et a!., 1997). The expression of IL-12 receptors is also increased at 
the site of disease (Zhang et al.. 1999). Three additional cytokines with IL-12-like 
activities have been identified, notably IL-I8, IL-23 and IL-27 (Vosse et ai., 2004). IL-
18, a novel p:-o-inflammatory cytokine shares many features with IL-1 (Dinarello et al., 
1998) and acts as an IFN-y inducing factor, synergistic with IL-12 (O'Neill and Greene, 
1998). It also stimulates the production of other pro-inflammatory cytokines, 
chemokines, and transcription factors (Netea et al., 2000). IL-15 is similar to IL-2 in its 
biological ac:ivities and stimulates T cell and NK cell proliferation and activation 
(Kennedy and Park, 1996). However, unlike IL-2, the production of IL-15 is mainly by 
monocytes and macrophages (Crevel et al., 2002). 
(v) IFN-y: 
Mycobacterium tuberculosis is an exceptionally successful human pathogen. A 
major component of this success is the ability of the bacteria to infect immunocompetent 
individuals and to evade eradication b\' an adaptive immune response that includes 
production of the macrophage-activating cytokine, IFN-*. Although IFN-* is essential for 
arrest of progressive tuberculosis, it is insufficient for efficacious macrophage killing of 
the bacteria, which may be due to the ability of M. tuberculosis to inhibit selected 
macrophage responses to IFN-• (Kincaid et al., 2007). Production of !FN-y is regulated 
by other cytokines, particularly IL-12. In the early phase of the immune response, IL-12 
drives the production of IFN-y from NK cells (Trinchieri. 2003). Several immune 
mechanisms, such as antigen presentation, leukocyte-endothelium cell interactions, cell 
growth and apoptosis. reactive nitrogen and oxygen intermediates as well as phagosome-
lysosome fusion can be modulated through the activity of IFN-y (Houben et al., 2006). 
Activation of macrophages by IFN-y also induces autopliagy, wliich is a normal 
degradative pathway implicated in innate immune mechanisms against M tuberculosis 
(OgawaetaL, 2005). 
(b) Anti-inflammatory cytokines: 
The pro-inflammatory response is antagonized by anti-inflammatory mechanisms. 
Soluble cytokine receptors prevent binding of cytokines to cellular receptors, blocking 
further signalling (Crevel et al., 2002). Anti-inflammatory cytokines are also important in 
immuno-regulation. 
(i) lL-10: 
In tuberculosis (TB), interferon-gamma (IFNy) is crucial to control intracellular 
growth of Mycobacterium tuberculosis while interleukin-10 (IL-IO) has an antagonistic 
role (Pacheco et al., 2008). IL-10 is produced by macrophages after M tuberculosis 
phagocytosis (Shaw et al., 2000) and after binding of LAM (Dahl et al., 1996), by 
dendritic cells and macrophages (Tufariello et al., 2003). IL-IO dovvnregulates the 
production of the pro-inflammatory cytokines IFN-y, TNF-a and IL-I2 (Fulton et al., 
1998; Hirsch et al., 1999). lL-10 can deactivate macrophages and dampen the immune 
response to prevent or limit pathology from an over-exuberant inflammatory response to 
a pathogen. This cytokine may have a role in the chronic phase of infection, since 
dovvnregulation of a type I immune response is likely to be beneficial to the host, at least 
in terms of lung pathology (Tufariello et al., 2003). IL-IO expression in tuberculosis has 
been demonstrated in circulating mononuclear cells, at the site of disease in pleural fluid 
and in alveolar lavage fluid (Barnes et al.. 1993; Gerosaetal.. 1999). 
(ii) TGF-P: 
TGF-p is produced by monocytes and dendritic cells following induction by 
mycobacterial products (Toossi et al., 1995). TGF-(3 suppresses cell-mediated immunit)'; 
in T cells it inhibits proliferation and IFN-y production; in macrophages it antagonizes 
antigen presentation, pro-inflammatory cytokine production, and cellular activation. 
TGF-P may be involved in tissue damage and fibrosis during tuberculosis, as it promotes 
the production and deposition of macrophage collagenases (Toossi and Ellner, 1998). 
(iii) IL-4: 
lL-4 has deleterious effects in tuberculosis, vvhicli have been ascribed to this 
cytokine's suppression of IFN-y production (Powrie and Coffman, 1993) and 
macrophage activation (Appelberg et al.. 1992). 
(5) N F - K B activation - Role in innate immunity: 
It is well established that the classical NF-KB pathway, based on IKKP-dependent 
IKB degradation, is essential for innate immunity (Bonizzi and Karin, 2004). The 
activation and nuclear translocation of classical NF-KB dimers is associated with 
increased transcription of genes encoding chemokines, cytokines, adhesion molecules 
[intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 
(VCAM-1) ard endothelial-leukocyte adhesion molecule-1 (ELAM-1)]. enzymes that 
produce secondary inflammatory mediators and inhibitors of apoptosis (Ghosh et al., 
1998). These molecules are important components of the innate immune response to 
invading microorganisms and are required for migration of inflammatory and phagocytic 
cells to tissues where NF-KB has been activated in response to infection or injury 
(Bonizzi and Karin, 2004). Indirect pathways that lead to NF-KB activation are illustrated 
by infection of pulmonary epithelial cells with M. tuberculosis, which results in the 
release of IL-1 and activation of the classical NF-KB pathway in adjacent cells 
(Wickremasinghe et al., 1999). 
(B) Specific acquired/adaptive immune response: 
(1) T-ceii mediated immunity: 
In most infected individuals, cell-mediated immunit}' develops 2-8 weeks after 
infection. The development of cell-mediated immunity is associated with the 
development of a positive result in the tuberculin skin test (Frieden et al., 2003). 
Macrophages and dendritic cells, the primary cell types involved in the innate immune 
response to M. tuberculosis, play a crucial roie in the initiation of adaptive immunity 
(Crevel et al., 2002). The initial interaction of M. tuberculosis with phagocytes through 
TLRs can affect induction of the adaptive response by inflammatory cytokine production, 
as well as begin the process of bacterial containment bv induction of antimvcobacterial 
functions. The initiation of the adaptive immune response to the organism is likely to be a 
major determinant of long-term control of the infection (Flynn and Ernst, 2000). Thus, 
TLRs are an important link between innate and adaptive immunity (Duin et al., 2005). 
The significance of TLRs in activating adaptive immunity is well established (hvasaki 
and Medzhitov, 2004); TLR-mediated activation of dendritic cells is a crucial step in this 
process. Other mechanisms involved include induction of expression of cytokines and co-
stimulatory proteins (Duin et al., 2005). Signalling through TLRs favours the 
development of a Thl-type response, in which IL-12 has an important role (Trinchieri, 
2003). CD4^ T cells have a crucial role in protection against tuberculosis (Selwyn et al,, 
1989; Tufariello et al., 2003). In human beings, CD8"^  T cells have been reported to be 
involved in the control of both acute and chronic infection (Rolph et al., 2001; Turner et 
al., 2001). CDS"^  T cells specific for M. tuberculosis can directly kill intracellular bacilli 
via a granule-associated protein, granulysin (Stenger et al., 1998). 
In brief, at the focal site of infection in the lungs, the dendritic cells that engulf 
bacteria mature (Hertz et al., 2001; Bodnar et al., 2001) and migrate to the required 
lymph node. Once there, 004"^ and CD8^ T cells are primed against mycobacterial 
antigens. Primed T cells expand and migrate back to the lungs and through the lung tissue 
to the focus of infection, presumably in response to signals such as chemokines produced 
by or in response to infected cells (Tufariello et al., 2003). M. tuherculosis-'mkcted 
macrophages release IL-12 and IL-18 which stimulate the CD4^ and CD8^ T cells to 
release IFN-y (Sodhi et al.. 1997; Ellner. 1997). IFN-y is crucial for the control of M 
tuberculosis infection (Flynn et al., 1993). It stimulates phagocytosis of M tuberculosis 
and also the release of TNF-a from macrophages, which is important in granuloma 
formation and control of the extent of infection (Flynn et al.. 1995: Bean et al., 1999). 
Three processes contribute to the infection of adaptive immunity: antigen 
presentation, costimulation. and cytokine production. These are discussed below: 
(a) Antigen presentation: 
The T lymphocyte response is antigen specific and is influenced by the major 
histocompatibility complex (MHC) (Flynn and Ernst, 2000). MHC class II molecules are 
expressed on professional antigen-presenting cells (APCs). The\ present mycobacterial 
proteins to antigen-specific C'D4' T cells. These antigens are processed in the 
phagolysosomes of APCs (Crevel et al., 2002). MHC class I molecules are expressed on 
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all nucleated cells. They present mycobacterial proteins to antigen-specific CDS T cells. 
This is imporiant for the presentation of cytosolic antigens, which may be important as 
certain mycobacteral antigens may somehow escape the phagosome (Mazzaccaro et al., 
1996). Pro-inflammatory cytokines, primarily IFN-y stimulate MHC expression, whereas 
anti-inflammatory cytokines inhibit its expression. Polymorphism of MHC may 
contribute to differences in disease susceptibility or outcome (Goldfeld et al., 1998). The 
expression of particular class I and class II MHC alleles in an individual determines 
mycobacterial antigens and epitopes (Crevel et al., 2002). Certain allelic human 
leukocyte antigen variants (HLA polymorphism) have been associated with tuberculosis 
and susceptibility to it (Goldfeld et al., 1998; Ravikumar et al., 1999). 
(b) Costimulation: 
MaturEtion of dendritic cells induced by TLR stimulation results in accumulation 
of antigen-MHC 11 complexes on the cell surface, thus facilitating antigen presentation 
(Cella et al., 1997; Hertz et al., 2001). Antigen presentation only leads to T cell 
stimulation in the presence of particular costimulatory signals. The co-stimulatory 
proteins CD8J (Kindler et al., 1989), CD86 (Sarno et al., 1991) and CD70 are 
upregulated on antigen-presenting cells after TLR activation (Iwasaki and Medzhitov, 
2004). These molecules (CD80 and CD86) bind to CD28 and CTLA-4 on T cells (Crevel 
et al., 2002). In the absence of proper co-stimulatory signals, antigen presentation may 
lead to increased apoptosis of T cells (Hirsch et al.. 2001). 
(c) Cytokine production: 
Cytokine production by activated macrophages and dendritic cells is important for 
T cell .stimulation. These c}lokines include lL-12, IL-18, and lL-23 as well as lL-1 and 
TNF-u (Dinarello, 1996; Tsenova et al.. 1999; Oppmann et al., 2000). IL-12 is the 
inducer cytokine that mediates protection (Ismail et al., 2002). During the ensuing 
immune response, lL-12 plays a key part in driving the activation, differentiation from 
CD4^ T cells, and expansion of antigen-specific Thl cells. These cells are a major source 
of IFN-y during the adaptive immune response and are necessary for the control of the 
chronic phase of infection (.lanevvay and Medzhitov, 2002). The activation of infected 
macrophages by IFN-y in synergy with TNF-a is a major effector mechanism of cell-
mediated immunity. M tuberculosis induces TNF-a synthesis by a TLR2-dependent 
patliway (Underhill et al., 1999). IFN-y, together with TNF-a, which is released by T 
cells and phagocytes, activates microbicidal mechanisms in mononuclear phagocvles 
(Vosse et al.. 2004). 
(2) Granuloma formation: 
Tuberculosis (TB) is characterized by an inflammatory response that leads to 
containment, but not eradication, of bacteria within granulomas in the lung (Bhatt and 
Salgame, 200'''). The granuloma is a hallmark protective immunopathological response 
of the host following infection with M. tuberculosis. It is considered to be a protective 
structure since it curtails the spread of the pathogen and at the same time localizes 
inflammation and damage to the lungs (Salgame, 2005). Primed T cells in the lymph 
nodes expand and migrate back to the lungs and then through the lung tissue to the focus 
of infection in response to chemokine signals especially TNF-a. This culminates in the 
formation of a granuloma, a characteristic feature of tuberculosis (Tufariello et al., 2003). 
Besides T cells and infected macrophages, additional immune host cells are recruited, 
including B cells, dendritic cells, endothelial cells, fibroblasts, and probably stromal cells 
(Gonzalez-Juarrero et al., 2001). The granuloma encompasses the bacilli, which reside 
within macrophages, and serves to wall off the bacteria from the rest of the lung, limiting 
spread. In addition, the granuloma functions as an immune microenvironment to facilitate 
interactions be:ween T cells, macrophages and cytokines. However, the granuloma can 
also provide a home for M. tuberculosis for an extended period, because some bacteria 
can avoid elimination within the granuloma (Tufariello et al.. 2003). The granuloma 
subsequently develops central areas of necrosis (called caseum, from the word 'cheese"), 
resulting in the death of the majority of the bacteria and destruction of the surrounding 
host tissue. The surviving bacilli exist in a latent state and can become reactivated to 
develop active disease (Grosset, 2003). Proteosome-mediated inactivation of NO stress is 
important for the survival of mycobacteria within granuloma structures (Darwin et al.. 
2003; Pieters and Ploegh, 2003). Although excessive replication of bacteria seems to 
result in loss o*" granuloma structure. extensi\e necrosis, and cavity formation, in most 
cases the granuloma contains the infection, but a limited number of bacilli survive, which 
is termed latent tuberculosis. A person who has a delayed type hypersensitivity response 
to mycobacterial antigens (PPD) without signs of active tuberculosis is deemed to have 
latent infection and not to be contagious. 
The Bacterium: 
Mycobacterium tuberculosis was first isolated and demonstrated to be the 
aetiological agent of tuberculosis by Robert Koch in 1882 (Koch, 1882). Mycobacterium 
tuberculosis is a Acid Fast aerobic bacterium that divides every 16-20 hours. It is a small 
rod-like bacillus which can withstand weak disinfectants and can survive in a dry state for 
weeks but can only grow within a host organism. 
(A) M tuberculosis cell envelope - Architecture and composition: 
M tuberculosis is surrounded by a complex envelope of unusually low 
permeability, which contributes to the resistance of this bacterium to host defense 
mechanisms (.larlierand Nikaido, 1994; Daffe and Draper. 1998). In general, the bacterial 
cell envelope is composed of a plasma membrane, a complex wall comprising a variety 
of covalently and non-covalently linked carbohydrates and lipids, and finally an outer 
layer (capsule) of polysaccharides, proteins and small amounts of lipids. The plasma 
membrane is a typical bilayer of proteins and phospholipids (Daffe and Draper, 1998). 
Similar to classical bacterial cell walls, the cell envelope of M tuberculosis contains a 
cell membrane and a peptidoglycan la\'er (Glickman and Jacobs, 2001). The thick 
peptidoglycan layer is covalently linked to a heteropolysaccharide, namely 
arabinogalactan. However, in other aspects, the M. tuberculosis cell envelope differs 
substantially from the canonical cell wall structures of both Gram-negative and Gram-
positive bacte-ia (Fig. IA & IB). The cell envelope is typiiled by the presence of a large 
hydrophobic layer of unusual long-chain fatty acids: mycolic acids, esterified to the cell 
wall, named the mycolyl arabinogalactan (mAG) (Glickman and .lacobs, 2001). Mycolic 
acids are long chain (60-90 carbon atoms), branched, a-P h}droxyl fatty acids that exist 
either covalently attached to the cell wall or non-covalently attached in the form of 
trehalose dim_\colate (TDM). The arabinan segments of arabinogalactan in the 
peptidoglycan layer are terminated by a hexa-arabinosyl unit esterified by the various 
types of mx'colic acid residues elaborated b\ the species (Daffe, 2000). These long-chain 
fatty acids are probably arranged into an asymmetric biiayer with other non-covalently 
linked lipids, which forms a virtually impermeable outer barrier obstructing access of 
hydrophilic substances. Mycolic acids are thought to play an important role in the 
structure of the cell wall and to contribute to the resistance of mycobacteria to many 
therapeutic agents (Jarlier and Nikaido, 1994). Among the non-covalently linked lipids 
that can be found in the outer biiayer are TDM, trehalose monomycolates (TMM), 
glycerol monomycolates and phospholipids. A wide array of unique lipids and 
glycolipids are non-covalently associated with the cell envelope and confer extreme 
hydrophobicit) to the outer surface of the organism (Daffe, 2000). 
Many of these molecules are potent immunomodulators, suggesting a role in 
virulence. For example, lipoarabinomannan, a major cell wall-associated glycolipid, has 
been extensively examined in vitro and can inhibit IFN-y activation of macrophages 
(Sibley et al., 1988; 1990), induce TNF-a release from macrophages (Chatterjee et al., 
1992), and scavenge oxygen free radicals (Chan et al.. 1991). TDM, a mycolic acid-
containing glycolipid, can produce granulomatous inflammation and thymic atrophy 
when injected into mice (Ozeki et al., 1997), in addition to affecting membrane fusion in 
model systems (Spargo et al., 1991). 
Like Gram-positive bacteria, the mycobacterial cell envelope contains proteins, 
including some with pore-forming ability (Daffe, 2000). The increasing number of 
enzymes recently identified as being involved in cell envelope biogenesis includes the 
three predomirant secreted proteins of M tuberculosis, antigens 85A, 85B and 85C 
(VVikerandHarboe, 1992). 
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(B) M. tuberculosis antigen 85 complex: 
Culture filtrates of Mycobacterium tuberculosis H37RV highly enriched with 
secreted proteins were used to identify antigens recognized by a serum pool from 
tuberculosis patients (Malen et al.. 2008). 
The antigen 85 complex consists of three internally cross-reacting antigens 
encoded by three independent genes, JbpA, fbpB, JhpC, found in the genomes of M 
tuberculosis, M. leprae and M avium (Wiker et al., 1990; Content et al., 1991; Daffe, 
2000). In antigen 85 complex, the gene for antigen 85A encodes a 294 amino acid mature 
protein (Borremans et al., 1989), which shows 79% homology with the deduced 285 
amino acid sequence of antigen 85B (Matsuo et al., 1988). The antigen 85 complex is 
often referred to as the 30/31 kDa doublet and the molecular masses of the individual 
components of the antigen 85 complex are as follows: antigen 85B. 30 kDa; antigen 85 A, 
31 kDa; antigen 85C, 31.5 kDa. Antigen 85C appears to be slightly heavier than antigen 
85A, and in most SDS-PAGE runs these two components are not properly resolved 
(Wiker and Harboe, 1992). Thus, the pattern in Western immunoblotting usually reveals 
a doublet in the 30 kDa region, as exemplified by using the monoclonal antibody HYT27 
(Schou et al.. 1985) which reacts with all three components of the complex (Wiker et al., 
1992). The components are clearly resolved in isoelectric focusing, providing three 
distinct bands (Vooren et al., 1991). In M tuberculosis H37Rv culture fluid obtained 
from a batch with minimal cell lysis, the quantitatively dominating components of the 
antigen 85 complex, antigens 85A and 858. constituted about 60% of total protein and 
there was slightly more antigen 858 than antigen 85A. Although antigen 85 complex is a 
major constituent of the mycobacterial culture fluid, it is also found in association with 
the bacterial surface. The antigen 85 complex proteins are strongly immunogenic in 
natural and experimental m}'cobacterial infections in terms of both induction of antibody 
synthesis and T-cell-mediated reactions (Wiker and Harboe. 1992). The monoclonal 
antibody HYT27 gave a positive signal in ELISA with whole M tuberculosis cells 
(Schou et al., 1985). The localization index for antigen 85A has consistently been found 
to be higher than for antigen 858, indicating that antigen 858 may be less cfficienti}' 
secreted and more closely associated with the bacterial surface (Wiker et al., 1991; Wiker 
and Harboe. 1992). Worsaae et al. (Worsaae et al., 1988) performed skin testing with the 
22 
antigen 85 complex affinity purified with monoclonal antibody HYT27. The available 
results indicate that antigen 85B is a relatively good skin test reagent whereas antigen 
85A is not. The information on antigen 85C remains to be established (Wiker and 
Harboe, 1992), 
Antigen 85B is a mycolyl transferase involved in cell wall biosynthesis. In an in 
vitro enzymatic assay, antigen 85B has been shown to catalyse the transfer of a mycolyl 
residue from one molecule of TMM to another, leading to the formation of TDM (or cord 
factor) (Belisle et al., 1997). it stimulates lymphocyte blastogenesis and IFN-y production 
in healthy individuals, but not in patients with pulmonary tuberculosis (Huygen et al., 
1988; Havliret ai., 1991). In contrast, antibody to the 85B antigen is increased in patients 
with tuberculosis (Torres et al., 1994). Interestingly, antigen 85B is immunodominant 
(Abou-Zeid et al., 1988) and potently induces TNF-a when complexed to fibronectin in 
mononuclear phagocytes (Aung et al., 1996). Fibronectins are a family of high molecular 
weight glycoproteins found in plasma and tissues that are involved in cell motility and 
adhesion, regulation of cell morphology, phagocytic function, and wound healing 
(Proctor, 1987). The expression of 85B in M tuherculosis-mkcted monocytes correlates 
positively with both the amount of secreted TNF-a and subsequent intracellular 
mycobacterial growth (Wilkinson et al.. 2001). Antigen 85B mRNA in both broth 
cultures and sputum specimens correlates well with the yield of viable M tuberculosis 
(Desjardin et al., 1999; Hellyer et al., 1999). 
Modern laboratory diagnosis of tuberculosis: 
The emergence of multidrug-resistant M tuberculosis strains, and increasing co-
infection with HIV has fuelled the current pandemic and global resurgence in 
tuberculosis (De Cock and Chaisson, 1999; Drobniewski et al., 2003). Early diagnosis of 
tuberculosis and drug resistance improves survival and by identifying infectious cases, 
promotes contact tracing, implementation of institutional cross-infection procedures, and 
other public health actions (Drobniewski et al., 2003). 
(A) Active disease: 
Patients with persistent cough (eg., lasting longer than 2 weeks) should be 
assessed for tuberculosis (WHO. 2003a). Other common SNmptoms include fever, night 
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sweats, weight loss, shortness of breath, haemoptysis and chest pain (American Thoracic 
Society, 2000). 
(1) Microscopy: 
Introduced by Robert Koch in 1882. microscop\' remains a cornerstone of 
tuberculosis control because it identifies sputum-smear-posilive (most infectious) cases 
(Drobniewski et al., 2003). It is rapid and inexpensive, although it has limited specificity; 
the smear is positive in only 50-80% of individuals with culture-confirmed primary 
tuberculosis (Grzybowski et al., 1975; Frieden et al., 2003). Fluorescent staining methods 
offer higher specimen throughput and possibly greater sensitivity (Drobniewski et al., 
2003). 
(2) Culture-
Culture is required for definite diagnosis and is essential for drug-susceptibility 
testing. Rapid automated continuous mycobacterial liquid culture systems should be used 
in addition to solid culture (eg., the egg-based Lovvenstein-.[ensen medium or the agar-
based Middlebrook formulations. 7H10 or 7HI1). Solid culture media allows 
examination of colony morphology and the identification of mixed cultures, whereas 
liquid culture enables more rapid diagnosis (Frieden et al.. 2003). This is because growth 
generally occurs within 7-21 days in liquid media (Morgan et al., 1983). Solid media 
allows prolonged and inexpensive incubation of cultures, with growth occurring in 6 
weeks or longer. Positive cultures from these systems are analyzed using DNA 
hybridization or comparable systems for the presence/identification of M. luberculosis 
(Drobniewski et al., 2003). 
(3) Radiographic findings: 
Findings indicative of tuberculosis include upper-lobe infiltrates, cavity 
infiltrates, and hilar or paratracheal adenopathy. However, radiographic findings may be 
subtle or difficult to interpret in HIV-infected patients (Perlinan et al., 1997; Frieden et 
al.,2003). 
(B) Latent infection: 
The condition of clinical latency in the presence of infection with live M. 
tuberculosis is described as latent tuberculosis infection (Drobniewski et al., 2003). This 
is demonstrated by a positive reaction to a tuberculin skin test. 
(1) Tuberculin skin test (TST): 
The tuberculin skin test (TST) has been used for diagnosis of both active and 
latent tuberculosis (Lee and Holzman, 2002). The intradermal administration of 
tuberculin has been used as a diagnostic test for tuberculosis infection since the early 
nineteenth century (Von Pirquet, 1909); the more consistent form of tuberculin, 
standardized purified protein derivative (PPD-S), has been used to assess latent M 
tuberculosis infection since 1939 (Seibert and Gltn, 1941; Lee and Holzman, 2002). The 
TST attempts to measure cell-mediated immunity in the form of a delayed-type 
hypersensitivity response to PPD, which is a crude mi.xture of antigens, many of which 
are shared among M. tuberculosis. M. bovis BCG and several non-tuberculous 
mycobacteria. Thus, its limitations include low sensitivity in immunocompromised 
patients (with depressed immunity eg., AIDS patients), cross-reactivity with bacille 
Calmette-Guerin (BCG) vaccine and a requirement that patients must return 48-72 hours 
after the test is done to have the result read b\' measuring the induration (Huebner et al.. 
1993). 
(2). Interferon-y release assay (IGRA): 
Current diagnostic tests for tuberculosis (TB) are not able to distinguish active 
disease from latent Mycobacterium tuberculosis infection, nor are they able to quantify 
the risk of a latently infected person progressing to active TB. There is interest, however, 
in adapting antigen-specific gamma interferon (IFN-y) release assays (IGRAs) to predict 
disease outcome (Gillian et al., 2008). 
This is a whole blood cellular immune-based test that quantifies IFN-y response. 
IGR.A is based on the principle that T cells of individuals sensitized with tuberculosis 
antigens produce IFN-y when they re-encountcr m)'cobacterial antigens (Andersen et al., 
2000). A level of IFN-y production therefore, is presumed to be indicative of tuberculosis 
infection. An enzyme-linked immunospot (ELISPOT) assay, wiiicli measures IFN-y 
production from whole blood or peripheral blood mononuclear cells (PBMC) stimulated 
with either PPD or more specific antigens has shown promise as a test for latency 
(Lalvani et al., 2001; Doherty et al., 2002). [GRAs have several advantages over the TST 
(Lalvani, 2003; Barnes, 2004). Because the test is done in vitro and does not involve 
measurements such as skin induration, the results are less subjective, and a single visit by 
the patient is adequate. Newer assays that use M (uberculosis-specific region of 
difference 1 (RDl) antigens may have advantages over the PPD-based TST, in terms of 
higher specificity (Andersen et al., 2000; Lalvani, 2003), better correlation with exposure 
to M. tuberculosis, and less cross-reactivity due to BCG vaccination and non-tuberculous 
mycobacterial infection. 
Treatment and control: 
The goals of treatment are to ensure cure without relapse, to prevent death, to stop 
transmission, and to prevent the emergence of drug resistance (Frieden et al., 2003). To 
control tuberculosis, WHO and lUATLD recommend the DOTS (WHO, 2002), which 
has five elements: political commitment, diagnosis primarily by sputum-smear 
microscopy among patients attending health facilities, short-course treatment with 
effective case management (i.e., direct observation), regular drug supply, and systematic 
monitoring to assess outcome of every patient started on treatment. The international 
targets for tuberculosis control by 2005 are to detect 70% of new pulmonary smear-
positive cases annually and to treat 85% of detected cases successfully (WHO, 2000). 
Tumor necrosis factor-alpha (TNF-a): 
TNF-a was first discovered in 1975 as a macrophage-derived molecule that 
induced a haemorrhagic necrosis of tumors transplanted subcutaneously in mice 
(Carswell et al.. 1975). It is a member of the TNF superfamily of cytokines, consisting 
mainly of homotrimeric proteins involved with immune regulation and inflammation that 
includes lymphoto.xin-a (TNF-P). CD40 ligand and Fas ligand (Darnay and Aggarvval. 
1999). TNF-a is a pleiotropic cytokine that plays a central role in inflammation and 
apoptosis (Sedgwick et al.. 2000; MacEwan, 2002). It is synthesized as a 26 kDa, type II 
transmembrane protein that is 233 amino acids in length (Pennica et al., 1984; MacEwan, 
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2002). It contains a 30 amino acids cytoplasmic domain, a 26 amino acids 
transmembrane segment, and a 177 amino acids extracellular region (Wang et al., 1985; 
Ishisaka et al., 1999). TNF-a is assembled intracellularly to form a transmembrane, non-
covalently-linked homotrimeric protein. The 157 amino acids residue soluble form of 
TNF-a (sTNF-a) is released from the C-terminus of the transmembrane protein through 
the activity of TNF-a-converting enzyme (TACE), a membrane-bound disintegrin 
metalloproteinase(Mosset al., 1997; Kriegler et al., 1988). 
The granulomatous immune response is characterized by delayed hypersensitivity 
and is mediated by various cytokines released by the stimulated mononuclear phagocytes, 
including TNF-a (Morimoto et al., 1989; Ellner and Wallis, 1989). TNF-a is a pro-
inflammatory cytokine and following appropriate stimulation, many cells produce TNF-
a. The main cellular sources of TNF-a during an inflammatory response are monocytes 
(Frankenberger et al., 1996) and macrophages (Sakurai et al., 1985), but it can also be 
produced by other cells including NK cells. T and B lymphocytes (Ware et al., 1992), 
mast cells (Bissonnette et al., 1995), dendritic cells (Zhou et al., 1995), astrocytes (Lee et 
al., 1993), osteoblasts (Modrovvski et al., 1995) and neurons (Tchelingerian et al.. 1996). 
Expression of the TNF-a gene in macrophages can be stimulated by both exogenous and 
endogenous factors: bacteria, viruses, parasitic organisms, irradiation, trauma, ischemia, 
cytokines [IL-lp, IL-2, IFN-y, granulocyte macrophage colony-stimulating factor (GM-
CSF) and macrophage colony-stimulating factor (M-CSF)] and by TNF-a itself (Larche 
et a!., 2005). Lipopolysaccharide (LPS) and bacterial products are strong stimuli of TNF-
a synthesis (Bazzoni and Beutler, 1996). TNF-a is recognized as a significant mediator of 
macrophage activation for intracellular killing of bacilli following ingestion b> 
phagocytic cells (Wallis et al., 1993). Evidence is accumulating that TNF-a is vital to 
host defense and antibacterial resistance against infections caused by facultative 
intracellular organisms, particularly by M. tuberculosis which is a potent inducer of 
cytokine production (Valone et al., 1988; Takashima et al.. 1990). 
Although this cytokine is involved in multiple cell regulatory and differentiation 
processes leading to immunity in tuberculous infection, however, TNF-a also mediates 
effects deleterious to the host contributing to the pathoph}siology of tuberculosis. High 
levels of the cytokine at the site of infection induce an excessive damaging inflammatory 
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response that overwhelms its beneficial effects (Bekker et al., 2000). Therefore, an 
understanding of the mechanisms that regulate TNF-a expression is important in 
achieving a harmonious balance between the outcome of both its beneficial and 
pathologic effects. 
(A) Ligand structure and receptors: 
The crystal structure of TNF indicates that it is biologically active as a trimer, 
both as a soluble and as a transmembrane factor (McWhirter et al., 1999; Idriss and 
Naismith, 2000). The type H transmembrane protein TNF can be considered as the 
prototype of the TNF cytokine superfamily, a core group of structurally related ligands 
[encompassing lymphotoxin (LT)a. LTp, and LIGHT] (Locksley et al., 2001; Granger 
and Ware, 2001). The TNF cytokine family members interact with more than one 
receptor of the corresponding superfamily of cognate receptors (Fig. 2). These cytokines 
and receptors play important roles in the coordinated development of the immune system 
and the protection from pathogens (Pfeffer, 2003). 
Both the homotrimer TNF receptors, TNFR-I (TNFRp55: 55 kDa) and TNFR-II 
(TNFRp75: 75 kDa) interact with, and are involved in binding and signal transduction to 
both soluble and transmembrane TNF (Ehlers, 2003). However, the membrane-associated 
form mostly binds to TNFR-II, whereas soluble TNF preferentially binds to TNFR-I, 
with greater functional consequences than the former (Papadakis and Targan, 2000). 
TNFR-I contains a characteristic structural cassette, termed death domain, in its 
intracytoplasmic sequence that is conserved within a distinct subset of other TNFR 
family members, such as CD95, DR3, DR4 and DR5 (Tartaglia et al., 1993; Locksley et 
al.,2001). 
(B) TNF-a signal transduction machinery: 
TNFR-I has been shown to be essential for surviving infections with 
intracellular bacteria, such as M tuberculosis, Salmonella typhimurium, M. avium, 
Listeria monocytogenes (Pfeffer et al., 1993; Everest et al., 1998; Ehlers et al., 1999). The 
death domain is required for the signal transduction of the physiological functions of 
TNFR-I//7v/vo(Piitzetal., 1999). 
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TNF-a exerts its functions by interaction with the death domain-containing 
TNFR-I and the non-death domain-containing TNFR-11 (Fig. 2). hnportant proteins that 
interact directly or indirectly with the cytoplasmic domains of TNFR-1 and TNFR-I! are 
receptor-interacting protein (RIP), a serine/threonine kinase, and TNF receptor-associated 
factor (TRAF)-l and -2 (Orlinick and Chao, 1998; Verrecchia and Mauviel, 2004). RIP is 
required for NF-KB activation in response to TNF-a but not IL-1 or LPS (Kelliher et a!., 
1998). TRAF-1 and -2 define a novel group of adaptor proteins involved in signal 
transduction by most members of the TNF receptor family, of IL-1 receptor and IL-17 
receptor, as well as some members of the TLRs family (Verrecchia and Mauviel, 2004). 
TRAF-2 is currently the best characterized TRAF family member, having a key role in 
mediating TNFRI-induced signalling cascades leading to activation of NF-KB and JNK 
(c-Jun N-terminal kinase) (Wajant and Scheurich, 2001; Chen and Goeddel, 2002). 
(1) NF-KB activation pathway: 
NF-KB proteins are a family of cytoplasmic heterodimeric transcription factors 
that are inactive due to their association with an inhibitory protein IKB (Verrecchia and 
Mauviel. 2004). Potent activators, such as TNF-a, lL-1, or LPS, activate IKK complex 
(Bonizzi and Karin, 2004) (Fig. 3), Once activated, IKK induces rapid degradation of the 
IKBS (especially kBa) within minutes. For kBa this degradation process consists of a 
series of well-characterized steps, which seem to be relevant to the other IKBS (Baldwin, 
1996; Ghosh et al., 1998). Inducible IKB phosphorylation, one of the earliest events in the 
common activation pathway, occurs at serines 32 and 36 in kBa, and mutation of either 
serine (even to a threonine) greatly inhibits the degradation process (Traenckner et al., 
1995: DiDonato et al., 1996). Phosphorylation leads to the immediate recognition of kBa 
by the recently identified F-box/WD40 E3RS''^/p-TrCP (Yaron et ai., 1998; Laney and 
Hochstrasser, 1999; Maniatis, 1999), which consequently results in the 
polyubiquitinylation of kBa primarily at lysines 21 and 22 by an SKpl-Cullin-F-box 
(SCF)-type E3 (Scherer et al., 1995; Baldi et al., 1996). This modification then targets 
k'Ba for rapid degradation by the 26S proteasome. 
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(2) MAP kinase pathway: 
JNK is typically activated by a variety of physical and chemical stresses, but also 
by cytokines like TNF-a. JNK can be triggered by two members of the MAPK kinase 
(MKK): MKK4 and MKK7, which are targets of a variety of MAP3Ks (such as apoptosis 
signal-regulating kinase: ASK-1) which interact with TRAF-2. Thus, the pathway from 
TNFR-I to JNK might include TRADD, TRAF-2 and a MAP3K, initiating the kinase 
cascade leading to JNK and cJun (Verrecchia and Mauviel, 2004). 
(C) Induction of TNF-a hy Mycobacterium virulence factors: 
TNF-a exhibits both beneficial and pathologic effects, a feature that requires 
rigorous control of its expression (Yao et al., 1997). Regulation of human TNF-a 
expression in cells of monocytic lineage is quite complex, involving controls at both 
transcriptional and post-transcriptional levels (Han etal., 1990). Mycobacterial cell walls 
contain the polysaccharide LAM, which has a capacity for induction of TNF-a, through 
CD 14 and synthesis at the transcriptional level (Zhang et al., 1993), similar to that of LPS 
in Gram-negative bacilli (Moreno et al., 1989), There are structural similarities between 
LAM and LPS. The promoter region of the human TNF-a gene contains a complex array 
of potential regulatory elements, and studies indicate that maximal LPS induction of the 
TNF-a promoter is mediated by concerted participation of at least two separate c/.s'-acting 
regulatory elements (Yao et al., 1997). LAM has been considered an important virulence 
factor of M. tuberculosis with ability to downregulate IFN-y-inducible genes in 
macrophages, inhibit protein-antigen processing by antigen-presenting cells, scavenge 
superoxide anion, and decrease protein kinase C activity (Sibley et al., 1990; Chan et al., 
1991). Proteins v\ith the capacity to induce monocyte cytokine production, such as the 58 
kDa protein may also be particularly immunogenic (Wailis et al., 1993). 
(D) Role of TNF-a in tuberculosis: 
Tumor necrosis factor (TNF) is a prototypic proinflammatory cytokine that 
contributes significantly to the development of immunopathology in various disease 
states (Chakravarty et al,, 2008). TNF-a is a pleiotropic cytokine, and its role in harmful 
or beneficial inflammatory processes is complex (Keane, 2005). Regulatory processes, 
influenced b\' TNF-a, supporting a beneflcial outcome for the host are the following: 
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TNF-a has been shown to modify the endothelium and induce chemol<ine expression, 
thereby facilitating extravassation of monocytes and T cells from the blood and directing 
this migration of cells to the infected site (Ming et a!., 1987; Wuyts et al., 1998). Thus, 
TNF-a with its ability to regulate the expression of chemokines, chemokine receptors, 
and adhesion molecules, is a potent modulator of cell migration, which is important for 
granuloma formation (Sedgwick et al., 2000; Mohan et al., 2001). TNF-a also acts as a 
macrophage-activating factor in mycobacterial infection, facilitating intracellular killing 
of bacilli following ingestion by phagocytic cells (Bermudez et al., 1990). In addition, 
TNF-a has a role in apoptosis of macrophages infected with M tuberculosis (Keane et 
al., 2000), mediating macrophage apoptosis, which can kill the infecting bacillus (Keane 
et al., 2002). TNF-a production is a requirement for formation of granulomas, which 
sequester mycobacteria and prevent their dissemination. TNF-a is necessary for the 
accumulation and organization of monocytes, macrophages, and lymphocytes into well-
differentiated granulomas (Kindleret al., 1989). 
However, in addition to these protective effects, TNF-a also has detrimental 
pathogenic effects to the host, such as damaging inflammation leading to tissue necrosis 
(Rothstein and Schrieber, 1988). Excessive production of TNF-a and increased tissue 
sensitivity to the cytokine have been implicated in the immunopathology of tuberculosis, 
such as caseous necrotising reactions, which promote the replication and dissemination of 
the bacteria (Gardam et al., 2003). TNF-a may also mediate induction of HIV expression 
in latently infected cells in HIV co-infected tuberculosis patients (Fauci, 1991). TNF-a is 
also an important mediator of systemic inflammation, clinically manifested by fever and 
wasting. Depending on the production. TNF-a thus promotes containment or 
dissemination of M. tuberculosis and can contribute to both immune protection and 
pathology (Rook and Hernandez, 1996; Kaplan and Freedman. 1996). In the chronic 
phase of M tuberculosis infection, TNF is essential for maintaining the structure of the 
tuberculous granuloma and may regulate the granulomatous response by exerting an anti-
inflammatory effect through modulation of the expression of proinflammatory mediators 
(Chakravartyetal.. 2008). 
33 
(E) TNF-a blockade: Anti-TNF-a agents: 
A complication of TNF blockade therapy, whicli is used increasingly for the 
treatment of chronic inflammatory diseases, is the reactivation of latent tuberculosis 
(Chakravarty et al., 2008). Attenuation of the biological activity of TNF has lately 
become an important therapeutic intervention in the management of a wide variety of 
chronic inflammatory diseases (Shanahan and St Clair, 2002). Currently two major 
protocols are being used for the treatment of various chronic inflammatory diseases: 
Infliximab, an anti-TNF-a neutralizing antibody, and Etanercept, a recombinant molecule 
made up of two identical chains of the human 75 kDa TNF receptor II fused to the Fc 
portion of human IgGI (Gardam et al., 2003). 
Infliximab is a human-murine (25% murine) chimeric monoclonal antibody with 
high binding affinity (Bekker et al., 2000) and specificity for TNF-a (Knight et al., 1993). 
It forms stable complexes with the monomeric and trimeric forms of soluble TNF-a and 
with the transmembrane forms of TNF-a (Scallon et al., 2002). It also has the ability to 
cross-link TNF-a molecules. Binding to transmembrane TNF-a results in macrophage 
and monocyte lysis by cytotoxicity that depends on antibodies and complement 
(Lugering et al., 2001). Infliximab does not bind to related cytokines, such as TNF-P, 
which is involved in the ThI response (Falcone et al., 1994). 
There are subtle differences in the mechanisms of action of these two agents; in 
particular, drug-mediated apoptosis and monocytopenia appear to be unique to infliximab 
(Gardam et al., 2003). Infliximab binds more avidly than etanercept does to 
transmembrane TNF-a and form a more stable complex. More infliximab than etanercept 
binds to transmembrane TNF-a. Infliximab is more effective at inhibiting transmembrane 
TNF-a-mediated activation of endothelial cells. Infliximab binds both the monomeric and 
trimeric form of soluble TNF-a, whereas etanercept effectively binds only to the trimeric 
form. Etanercept-TNF-a complexes are unstable, resulting in the release of soluble TNF-
a. On the basis of these differences, infliximab might be predicted to have a more 
significant effect on the host's ability to suppress M. tuberculosis infection (Gardam et 
al.,2003). 
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Antibiotics: 
An antibiotic is a ciiemotherapeutic agent that inhibits or abolishes the growth of 
bacteria. The term originally referred to any agent with biological activity against living 
organisms, or more recently against micro-organisms, including bacteria, fungi, or 
protozoa; however modern usage of the term "antibiotic" is specific to agents with 
antibacterial activity. 
Streptomycin: 
Streptomycin is an antibiotic drug, the first of a class of drugs called 
aminoglycosides to be discovered, and was the first antibiotic remedy for tuberculosis 
(Blanchard, 1996). Streptomycin stops bacterial growth by hurting cell membranes and 
inhibiting protein synthesis. Specifically, it binds to the I6S rRNA of the bacterial 
ribosome, interfering with the binding of formyl-methionyl-tRNA to the 30S subunit. 
This prevents initiation of protein synthesis. Humans have structurally different 
ribosomes from bacteria, thereby allowing the selectivity of this antibiotic for bacteria. 
Second-line antituberculous therapy drugs are reserved for the treatment of tuberculosis 
in special situations in which there is drug intolerance or resistance to first-line therapy. 
Streptomycin, whose structure is depicted in Fig. 4A, is now considered a second-line 
drug because of the increasing prevalence of resistance in many parts of the world 
(Blumberg et al., 2003; Peloquin, 1993). 
Rifampicin: 
Rifiimpicin or rifampin (Fig. 4B), is a bactericidal antibiotic drug of the rifamycin 
group (Masters et.al.. 2005). Rifampicin was introduced in 1967, (Long and James, 1991) 
as a major addition to the cocktail-drug treatment of tuberculosis and inactive meningitis, 
along with isoniazid, ethambutol, and streptomycin. Rifamycin is the most commonly 
used as first-line therapy in combination with other agents for the treatment of 
mycobacterial infections, including tuberculosis (Centers for Disease Control 1994). 
Rifampicin resistance develops quickly during treatment and rifampicin monotherapy 
should not be used to treat these infections — it should be used in combination with other 
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antibiotics. With multidrug therapy (MDT) used as the standard treatment of leprosy, 
rifampicin is always used in combination with dapsone and clofazimine. 
Isoniazid: 
Isoniazid is also called isonicotinyl hydrazine or INH. Isoniazid is a first-line 
antituberculous medication used in the prevention and treatment of tuberculosis. 
Isoniazid (INH) (Fig. 4C) is the most prescribed chemotherapeutic agent for active TB 
and prophylaxis and requires activation by the catalase-peroxidase activity of KatG 
(Santos, 2008). Resistance to isoniazid (INH) is the most common form of drug 
resistance seen among Mycobacterium tuberculosis isolates (Kim, 2008). Isoniazid is 
bactericidal to rapidly-dividing mycobacteria, but is bacteriostatic if the mycobacterium 
is slow-growing. 
The current vaccine BCG is an attenuated strain of M bovis, which primarily 
causes bovine disease and is a close relative of M tuberculosis. This strain was generated 
in the early 1920s by the French researches Albert Calmette and Cannille Guerin b}' 
cultivation on solid medium containing bile (Kaufmann, 2005). Most studies have 
demonstrated that BCG vaccines afford a higher degree of protection against severe 
forms of tuberculosis, such as meningitis and disseminated tuberculosis, than against 
moderate forms of the disease (Girard et al., 2005). Even with high coverage, BCG has 
not had any substantial effect on transmission or incidence, because its main action is to 
prevent serious (but infectious) disease in children (Styblo, 1991). Adverse events from 
BCG vaccination can occur, including local subcutaneous abscess and ulcers, suppurative 
lymphadenitis, and, more rarely, disseminated disease (Lotte et a!., 1988). In addition. 
BCG vaccination may only provide protection against primary infection and be of little 
help in already infected individuals or in cases of reactivation tuberculosis (Smith and 
Starke, 2004). Despite continuing efforts to develop more effective tuberculosis vaccines, 
none have been identified to date. Even if one were to be developed, it might not prevent 
progression to active disease among the more than two billion people already infected 
with M. tuberculosis. Therefore, even if a new vaccine were to be implemented 
worldwide, more effective treatment systems would be required for decades (Frieden et 
al.,2003). 
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Fig. 4A: Chemical Structure of Streptomycin (C21H39N7O12) 
Fig. 4B: Chemical Structure of Rifampicin (C43H58N4O12) 
NH. 
Fig. 4C: Chemical Structure of Isoniazid (C6H7N3O) 
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Drawback of current treatment and control regimens: 
There is a growing body of clinical evidence that neutralization of TNF-a is 
associated with an increased risk of opportunistic infections, including mycobacterial 
diseases (Dinarelio, 2003). A major side effect of anti-TNF-a therapy is the increased risk 
of developing tuberculosis (Gardam et a!., 2003). TNF-blockade-associated tuberculosis 
shows granuloma disorganization, which may be deficient in restricting inflammation to a 
localized environment. This could lead to extension of the inflammatory response into 
otherwise unaffected lung tissues, resulting in the aberrant pathology observed in 
tuberculous patients treated with TNF blockade (Mohan et al., 2001). Treatment with 
anti-TNF-a antibodies readily leads to tuberculosis reactivation in patients with 
rheumatoid arthritis (Maini et al., 1999). 
In addition, drug-induced hepatotoxicity, a leading cause of liver injury, is an 
important and commonly encountered adverse effect with anti-tuberculosis treatment 
with three potential hepatotoxic drugs: isoniazid, rifampicin and pyrazinamide (Sharma, 
2004). Pyrazinamide was found to significantly contribute to the development of 
hepatotoxicity when given along with isoniazid and rifampicin (Yee et al., 2003). The use 
or misuse of these drugs over the years has led to an increasing prevalence of N4DR 
strains, establishing an urgent need to develop new effective agents (Cox et al., 2003). 
MDR-tuberculosis is defined as the disease due to tuberculosis bacilli resistant to atleast 
isoniazid and rifampicin, the two most powerful anti-tuberculosis drugs (Girard et al., 
2005). MDR TB is a form of drug-resistant TB in which the T'B bacteria can no longer be 
killed by at least the two best antibiotics, isoniazid (INH) and rifampin (RIF), commonly 
used to cure TB. As a result, this form of the disease is more difficult to treat than 
ordinary TB and requires up to two years of multidrug treatment (Meacci et al., 2005). 
The emergence and spread of multidrug-resistant (MDR) Mycobacterium 
tuberculosis (MTB) represents a worldwide health care problem because of the difficulty 
in treating these infections. Development of drug resistance in MTB arises mainly by 
mutation of chromosomal genes (Meacci et al., 2005). Molecular analysis of the drug 
resistance-related genes revealed that discrete subpopulations evolved over time from the 
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parental strain by acquiring and accumulating resistance-conferring mutations to 
isoniazid, rifampin, and streptomycin (Meacci et al., 2005). 
Natural products in tuberculosis prevention - Azadirachta indica 
(neem) extract: 
Scientists, of course, must go beyond myth and deal with factual evidence. 
Although the range of uses for Azadirachta indica, commonly known as neem, is 
amazingly di '^erse, interestingly, the intense scientific scrutiny paid to this ultimate herb 
has led to medical validation for many of these applications. Azadirachta indica is well 
known in India and its neighboring countries for more than 2000 years as one of the most 
versatile medicinal plants (Biswas et al., 2002). Azadirachta indica has attracted 
worldwide prominence in recent years, owing to its wide range of medicinal properties 
(Subapriya and Nagini, 2005). The neem tree is considered as the panacea for all diseases 
and has also been hailed as 'heal all', 'divine tree', 'village dispensary' and 'nature's 
drugstore' (Puri, 1999). 
Neem has been extensively used in Ayurveda, Unani and Homoeopathic medicine 
and has become a cynosure of modern medicine. Neem elaborates a vast array of 
biologically active compounds that are chemically diverse and structurally complex. 
More than 140 compounds have been isolated from different parts of neem. All parts of 
the neem tree- leaves, flowers, seeds, fruits, roots and bark have been used traditionally 
for the treatment of inflammation, infections, fever, skin diseases and dental disorders 
(Subapriya and Nagini, 2005). The oil from the neem leaves is recognized to possess 
antibacterial activity against a wide spectrum of Gram-negative and Gram-positive 
microorganisms, including M.tuberculosis and Streptomscin-resistant strains (Chopra el 
al.. 1952). Neem leaf is known to inhibit Vibrio cholerae, Klebsiella pneumoniae, M. 
tuberculosis and M. pyogenes in vitro (Satyavati et al., 1976). Mahmoodin, a limonoid 
isolated from A.indica showed significant antibacterial activity (Siddique et al., 1992). 
Neem leaves may affect spermatogenesis through antispermatogenic and antiandrogenic 
properties (Kasturi et al., 2002). 
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Fig. 5: Himalaya Neem is a pure herb extract. All parts of the tree including leaves, 
twigs, flowers, fruit and seeds are used. 
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Aqueous extracts of old and tender neem leaves were shown to completely 
immobilize and kill human spermatozoa within 20 seconds (Khillare and Shrivastav, 
2003). The water-soluble portion of 70 per cent ethanolic neem leaf extract was found to 
possess anti-inflammatory activity in rats (Chattopadhyay, 1998). A 75 per cent 
ethanolic extract of neem leaves in doses of 400 to 800 mg/kg had pronounced anti-
inflammatory effect on carrageenin-induced oedema in rats (Okpanyi and Ezeukwu, 
1981). The medicinal utilities have been described especially for neem leaf, its 
constituents have been demonstrated to exhibit immunomodulatory, anti-inflammatory, 
antihyperglycaemic, antiulcer, antimalarial, antifungal, antibacterial, antiviral, 
antioxidan';, antimutagenic and anticarcinogenic properties (Subapriya and Nagini, 2005). 
The aqueous extract of neem leaf exerts its immunostimulant activity by enhancing both 
humoral and cell mediated responses (Sen et al., 1992; Ray et al., 1996). Selective 
activation of the TH-1 component of lymphocyte population by neem leaf is believed to 
elicit and enhance cell-mediated immune response. Neem leaf extracts have been found 
to decrease both the classical and alternative C pathways and enhance the phagocytic 
activity of macrophages (Upadhyaya et al., 1993; Upadhyaya and ' Dhawan, 1994). 
Radical scavenging properties of neem leaf has reported (Chattopadhyay, 1998). Neem 
leaf has been documented to decrease the extent of lipid peroxidation. Experiments from 
this laboratory have shown that both aqueous as well as 70 percent ethanolic neem leaf 
extracts significantly reduce Nmethyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced 
lipid peroxidation, by enhancing the activities of glutathione dependent antioxidants as 
well as superoxide dismutase (SOD) and catalase (CAT) (Arivazhagan et a!., 2000; 
Subapriya etal., 2003). 
Aradirachta indica, is a common plant with rich medicinal attributes. 1~he 
aqueous extract is reported to contain several active substances and is known to posses 
anti-intlammatory. and immunomodulator> activities (Van Der Nat. 1987). The 
immunomodulatory activity of the neem-bark extract has also been reported (Van Der 
Nat, 1987). Anti-inflammatory, immunostimulant and antiulcerogenic actions have also 
been reported in the extracts of A. indica (Sen el al., 1992; Ray et al., 1996; Pillai et al.. 
1978; Balakrishnan et al., 1985). Anti-inllammatory action of Azadirachta indica show-
different i\pes of activity against acute and chronic intlammation. Azadirachta indica 
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shows strong inhibition of immediate or acute inflammation suggests it prevents the 
release of inflammation-inducing neurochemicals including prostaglandins. In fact, one 
1977 stud> showed neem extract to be more effective than aspirin in inhibiting 
prostaglandins (Journal of the West African Science Association, 1977, vol. 22). There 
have been attributed by several researchers to a strong Thl cytokine response, 
particularly IFN-gamma and TNF (Talwar et al; 1997). Increases in CDS cells have been 
reported (Talwar et al., 1997). Talwar also reports that Neem has "inhibitory action on a 
wide spectrum of micro-organisms, including Candida albicans, C tropicalis, 
gonorrhoeae, the multidrug-resistant Staphylococcus aureus and urinary tract Escherichia 
coli. Herpes simplex-2 and HlV-1." (Talwar et al., 1997). 
Furtiiermore, a neem compound azadirachtin also has great application in herbal 
medicine/healthcare products, especially for major skin diseases, anti-malarial, anti-
tuberculosis, anti-viral, anti-bacterial etc (National Research Council 1992). Oil from the 
leaves, seeds and bark possesses a wide spectrum of antibacterial action against different 
micro-organisms, including M. tuberculosis and streptomycin-resistant strains (Chopra et 
a!., 1952). In vitro, it inhibits M. tuberculosis and M. pyogenes (Satyavati, et al., 1976). 
Nimbidin, a major crude principle extracted from neem oil, has been identified as 
the active constituent of the oil (Pillai and Santhakumari, 1981; Biswas et al., 2002). It is 
a mixture of tetranortriterpenes including nimbin, nimbinin, nimbidinin, nimbolide and 
nimbidic acid and possesses potent anti-inflammatory, antiarthritic and antiulcer activities 
(Pillai and Santhakumari, 1981; Siddiqui and Mitra, 1945). Nimbidin also inhibited nitric 
oxide (NO) and prostaglandin E2 (PGE2) production in lipopolysaccharide (LPS) 
stimulated macrophages following in vitro exposure (Kauri et al., 2004). Inducible nitric 
oxide synthase (iNOS) activity measured in the presence or absence of nimbidin in 
CN'tosolic preparation of macrophages cultured with lipopolysaccharide (LPS) for 24 h but 
the concentration. 100 (ag/ml was not determined due to cytotoxicity of nimbidin (Kaur et 
al.. 2004). Nimbidin is, as such, a general anti-inflammatory drug and is effective in both 
acute and chronic states of inflammation. However, the mechanism of its action is 
ambiguous. Therefore, the present investigation probed into the mechanism of anti-
inflammatorv action of nimbidin and found it to significantly suppress some of the 
functions of macrophages and neutrophils relevant to inflammation (Kaur et ai., 2004). 
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Nimbidin is a major active principle of Azadirachta indica that helps in inflammation. 
Neem leaves and their constituents exhibit immunomodulatory, anti-inflammatory, 
antibacterial, antioxidant, and anticarcinogenic effects (Subapriya and Nagini, 2005). 
These properties are of immense value in skin conditions like acne and pimples, eczema, 
and dermatitis, it is also useful in preventing free radical-induced skin damage. 
Several workers studied the medicinal properties of the plant Azadirchata indica. 
The antipyretic effect (Okpanyi and Ezeukwk, 1981) anti-malarial effect, (Khattak et al., 
1985; Telia, 1977) anti-tumour effect, (Rochankij et al., 1985) anti-ulcer effect, 
(Fujiwara et al., 1982) anti-diabetic effect, (Pillai and Santhakumari, 1984), anti-fertility 
effect, (Shukia et al., 1973) effect on the central nervous system, (Sinha et al., 1984; Pillai 
and Shanthakumari, 1984) and cardiovascular effect (Singh et al., 1987) were some of 
the studies of the earlier workers. The International Scientific Communities neglected 
neem for a long time too. In 1992, US National Academy of Science published a report 
entitled, Neem—a tree for solving global problems (N.R.C., 1992). Immunomodulatory 
properties of different neem preparations (Biswas et. al. 2002) such as, activation of B 
cells, T cells and macrophages (Ray et al., 1996) have been reported earlier. Neem kernel 
oil induces secretion of gamma interferon (Upadhyay et al., 1992) and tumor necrotic 
factor-alpha (Thatte et al„ 1997). 
In tae present study, a pure herb extract of neem from Himalaya Company, India, 
available in capsules (250 mg) was employed for all investigations. It contained all parts 
of the tree including leaves, twigs, flowers, fruit and seeds are used (Fig. 5). Its principal 
constituents are nimbin. nimbinin and nimbidin. 
Objectives of the present study: 
The human immune response to M tuberculosis is not well characterized. To 
better understand the cellular immune response to tuberculosis, in the present study, a 
human monocyte culture system infected with M tuberculosis at an infective ratio of 1:1 
(bacteria:ce!l) was employed. Here we have examined the interaction of virulent M. 
tuberculosis (H37RV) with human monocytes, focussing on the role of TNF-a and M. 
tuberculosis 85B. In this investigation, a systematic study was carried out to characterize 
the sera md monocytes of tuberculosis patients with respect to TNF-a and M. 
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tuberculosis 85B by real-time RT-PCR, direct binding ELISA and competition ELISA. 
The modulatory effects of the natural antioxidant neem extract on M tuberculosis 85B 
expression in H37RV cultures were evaluated by real-time RT-PCR, SDS-PAGE. gel 
retardation assay, direct binding ELISA and competition ELISA. The interaction of M 
tuberculosis 85B and TNF-a after 24 hours of infection of human monocytes with M 
tuberculosis was investigated by RT-PCR and real-time RT-PCR. To fully delineate the 
contribution of the innate immune response to the pathogenesis of M tuberculosis 
infection, the roles played by reactive oxygen species (ROS), induction of TNF-a, 
activation of NF-KB and monocyte activation, in the expression of M tuberculosis 85B 
were examined. 
Toxicity assessment of neem extract on viability of human monocytes was 
assessed by cell viability assays like MTT and trypan blue exclusion assay as well as by 
assessing human housekeeping gene 18S rRNA by real-time RT-PCR. The effects of 
neem extract on expression of TNF-a and M. tuberculosis 85B in M tuberculosis-
infected monocytes after 24 hours of infection were probed by real-time RT-PCR and 
ELISA. The repertoire of TNF-a in supernatants of M tuberculosis-\nfQCit(^ monocyte 
cultures that were treated and untreated with neem extract was assessed by commercially 
available ELISA kits. Glutathione peroxidase activity as well as MDA levels was also 
evaluated in M tuberculosis-'mftcitA monocytes after 24 hours of infection in the 
presence or absence of neem extract. Furthermore, an attempt was also made to compare 
the effectiveness in down-regulating TNF-alpha and MTB 85B by neem extracts versus 
known antibiotics for TB. 
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Materials: 
Recombinant human (rh) TTvlF-a, monoclonal anti-TNF-a antibody, soluble 
TNFR-1, N-acetyl-cysteine (NAC), H2O2, SN50 (an inliibitor of NF-KB) and its analogue 
SN50/M, oxidized ATP (oATP), N*^-monomethyl-L-arginine-monoacetate, nonoate-9, 
sodium nitroprusside (SNP), agarose, bovine serum albumin, Coomassie Brilliant Blue 
G-250 and R-250, p-nitrophenyl phosphate, anti-human IgG alkaline phosphatase 
conjugate, Tween-20, TEMED (N,N,N'N'-Tetramethylethylinediamine), dithiothreiotol 
(DTT), phenylmethylsulphonyl fluoride (PMSF), protein A sepharose CL-4B, sodium 
azide, ethidium bromide, cumene hydroperoxide were from Sigma Chemical Company, 
U.S.A. Standard protein markers (PMW-B, Broad range) was from Genei, India. 
Chloroform and isoamyl alcohol were from Qualigens, India. Reduced glutathione, 
glutathione reductase and reduced ^-nicotinamide adenine dinucleotide phosphate were 
from HiMedia Chemical Company, India. SN50 is a hybrid peptide containing nuclear 
localization sequence of p50 subunit of NF-KB heterodimer and has been shown to 
completely inhibit the translocation of NF-KB in human cell lines at 100 jig/ml (Lin et al., 
1995). 
Neem extract from neem capsule was obtained from Himalaya Drug Company 
(Pure Herbs;), India. Ficoll-Paque was from Pharmacia, Piscataway, NJ, U.S.A. 
Middlebrook 7H9 broth, Middlebrook ADC enrichment fluid, RPMI-1640 medium were 
from HiMedia, India. MTT cell viability assay kit and immunoassay kits for TNF-a and 
its receptors were from R & D Systems, U.S.A. 12-wells tissue culture plates were 
obtained from Techno Plastic Products (TPP), Switzerland. Polystyrene microtitre flat 
bottom ELISA plates having 96 wells (7 mm diameter) were from NUNC, Denmark. All 
other chemicals were of the highest analytical grade available. 
Study subjects: 
Venou;< blood was obtained from healthy nonsmoking adult volunteers with no 
history of tuberculosis or positive tuberculin skin test. Also, blood from patients with 
active pulmonary tuberculosis was obtained from the patients admitted to J.N. N4edical 
College Hospital of A.M.U. The diagnosis of tuberculosis was based on demonstration of 
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acid-fast bacilli on sputum smear and later confirmed by positive culture of M 
tuberculosis. Serum was separated and stored at -20°C until required. 
Determination of protein concentration: 
Proteir was estimated by the methods of Lowry et al. (1951) and Bradford (1976). 
(A) Protein estimation by the Lowry (Foiin-Ciocalteau) method: 
Proteir estimation by this method involves complexing of the protein's peptide 
bonds with Cu"* under alkaline conditions (Lowry et al., 1951). The resultant Cu^ 
appears to catalyze the oxidation of tyrosine and tryptophan residues by reducing 
phosphomolybdotungstate anions in the Folin reagent (a mixture of sodium tungstate, 
molybdate and phosphate), added subsequently. This reaction develops a blue colour due 
to the formation of heteropolymolybdenum blue, which can be quantified by its 
absorbance at 660 nm. 
Reagents: 
(i) Folin-Ciocalteau reagent 
The reagent was diluted 1:4 with distilled water before use. 
(ii) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(a) 2% sodium carbonate in 100 mM NaOH 
(b) 0.5% copper sulphate in 1% sodium potassium tartarate 
The working reagent was prepared fresh before use by mixing the two 
compo Tents in the ratio 50:1, respectively. 
Procedure; 
To 1.0 ml of protein sample was added 5.0 ml of freshly prepared alkaline copper 
reagent. After thorough mixing, the reaction mixture was allowed to stand at room 
temperature for 10 minutes, followed by the addition of 1.0 ml of 1:4 times diluted Folin-
Ciocalteau reagent. The contents were mixed immediately. The reaction was allowed to 
proceed for 30 minutes at room temperature and each tube was subsequently monitored at 
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660 nm. The protein content of the unknown sample was determined by using bovine 
serum albumin to construct a standard calibration curve. 
(B) Protein estimation by the Bradford method: 
This method is based on strong binding of the dye Coomassie Brilliant Blue G-
250, in acidic medium, to protein hydrophobically, and at positively charged groups 
(Bradford, 1976). In the environment of these positively charged groups, protonation is 
suppressed and a blue color develops (A,max-595 nm). 
Preparation of dye: 
100 mg of Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% 
ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting solution 
was diluted to a final volume of 1.0 litre and filtered through Whatman No. I filter paper 
to remove undissolved particles. 
Procedure: 
To 1.0 ml of solution containing 10-100 fig protein was added 5.0 ml of dye 
solution. The contents were mixed thoroughly by vortexing. The absorbance was read at 
595 nm after 5 minutes against a reagent blank. 
Polyacrylamide gel electrophoresis of proteins: 
Polyacrylamide gel electrophoresis was performed under denaturing conditions as 
described by Laemmli (1970). 
Reagents: 
(i) Acr}'lainide-bisacrylaniide (30:0.8) 
A stock solution of 30% acrylamide containing 0.8% bisacrylamide was prepared 
by dissolving 30 gm of acrylamide and 0.8 gm of bisacrylamide in a total volume of 100 
ml. The solution was stored at 4"C in an amber coloured bottle. 
(ii) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48 ml of ! N 
HCl. The contents were mixed. pH adjusted to 8.8 and the final volume brought to 100 
ml with distilled water. 
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(iii) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH adjusted to 6.8 with 1 
N HCI and the final volume adjusted to 100 ml with distilled water. 
(iv) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled water, 
pH adjusted to 8.3 and the final volume made up to 1.0 litre with distilled water. 
(v) Sample buffer 
(a) 6.0 gm of Tris was dissolved in 80 ml distilled water and pH adjusted to 6.8 
with phosphoric acid. The final volume was brought to 100 ml with distilled 
water. 
(b) 1.0 mg of bromophenol blue and 12.5 ml of glycerol were added to 12.5 ml 
of the above solution. P-mercaptoethanol was added just before use. 
Recipe for 6-15% Gradient Gel 
Resolving Gel (total volume: 30 ml) 
Reagents 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10% SDS 
10% Ammoaium persulphate (APS) 
TEMED 
6% 
3.0 ml 
3.8 ml 
150[xl 
50^1 
12 (^1 
15% 
7.5 ml 
3.8 ml 
150^1 
50^1 
6 III 
The final volume was raised to 10 ml with distilled water. 
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2.5% Stacking Gel (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Stacking gel buffer 
10%SDS 
10% Ammonium persulphate 
TEMED 
0.8 ml 
2.5 ml 
100 ^l 
75^1 
25^1 
The final volume was raised to 10 ml with distilled water. 
Procedure: 
The glass plates (18 cm x 16 cm) were soaked in chromic acid and thoroughly 
washed with tap water followed by a final rinse with distilled water and ethanol. The 
plates were dried and sealed with 1% agarose using 1.5 mm thick spacers. The reagents 
were mixed and poured between the glass plates. The resolving gel was allowed to 
polymerize at room temperature, following which, the stacking gel was layered on top. A 
well-forming comb was inserted immediately and the gel was left to polymerize at room 
temperature. In case of gradient gels, a gradient of resolving gel was formed with the help 
of a gradient former (Bio-Rad, Model 385). After ensuring complete polymerization, the 
protein samples (20-100 ).ig) in one-fourth volume of sample buffer were electrophoresed 
at 80 volts at "oom temperature. The gels were stained using 0.25% Coomassie Brilliant 
Blue R-250 or with silver stain reagent. 
Silver staining: 
Silver staining was done by the method of .Merril et al. (1983). Briefl}'. the gel 
was incubated in 40% methanol and 12% acetic acid for 45 minutes followed by 
incubation in 50% ethanol for 30 minutes. Next the gel was treated with 0.02% hypo 
(sodium thiosilphate) for 1 minute. After washing with distilled water, the gel was placed 
in 0.2%) silver nitrate (with 0.05% v/v formaldehyde), washed again with distilled water, 
and transferred to a 6%) solution of sodium carbonate (with 0.05% v/v formaldehyde). 
After colour d^welopment, the gel was washed with distilled water and the reaction was 
arrested by treating the gel with 3% v/v acetic acid and 5% \7v methanol. All the reagents 
used in this procedure were freshly prepared. 
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Agarose gel electrophoresis: 
Agarose gel was prepared by bringing 2% agarose to molten state in 
electrophoresis buffer (0.04 M Tris acetate, pH 8.0 containing 0.002 M EDTA). Molten 
agarose was poured on the gel tray and allowed to solidify for ] hour at room 
temperature. The nucleic acid samples in one-tenth yolume of stop-mix (30% ficoil, 
0.025% xylene cyanole FF and 500 mM EDTA in lOX TAE buffer) were electropheresed 
for 2-4 hours at 30 mA in the same buffer. The gel was stained with ethidium bromide 
(0.5 ^g/ml). 
Fractionation of Mycobacterium tuberculosis culture filtrate proteins 
by gel filtration chromatography: 
The protein antigens in the culture filtrate were fractionated on a Sephadex G 200 
gel filtration column using equilibrating eluting buffer (15 mM phosphate buffered saline, 
pH 7.2 containing 0.05%) PMSF) (Garg et al., 2004). Protein was estimated in the 
fractions (each of 3.0 ml) by the Bradford method and the molecular weight was 
determined by the SDS-PAGE analysis of peak fractions along with standard protein 
markers (6-15% gradient PMW-B, Broad range; Genei, India). 
Enzyme-linked immunosorbent assay (ELISA): 
Antibodies were detected and quantified by ELISA using polystyrene flat-bottom 
microtitre plates as solid phase. The method described by Alam and Ali (1992). Islam and 
Ali (1998) were followed for the assay. 
Buffers and reagents: 
(i) Tris-buffered saline (TBS) 
lOmMTris, 150 mM NaCI, pH 7.4 
(ii) Tris-buffered saline Tween-20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCI and 1.0 ml/litre Tween-20, pH 
7.4 
(iii) Bicarbonate buffer 
15 mM sodium carbonate. 35 mM sodium bicarbonate, pH 9.6 
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(iv) Substrate buffer (for anti-human IgG alkaline phosphatase 
conjugate) 
15 mM sodium carbonate, 35 mM sodium bicarbonate and 2 mM 
magnesium chloride, pH 9.6 
Substrate: 0.5 mg/ml of p-nitrophenyl phosphate (p-NPP) 
(A) Direct binding ELISA: 
Polystyrene microtitre plates were incubated with 100 pi of protein antigen (30 
pg/ml in carbonate/bicarbonate buffer, pH 9.6) for two hours at room temperature 
followed by overnight incubation at 4°C. The plates were washed thrice with TBS-T and 
unoccupied sites were blocked by 150 pi of BSA (1.5% in TBS, pH 7.4) for 4-6 hours at 
room temperature. Serially diluted sera in TBS were added to antigen-coated as well as 
control (antigen uncoated) wells. The antigen-antibody interaction was allowed to 
proceed for two hours at room temperature followed by overnight incubation at 4°C and 
subsequently the plates were washed four times with TBS-T in order to remove the 
unbound antibodies. Bound a/itibodies were assayed by means of appropriate anti-
immunoglobulin alkaline phosphatase conjugate using p-NPP as substrate. The 
reaction was stopped with 3 N NaOH and the absorbance of each well was 
monitored at 405 nm on an ELISA microplate reader (Qualigens, India). Each 
sample vvas coated in duplicate and the results were expressed as a mean of Au-si -
''V c o n t r o l -
(B) Inhibition ELISA: 
The antigen binding specificity of antibody was determined by inhibition 
experiments (Hasan et al.. 1991). Varying concentration of inhibitors (0-20 pg/'ml) were 
mi.xed with a constant amount of antiserum or IgG. The mixture vvas incubated for two 
hours at 37T followed by overnight incubation at 4"C. The resulting immune complex 
was employed in the immunoassay instead of serum. The rest of the steps were as in 
direct binding ELISA. The results were expressed as percent inhibition. 
Ainhibited 
Percent inhibition = (1 ) x 100 
'^unin hibilt'd 
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Preparation of mycobacteria: 
Virulent laboratory-adapted M. tuberculosis (H37RV) strain were grown in 
Middlebrook 7H9 broth supplemented with Middlebrook ADC enrichment fluid at 37°C 
in 5% CO:. Mycobacterial cultures were harvested at midlogarithmic (14 days) phase. 
Aliquots of the stock were kept at -70°C until use. The viability of the stock remained 
>99% at 1 year. Before use, aliquots were defrosted, then vortexed with glass beads for 
15 minutes, followed by equilibration at 37°C for 45 minutes. This treatment results in 
single cell suspension of mycobacteria (Toossi et al., 1996). 
Preparation of neem extract: 
Azadirachta indica (neem) capsule was purchased from Himalaya Drug Company 
(Pure Herbs), India. The neem extract from capsule was dissolved in dimethyl sulfoxide 
(DMSO) (< 0.1%) and prepared in RPMI 1640 media. Thereafter the supernatant was 
collected by centrifugation at 1500 rpm and was membrane (0.22 ^m) filtered for in vitro 
uses. DMSO in culture media never exceeded 0.1% (v/v). For in vitro studies, nimbidin (a 
major crude principle extracted from neem oil) was dissolved in dimethyl sulphoxide, 
whose final concentration never exceeded 0.1% (Kaur et al., 2004). 
Isolation of mycobacterial antigens: 
Midlogarithmic mycobacterial cultures (14 days) were heat-killed at I00°C for 
one hour in a Doiling water bath, followed by centrifugation at 10,000 rpm for 30 minutes 
at 4°C. The culture filtrate containing secreted proteins was separated and stored at - 2 0 ^ 
until further use. 
(A) Desalting ofM. tuberculosis culture filtrate (MTCF) proteins: 
The supernatant was sterilized by filtration through a 0.22-micron pore size 
membrane (Millipore Corp., USA). MTCF was concentrated 50 fold by ammonium 
sulphate and dialyzed against 10 mM PBS, pH 7.4 for desalting. The protein content was 
determined by the method of Lowry et al. (1951) against a BSA standard. The culture 
filtrate preparations were stored in small aliquots at -20''C. 
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(B) M. tuberculosis sonic extract (MTSE) proteins: 
Heat-kilied bacilli were washed with sterile TBS, pH 7.4 and suspended in 
sonicating buffer containing I mM DTT, i mlM PMSF, 1.0 ^l/ml p-mercaptoethanol and 
proteinase inhibitors cocktail in TBS, pH 7.4. The cell suspension was disrupted by 
sonicating at 4°C for 15 minutes in a sonicator and the cell debris was removed by ultra 
centrifugal;on at 20,000 rpm for 15 minutes. The protein content was determined by the 
method of Lowry et al. (1951). The sonic extract preparations were stored at -20°C in 
small aliquots until required. 
Preparation of RPMI-1640 medium: 
Dehydrated RPMI-1640 medium of one unit vial (16.3 gm) (HiMedia, India), was 
suspended in 950 ml of tissue culture-grade water at room temperature with constant, 
gentle stirring until the medium was completely dissolved. The container was rinsed with 
tissue culture grade water to remove all traces of powder and added to the above solution. 
3.7 gm sodium bicarbonate was added to the medium and stirred until dissolved. The 
final volume was brought to 1000 ml with tissue culture grade water. The medium was 
sterilized immediately by filtering through a sterile membrane filter with a porosity of 
0.22 micron using positive pressure rather than vacuum to minimize the loss of carbon 
dioxide, and stored at 4°C until! use. 
Preparation of PBMC: 
Step 1: In order to isolate peripheral blood mononuclear cells (PBlVlC's), 60 ml of blood 
was drawn from a healthy volunteer into 60 cm' syringes containing 3.8 units 
heparin/ml. The heparinized blood, in 15 ml aliquots. was transferred to sterile 50 
ml polypropylene centrifuge tubes and diluted 1:1 with sterile 10 mM, PBS, pH 
7.4 at room temperature, followed by gentle mixing by inverting the tube a few 
times. 
Step 2: Diluted blood was underlayered with 15 ml of Ficoll-Paque at room temperature 
using an 18 gauge spinal needle. Care was taken to prevent mixing of the la\'ers. 
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The gradient was centrifuged at 1800 rpm for 30 minutes at room temperature with 
the centrifuge brake turned off 
Step 3: Using a sterile pipette, the upper clear layer containing plasma was removed. The 
PBMCs appeared as a dense white band (buffy layer) above the red blood cells 
and granulocytes layer. This was removed with another sterile pipette. The 
banded cells or buffy layer were combined in 10 ml aliquots. 
Step 4: Ten milliliters of banded PBMCs were diluted with 25 ml of PBS in sterile 50 
ml polypropylene centrifuge tubes and centrifuged at 1100 rpm for 12 minutes at 
room temperature to remove platelets, which remain in the supernatant. The 
PBMC pellets were combined to four tubes, diluted in 30 ml PBS and centrifuged 
at 1100 rpm for 10 minutes at room temperature. This wash was repeated. 
Step 5: The pellets were then combined and resuspended in 30 ml complete medium 
(CM) (RPMI-1640 medium containing 2 M L-glutamine, 25 mM HEPES, and no 
antibiotics). An aliquot was diluted 20-fold and counted using a hemocytometer 
under a light microscope using I Ox ocular and 40 x objective. 
Preparation of autologous serum for monocyte culture; 
From the same donor, 30 ml of blood was drawn without anticoagulant and 
transferred to serum separator tubes. The blood was allowed to clot for at least 30 
minutes, then centrifuged at 3000 rpm for 15 minutes at room temperature and the serum 
filtered through a sterile 0.22 p.m filter unit. Autologous serum can be stored for a year or 
longer at -20"C. 
Cell culture: 
PBMCs (5xl0^cells/vvell) were added in 12-vvells tissue culture plates in 
complete RPMI-1640 medium, and were subsequently incubated at 37°C, 5% CO2 for 1-
2 hours for adherence. Thereafter, non-adherent cells were removed by washing the 
plates extensively 4 times with RPMI-1640 medium. The adherent monocytes were 
cultured in RPMI-1640 supplemented with 2% autologous serum, followed by overnight 
resting at 37°C. 5% CO;. This population of adherent cells is up to 95% monocytes, as 
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observed by c>tostaining and is 99% viable (Toossi et a!., 1996). Prior to infection, the 
plates were washed twice with RPMl-1640 medium. 
Infection and co-culture of monocytes with supplements: 
Monocytes were infected with M. tuberculosis (H37RV) at 1:1 (bacteria/cell) in 
30% autologous unhealed serum for 90 minutes at 37°C, 5% CO2. Subsequent to this, the 
infected monocytes were washed four times with complete medium. Cells harvested at 
this time point were considered as time zero after infection (to). Other cultures received 
RPMl-1640 medium with 2% autologous serum. As per experimental design, some 
cultures, immediately after infection received 10 ng/ml anti-TNF-a antibodies, varying 
doses of neem extract (0-1000 pg/ml), 0-10 mM NMMA, 0-10 mM NAC, 0-100 ^g/ml 
Streptomycin, 0-100 (Jg/ml Rifampicin and 0-100 ng/ml Isoniazid. Also, some cultures 
received 10 nM H2O2, 100 )ig/ml SN50 and SN50/M. Cultures were then harvested after 
24 hours and cells were lysed in 0.5 ml of TRIZOL Reagent (Invitrogen Inc. Carlsbad. 
CA, USA). The cell-free culture supernatants were kept at -70°C. 
Treatment ynXh neem extract and monocytes viability assay: 
The effect of neem extract (0-1000 |ig/ml) on the viability of monocytes was 
assessed by using MTT Cell Viability Assay Kit ( R & D Systems) according to the 
manufacture's instructions provided. 
Reagents supplied in the kit: 
Component 
MTT reagent 
Detergent reagent 
Quantity 
25 ml 
250 ml 
Storage conditions 
2-8°C 
18-24°C 
Assay procedure: 
Adherent monocytes infected with M. tuberculosis (H37RV) at 1:1 (bacteria/cell) as 
described above were gently scraped with RPMl-1640 medium. After this, monocytes (3 
X 10 cells/well in 100 \i\) were added in 96-well tissue culture plates. Cells were 
incubated in RPMl-1640 with 2% autologous serum containing neem extract (100, 200, 
400, 600. 800 and 1000 Mgs/ml) for 24 hours at 37°C, 5% CO.. After 24 hours, 10 M1 of 
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MTT reagent (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) was added 
to each well and incubation was continued for an additional two hours. When a purple 
precipitate was clearly visible under the microscope, 100 \x\ of detergent reagent was 
added to all wells, including control wells and incubated for two hours in the dark at 20°C. 
After incubation, the precipitate was solubilized and the absorbance of the resulting 
solution was measured at 570 nm using a microplate reader. Control cells were treated 
exactly the same except that no neem extracts was added to the wells. The percentage of 
viable cells was calculated by the formula as described by (Islam et al., 2000) and the 
results were expressed as "Viable cells (% of control cells)". 
Absorbance value of control cells 
Viable monocytes (% of control cells) = x 100 
Absorbance value of treated cells 
Trypan blue exclusion assay for monocytes viability: 
Adherent, monocytes were gently scraped in RPlVII-1640 medium. Trypan blue 
suspension (1.6 mg/ml in saline solution) was added to the monocytes at a final 
concentration of 0.8 mg/ml. The cells were kept at 37°C for 7 minutes in a CO2 chamber 
(5%), mounted on a hemocytometer and then observed under light microscope. The cells 
taking up Trypan blue (dead cells), and cells excluding the dye (viable cells) were 
counted. Percentage of viable cells was calculated by the following formula: 
Total viable cells (unstained) 
% Cell viability = — x 100 
Total cells (stained plus unstained) 
TNF-a Immunoassay: 
The concentration of TNF-a in various monocyte culture supernatants as well as 
in serum of tuberculosis patients was determined by use of a commercial ELISA Kit (R 
& D Systems). This assay employed the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for TNF-a was available pre-coated onto a 
microplate. Standards and samples were pipetted into the wells and any soluble TNF-a 
present was bound by the immobilized antibody. After washing away any unbound 
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substances, an eizyme-linked polyclonal antibody specific for TNF- a was added to the 
wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate 
solution was added to the wells and colour developed in proportion to the amount of 
TNF-a bound in the initial step. The colour development was stopped and the intensity of 
the colour was measured. 
Reagents supplied in the kit: 
TNF-a microplate - 96 well polystyrene microplate (12 strips of 8 wells) coated with a 
mouse monoclonal antibody against TNF-a. 
TNF-a conjugate - 21 ml of polyclonal antibody against TNF-a conjugated to 
horseradish peroxidase, with preservatives. 
TNF-a standard - 10 ng of recombinant human TNF-a in a buffered protein base with 
preservatives, Ij'ophilized. 
Assay diluent RDIF - 6 ml of a buffered protein base with preservatives. It contained a 
precipitate and was mixed well before and during use. 
Calibrator diluent RD6-35 - 21 ml of animal serum with preservatives. 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution of buffered 
surfactant with preservatives. 
Colour reagent A - 12.5 ml of stabilized hydrogen peroxide. 
Colour reagent B - 12.5 ml of stabilized chromogen (tetramethylbenzidine). 
Stop solution - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Working reagents: 
Wash buffer - 20 ml of wash buffer concentrate was diluted into deionized or distilled 
water lo prepare 500 ml of wash buffer. 
Diluted calibrator diluent RD6-35 - 20 ml of calibrator diluent RD6-35 was mi.xed with 
80 ml ofdeionzed or distilled water to yield 100 mi of diluted calibrator diluent RD6-35. 
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Substrate solution - Colour reagents A and B were mixed together in equal volumes 
within 15 minutes of use to form substrate solution. It was protected from light. 
TNF-a standard - TNF-a standard was reconstituted with 1.0 ml of distilled water. This 
reconstitution produced a stock solution of 10,000 pg/ml. The standard was allowed to sit 
for a minimum of i 5 minutes with gentle agitation prior to making dilutions. 
Assay procedure: 
50 \i\ of assay diluent RDIF was added to each well of 96 well polystyrene 
microplate coated with a mouse monoclonal antibody against TNF-a. Thereafter, 200 1^ 
of standards, samples, or control per well was added, covered with the adhesive strip 
provided and incubated for 2 hours at room temperature. The plate was washed four 
times by filling each well with wash buffer using a squirt bottle. After washing, 200 |LII of 
TNF-a conjugate was added to each well, covered with a new adhesive strip and 
incubated for I hour for cell culture supernatants and 2 hours for serum samples at room 
temperature. After four washings with wash buffer, 200 1^ of substrate solution was 
added to each well and incubated for 20 minutes at room temperature in the dark, a blue 
colour appeared. Thereafter, 50 jul of stop solution was added to each well to stop the 
reaction. Then the absorbance of each well was determined within 30 minutes, using a 
microplate reader set to 450 nm. The cut off or lower limit of sensitivity was 4.4 pg/ml. 
Soluble TNFR-I and TNFR-II Immunoassay: 
The concentration of soluble TNFR-I in various culture supernatants was 
determined by use of commercial ELISA Kits (R&D Systems). 
Reagents supplied with TNFR-I kit: 
sTNFR-I microplate - 96 well polystyrene microplate (12 strips of 8 wells) coaled with 
a mouse monoclonal antibody against sTNFR-I. 
sTNFR-I conjugate - 21 ml of polyclonal antibody against sTNFR-i conjugated to 
horseradish peroxidase, with preservatives. 
sTNFR-I standard - 2.5 ng of recombinant human sTNFR-f in a buffered protein base 
with preservatives, lyophilized. 
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Assay diluent HDl-7 - 6 ml of a buffered protein base with preservatives. 
Calibrator diluent RD5-5 - 2 vials (21 ml/vial) of a buffered protein base with 
preservatives. 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution of buffered 
surfactant with preservatives. 
Colour reagent A - 12.5 ml of stabilized hydrogen peroxide. 
Colour reagent B - 12.5 ml of stabilized chromogen (tetramethylbenzidine). 
Stop solutio:n - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Reagents supplied with TNFR-II kit: 
sTNFR-II microplate - 96 well polystyrene microplate (12 strips of 8 wells) coated with 
a mouse monoclonal antibody against sTNFR-ll. 
sTNFR-II conjugate - 21 ml of polyclonal antibody against sTNFR-ll conjugated to 
horseradish peroxidase, with preservatives. 
sTNFR-II standard - 2.5 ng of recombinant human sTNFR-(I in a buffered protein base 
with preservatives, lyophilized. 
Assay diluent RDl-6 - 11 ml of a buffered protein base with preservatives. 
Calibrator diluent RD5-5 - 2 vials (21 ml/vial) of a buffered protein base with 
preservatives 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution of buffered 
surfactant with preservatives. 
Colour reagent A - 12.5 ml of stabilized hydrogen peroxide. 
Colour reagent B - 12.5 ml of stabilized chromogen (tetramethylbenzidine). 
Stop solution - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
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Working reagents: 
Wash buffer - 20 ml of wash buffer concentrate was diluted to 500 ml with distilled 
water to prepare wash buffer. 
Substrate solution - Colour reagents A and B were mixed together in equal volumes 
within 15 miiutes of use. 
sTNFR-I and sTNFR-II standards - sTNFR-1 or sTNFR-ll were reconstituted with 5 
ml of calibrator diluent RD5-5 to make a stock solution of 500 pg/ml. 
Assay procedure: 
50 n\ of assay diluents HDl-7 for sTNFR-1 and RDl-6 for sTNFR-II were added 
to each well of microplate coated with mouse monoclonal antibody against sTNFR-1 and 
sTNFR-II, respectively. Thereafter, 200 )il of standards and each sample (culture 
supernatants) were added to the wells and incubated for 2 hours at room temperature, 
followed by washing three times with wash buffer. 200 ^\ of sTNFR-I conjugate or 
sTNFR-ll conjugate were added to each well, incubated for 2 hours for TNFR-1 or 1 hour 
for TNFR-II at room temperature and washed thrice. Thereafter, 200 jil of substrate 
solutions were added and incubated for 20 minutes at room temperature, followed by the 
addition of 50 |.il of stop solution to each well to stop the reaction. Absorbance of each 
well was determined at 450 nm using a microplate reader. 
Measurement of M tuberculosis 85 complex protein by ELISA: 
An E-LISA for detection of the mycobacterial 85 complex (includes M 
tuhercidosis 85A. B. and C proteins) was used by the method of Islam et al.. 2004. 
Immunoplates of 96-wells were coated with 100 f.il of monoclonal antibody to 
mycobacterial 85 complex (CS-90; Colorado State University, Fort Collins) and 
incubated overnight at 4°C. The wells were then washed twice and then non-specific sites 
in the coated wells were blocked by the addition of 150 \x\ of 1.5% BSA and incubated 
for 4-6 hours at room temperature. The blocking solution was then removed from the 
w-eils. 100 \i\ of the samples was added to the wells and incubated at 37°C for 90 minutes. 
The wells were again washed two times. 100 \i\ of polyclonal rabbit ax\{\-A4ycohacteriiim 
bovis antibod) (Dako. Carpinteria. CA. US.A) as detection reagent was added to the wells 
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and incubated for 2 hours at room temperature. The wells were again washed four times. 
100 JJI of alkaline phosphatase-conjugated anti-rabbit IgG diluted 1:10,000 in TBS was 
added into the wells and incubated for 2 hours at room temperature. After another four 
washings, 100|al of p-NPP substrate solution was added into the wells and incubated at 
room temperature for about 30 minutes. The absorbance of each well was read at 405 nm 
on a microplate reader. Purified antigen 85 complex (Colorado State University) was 
used as a standard. The results from the specimens were compared to those of a serially 
diluted standard at 1-1000 pg/ml. 
Glutathione peroxidase assay: 
The activity of glutathione peroxidase (GPx) was measured as described 
elsewhere (Mohandas et al., 1984; Mates et al., 1999; Hasan et al., 2006). The oxidized 
glutathione (GSSG) produced during GPx reaction was immediately reduced by NADPH 
and glutathione reductase. Therefore, the rate of NADPH consumption was regarded as 
the rate of GSSG formation during the GPx reaction. M. tuberculosis-lnkcled monocytes 
v e^re co-cultured for 24 hours with or without 10 mM NAC, 100 i^g/ml SN50, 100 (^ g/ml 
SN50/M and 0-1000 t^g/ml neem extract in the presence or absence of 10 nM H2O2. 
Thereafter, cells were gently scraped with lysis buffer containing protease inhibitors (50 
mM Tris/HCl, pH 7.4; 1 mM EDTA; 500 mM PMSF). The ceil suspension was 
homogenized with a sonicator on ice and centrifuged at 10,000 rpm for 10 minutes. 
Protein concentrations of supernatants were determined by the method of Bradford with 
BSA as the standard, and were subjected to GPx activity determination. The reaction 
mixture (1.0 ml) containing 50 mM potassium phosphate (pH 7.0). 1 mM sodium azide, 2 
mM GSH. 0.2 mM NADPH, 1 unit/ml glutathione reductase, 1.5 mM cumene 
hydroperoxide, and 20-100 )al of samples were incubated at 25°C for 5 minutes. The 
reaction was initiated by the addition of cumene hydroperoxide. The kinetic change was 
spectrophotometricaliy recorded at 340 nm (37°C) for 3 minutes. GPx activity was 
calculated after subtraction of the blank value, as (.unol of NADPH oxidized/minute/mg 
protein (U/mg protein). 
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RNA extracitlon: 
After lysis of adherent infected/uninfected monocytes in 0.5 ml TRIZOL Reagent, 
the cell lysates were agitated with glass beads to complete cell wall disruption. After 
cooling on ice the tubes were again subjected to repeated disruption as above. The tubes 
were cooled and 200 fil of chloroform was added to each sample, followed by vortexing 
for 2 minutes, and centrifugation at 3000 rpm for 5 minutes. Samples were then 
transferred to fresh eppendorf tubes and centrifuged at 14,000 rpm for 15 minutes at 4"C. 
The aqueous layer was harvested and transferred to a fresh tube. After addition of 100 fil 
Cleanascite (CPG Inc., Lincoln Park, NJ, USA) (only for infected cells), samples were 
gently rocked for 10 minutes and then centrifuged at 14,000 rpm for one minute. The 
aqueous layer obtained was mixed with 500 (j.1 of chloroform-isoamyl alcohol (24:1) and 
vortexed. RNA was precipitated using 50 fil of I M sodium acetate and 475 \x\ of 
isopropanol at -20°C for 3 hours in the presence of glycogen. This was followed by 
centrifugation at 14,000 rpm and the pellet obtained was washed two times with 75% 
ethanol, and resuspended in 87 |il DEPC-water. DNAase 1 digestion (10 |.il of lOX 
DNAse I buffer in 0.5 M Tris pH 7.5, 0.1 M MgCb, I mM DTT; and 50 fig/ml BSA, 2.0 
jLiI RNAase inhibitor; lOU RNAase free DNAase 1) was employed to remove DNA. The 
reaction was stopped by the addition of 700 (il of 0.5 M NH4OAC and the RNA was re-
extracted using 500 ).il of acid phenol-chloroform (1:1). The aqueous layer was harvested, 
extracted again with chloroform-isoamyl alcohol and precipitated. 
Reverse transcriptase polymerase chain reaction (RT-PCR): 
The DNAase-treated RNA was subjected to reverse transcription using oligo (dT) 
primers with Superscript 11 reverse transcriptase (Invitrogen, Life Technologies, USA) 
according to the manufacturer's instructions. RNA (2 f,ig) was transcribed into cDNA in a 
20 jil reaction volume containing 50 mM Tris-HCl, pH 8.3, 75 mM KCI, 3 mM MgCb, 
10 mM DTT, 0.5 mM of each deoxynucleotide triphosphate, 25 f-ig/ml oligo(dT))2.i8 
primers and 10 U/\x\ of Superscript 11 reverse transcriptase, at 42"C for 50 minutes. The 
reaction was then stopped by heating at 70°C for 15 minutes followed by rapid chilling 
on ice. 
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PCR: The primers used in the PCR are listed in Table 1. cDNA for P-actin was 
amplified with various primer sets supplied by (Stratagene, La Jolla, CA, USA). For 
PCR, 2.0 )il of each cDNA sample was used as template in the PCR amplification. The 
reactions were carried out in a 50 j.il reaction volume containing 20 mM Tris-HCl, pH 
8.4, 50 mM KCl, 1.5 mM MgCb, 0.2 mM of each of the four dNTPs. 2U of Taq DNA 
polymerase (invitrogen) and 0.2 )iM of each forward and reverse primers. After initial 
denaturation for 2 minutes at 95°C, 35 cycles at 95°C for 15 seconds, 60°C for 45 
seconds were performed, followed by 72°C for I minute. The reaction products were 
visualized by electrophoresis in 2% agarose after staining with 0.5 fig/ml ethidium 
bromide. 
Quantitative Real-time RT-PCR: 
Real-time quantitative reverse transcriptase PCR (RT-PCR), provides a sensitive, 
reproducible, and accurate method for determining mRNA levels in tissues or cells. The 
method is based on the detection of a fluorescent signal produced and monitored during 
the amplification process, without the need for post-PCR processing (Held et al., 1996). 
Two important findings led to the discovery of real-time PCR. First, the Taq 
polymerase has a 5'-3' exonuclease activity (Holland et al., 1991), apart from its 
polymerase activity. Second, dual-labelled fluorogenic oligonucleotide probes have been 
created which emit a fluorescent signal only upon cleavage, based on the principle of 
fluorescence resonance energy transfer (Cardullo et al., 1988). In the TaqMan assay 
(Applied Biosystems, Foster City, CA, USA), these two principles are combined. In this 
system, a probe, the so-called TaqMan probe, is designed to anneal to the target sequence 
between the classical forward and reverse primers. The probe is duali> labelled, with a 
reporter fluorocnrome (eg., 5-carbofluorescein, or FAM) at one end and a quencher dye 
(eg., N,N,N',N'-tetramethyl-6-carborhodamine, or TAMRA) at the other end. In the intact 
probe, the fluorescence emission of the reporter dye will be absorbed by the quencher 
dye. The probe will be degraded during the extension phase by the 5-3 ' exonuclease 
activity of the Taq polymerase, separating the reporter and quencher, thus resulting in an 
increase in reporter fluorescence emission. The amount of fluorescence released is 
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directly proportional to the amount of product generated in each PCR cycle and thus can 
be applied as a quantitative measure of PCR product formation. 
Procedure: 
Internal fluorescent hybridization probes were used in ABl Prism 7700 Detection 
System (ABI/PerkinElmer (PE) Biosystems, Foster City, CA, USA), which allows the 
sensitive and specific quantification of individual host (Hartel et al., 1999), as well as M. 
tuberculosis RNA, transcripts (Wilkinson et al., 2001) by quantitative real-time RT-PCR. 
TaqMan PCf^  primers and probes as well as target-specific RT primer for each assay 
were designed as described elsewhere (Wilkinson et al., 2001; Islam et al., 2004). The 
primer and probe sequences used as depicted in Table. 1, have been previously reported 
(Islam et al., 2004; Hasan et al., 2006). The primer and probe combination for M. 
tuberculosis 858 is specific for 85B and does not detect the closely related 85A or 85C 
sequences. All probes were dually labeled with FAM at the 5' end and TAMRA at the 3' 
end. The proximity of the dye (FAM) and the quencher (TAMRA) on the intact probe 
prevents detection of any fluorescence. However, degradation of the probe during the 
course of PCR allows the release and detection of FAM (Holland et al., 1991). The PCRs 
for all amplifications were similar: 5 jxl of each cDNA, 20 jal of Taqman Universal PCR 
Master Mix (PE Biosystems), which contains optimal amounts of AmpliTaq Gold DNA 
polymerase (which protects against amplicon carryover) and of dNTPs, and optimal 
amounts of probe and primers calibrated to allow measurement of the targets. First, 
cDNA was synthesized in the presence of 0.5 jil of murine leukemia virus enzyme 
(Invitrogen, USA)/reaction and 10 (iM each RT primer. dNTPs, and other substrate. 
Conditions for PCR were similar for all products (1 cycle of 2 minutes at 50"C and 1 
cycle of 10 minutes at 95"C and then 40 cycles of 15 seconds at 95"C and 1 minute at 
60"C). The cycle threshold for each sample was compared with the cycle threshold values 
of known amomts of a standard DNA constructed for each target and amplified 
simultaneously. To assure lack of DNA contamination in the RNA samples, in some 
experiments, a duplicate tube of sample with no RT enzyme was included as control. DNA 
contamination remained negligible. In each sample, host 188 ribosomal RNA was used as 
the internal control. 
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Table 1. Sequences of primers and probes for quantification of iiuman TNF-a and M. 
tuberculosis 85B mRNA in infected monocytes. 
Target, strain, 
primer 
PCR primer sequence, Taqman probe sequence, 
J —>-? 
Human 
TNF-a 
RT 
Forward 
Reverse 
R18 
RT 
Forward 
Reverse 
CCAGAGGGAAGAGTTCCCCAGGGAC 
GGTTTCTACAACA 
AGGCGGTGCTTGTTCCTCA 
GTTCGAGAAGATGATCTGACTGCC 
ACCGGCGCAAGACGGACCAGA 
GACGGTATCTGATC 
CGCCGCTAGAGGTGAAATTC 
CATTCTTGGCAAATGCTTTC 
M. tuberculosis 
85B 
RT 
Forward 
Reverse 
16S 
RT 
Forward 
Reverse 
TCGAGTGACCCGGCATGGGAGCG 
TGTTGTTTGCGA 
TCAGGGGATGGGGCCTAGCC 
GCTTGGGGATCTGCTGCGTA 
AGCACCGGCCAACTACGTGCCAG 
CCCAGTAATTCC 
TTCTCTCGGATTGACGGTAGGT 
CGCTCGCACCCTACGTATTAC 
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Expression of TNF-a mRNA was corrected to internal control (iiost 18S rRNA) in the 
same sample and was expressed as copies of TNF-a in 10'° copies of R18 (equivalent to 1 
X 10 monocytes). M tuberculosis 85B mRNA was corrected to mycobacterial 16S rRNA 
in the same sample and expressed as 85B:16S. 
Intramonocyte Glutathione Assay: 
Glutathione (GSH) levels in treated or control monocytes were assayed by 
spectrophotometry, using a GSH assay kit (Calbiochem) as previously described by us 
(Hasan et a!., 2007). Monocytes were mixed with equal volume of ice cold 5% 
metaphosphoric acid and centrifuged at 3000 rpm for 15 min. Supernatants were used for 
GSH assay, as per the manufacturer's instruction. 
Assay for Malondialdehyde (MDA) levels: 
As a matter of fact, free radicals, because of their unstable and transient nature are 
difficult to measure directly. Their tendency to cause lipid peroxidation has been used as 
an indirect measure. Hence estimation of lipi.d peroxides (markers of lipid peroxidation), 
was carried out by measuring MDA (Malondialdehyde) as described earlier (Philpot, 
1963). 
Principle: One molecule of MDA reacts stoichiometrically with two molecules of 
thiobarbituric acid (TBA) at pH 3.5. The pink colour chromogen can be measured 
spectrophotometrically at 532 nm. 
Procedure: For assay 1 ml of serum was mixed with 2.5 ml of 20% trichloroacetic acid 
(TCA) and 1 ml of 0.67% of aqueous solution of TBA. The mixture was heated for 30 
minutes in boiling water bath, the pink pigment was extracted with 2 ml of n-Butanol and 
its absorbance vvas read at 532 nm against n-Bulanol as blank: 
OD of sample 
MDA X Cone, of standard MDA 
OD of standard 
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IFN-y assay: 
The amount of soluble secreted IFN-y in various culture supernatants was 
determined by use of commercial ELISA Kits ( R & D systems), according to the 
manufacturer's specifications (Hasan et al., 2007). 
Statistical analysis: 
Results were analyzed by paired t-test and the data expressed as mean ± SEM of 
six experiments unless otherwise specified. P<0.05 was considered statistically 
significant. 
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[A]: PRELIMINARY STUDIES ON CAUSATIVE ORGANISM THAT WERE 
EITHER UNTREATED OR TREATED WITH SUPPLEMENTS: 
(a) Effect of oeem extract on the expression of antigen 85 complex in H37RV 
cultures: 
M. tuberculosis (H37RV) was co-cultured in Sauton's media for 14 days with 
varying concentrations of neem extract (0, 200, 400, 600, 800 and 1000 |ag/ml). 
Thereafter, cultures were harvested and the bacilli were subjected to sonication to liberate 
intracellular proteins. Protein content was estimated in the untreated/treated M 
tuberculosis sonic extracts (MTSE) as well as M tuberculosis culture filtrate (MTCF). It 
is to be pointed out here that prior to any further study, the presence of 30/31-kDa 
protein band in the electrophoresed gel was ascertained b> El.ISA using anti-antigen 85 
complex antibody. As evident from Fig. 6A. the effect of neem extract on expression of 
M. tuberculosis antigen 85 complex (30/31 kDa) in M tuberculosis culture filtrate and 
sonic extract as revealed by gradient SDS-PAGE was found to be dose-dependent. Thus, 
in comparison to control cultures devoid of any neem extract (Lane 2), concentration of 
600, 800 and 1000 |igs/ml of neem extract proved lo be a potent inhibitor of antigen 85 
complex (30/31 kDa) protein expression. The inhibition was found to be dose -
dependent. Similar pattern were observed with sephadex G-200 purified MTCF (Fig .6B) 
as well as in MTSE (Fig. 6C). 
In addition, supernatants obtained from 14 da\s M. tuberculosis cultures (mid-
logarithmic phase), that were treated with various doses of neem extract, were subjected 
to ELISA to eva uate secreted M. tuberculosis antigen 85 complex. As evident from 
Fig. 7. the inhibiiion in secretion of antigen 85 complex b\ varying concentration of 
neem extract was found to be dose-dependent. Hence, this decrease in antigen 85 
complex secretion substantiates the above SDS-PAGE results. 
(b) Effect of Hydrogen per oxide on the expression of antigen 85 complex in 
H37RV cultures: 
M. tuberculosis {HyK\) was cultured in modified Sauton's media for 14 da)s 
with varying concentrations of hydrogen peroxide (0. 5. 10 and 20 nmol) in order to 
ascertain the proliferative effect of reactive oxygen species (ROS) on MTB Ag 85 
complex. Thereafter, cultures were harvested and the bacilli were subjected to sonication 
to liberate intracellular proteins. Protein content was estimated in the untreated/treated 
sonic extracts as well as culture supernatants (MTCF). As evident from Figs. 8 A&B, the 
effect of hydrogen peroxide on expression of M tuberculosis antigen 85 complex (30/31 
kDa) in M. tuberculosis culture filtrate (Fig. 8A) and sonic extract (Fig. 8B) as revealed 
by gradient SDS-PAGE was found to be dose-dependent. Thus, in comparison to control 
cultures devoid of any hydrogen peroxide, 10 and 20 nmol of hydrogen peroxide proved 
to be a potent enhancer of antigen 85 complex (30/31 kDa) protein expression. 
In addition, supernatants obtained from 14 days M. tuberculosis cultures, treated 
with various doses of hydrogen peroxide, were subjected to ELISA to evaluate secreted 
M. tuberculosis antigen 85 complex. As evident from Fig. 9. the secretion of antigen 85 
complex was found to be dose-dependent and increased linearly by an appreciable 
amount with 5,10 and 20 nmol of hydrogen peroxide reactivity. Hence, this increase in 
antigen 85 complex secretion substantiates the above SDS-PAGE results. 
(c) Effect of Hydrogen peroxide versus N- acetyl-L- cysteine (NAC) on the 
expression of antigen 85 complex in H37R^  cultures: 
M tuberculosis (H37RV) was cultured in Sauton's media for 14 days separately 
with varying concentrations of hydrogen peroxide (0, 5. 10 and 20 nM) as well as 10 mM 
NAC. Thereafter, cultures were harvested and the bacilli were subjected to sonication to 
liberate intracellular proteins. Protein content was estimated in the untreated/treated sonic 
extracts as well as culture supernatants (MTCF). As evident from Fig. 10. the effect of 
hydrogen peroxide on expression of ;l-/. tuberculosis antigen 85 complex (30/31 kDa) in 
A/, tuberculosis culture filtrate and sonic extract as revealed b> gradient SDS-PAGE was 
found to be dose-dependent. Thus, in comparison to control cultures devoid of any 
hydrogen peroxide (Lane 4-6 ). 5, 10. and 20 nmol of hydrogen peroxide proved to be a 
potent enhancer of antigen 85 complex (30/31 kDa) protein expression. On the contrary, 
co-culturing with NAC (10 mM), a decreased level in the expression of 85 complex was 
recorded (Lane 3, Fig. 10). 
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Fig. 6A: SDS-PAGE of Mycobacterial Protein: MTB (H37RV) was grown in modified 
Sauton's Media with different doses (0-1000 |ig/ml) of neem extract. Midlogaritliniic 
Mycobacterial cultures (14 days) were harvested and mycobacterial culture filtrate 
(MTCF) protein of 15 |ig of each sample were resolved by 6-15% gel SDS-PAGE 
under reducing condition. The gel was visualized by silver staining. Lane 1-marker 
and lane (2-7): 0,200, 400, 600, 800,1000 |ig/ml neem extract respectively. 
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Fig. 6B: SDS-PAGE of Mycobacterial Protein: MTB (H37RV) was grown in 
modified Sauton's Media with different doses (0-1000 |ig/ml) of neem extract. 
Midlogarithmic Mycobacterial cultures (14 days) were harvested and purified by 
sephadex G 200, mycobacterial culture filtrate (MTCF) protein (30/31 KD) of 15 
^g of each sample were resolved by 6-15% gel SDS-PAGE under reducing 
condition. The gel was visualized by silver staining. A single band obtained from 
lane (1-6): 1000, 800, 600, 400, 200 and 0 i^g/ml neem extract respect vely. 
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Fig. 6C: SDS-PAGE of Mycobacteria! Protein: Ml'B (H37RV) was grown in 
modified Sauton's Media with different doses (0-1000 [ig/m\) of neem extracl 
Midlogarithmic Mycobacterial cultures (14 days) were harvested and 
mycobacterial sonic extract (MTSE) protein of 15 ^g of each sample were 
resolved by 6-15% gel SDS-PAGE under reducing condition. The gel v/as 
visualized by silver staining. Lane 1-marker and lane (2-7): 0, 200, 400, 600, 800, 
1000 |ag/ml neem extract respectively. 
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Fig. 7: Dose response effect of Neem extract (0-1000 (ig/ml) on the secreted Ag 
85B protein in 14 days culture supernatants of Mycobacterium tuberculosis 
H37RV. The results are mean of 3 experiments (p<0.001). 
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Fig. 8A: SDS-PAGE of Mycobacterial Protein: MTB (H37RV) was grown in 
modified Sauton's Media with different doses of H2O2. Midlogarithmic 
Mycobacterial cultures (14 days) v.ere harvested and mycobacterial culture 
filtrate (MTCF) protein of 15 |ug of each sample were resolved by 6-15% gel 
SDS-PAGE under reducing condition The gel was visualized by silver staining 
Lanes (1)- Marker, (2)- cotiTrol, (3)- 5 nM H2O2, (4)- 10 nM H2O2, (5)- 20 nM 
H2O2 respectively. 
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Fig. 8B: SDS-PAGE of Mycobacterial Protein: MTB (H37RV) was grown in 
modified Sauton's Media with different doses of H2O2, Midlogarithmic 
Mycobacterial cultures (14 days) were harvested and mycobacterial sonic extract 
(MTSE) protein of 15 |ig of each sample were resolved by 6-15% gel SDS-PAGE 
under reducing condition. The gel was visualized by silver staining. Lanes (l)-
Marker (2)-control, (3)- 5 nM H2O2, (4)- 10 nM H2O2, (5)- 20 nM H2O2 
respectively. 
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Fig. 9: Dose response effect of Hydrogen peroxide (0-20 nM) on the secreted Ag 
85B protein in 14 days culture supernatants of Mycobacterium tuberculosis 
H37RV. The results are mean of 3 experiments (p<0.001). 
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Fig. 10: SDS-PAGE of Mycobacterial Protein: MTB (H37RV) was grown in 
modified Sauton's Meoia with different doses (0-20 nmol) of H2O2. 
Midlogarithmic Mjcooacterial cultures ( 4 days) were harvested and 
mycobacterial culture filtrate (MTCF) protein of 15 \ig of each sample were 
resolved by 6-15% gel SDS-PAGE unaei reducing condition. The gel was 
visualized by silver s aining. Lane (1) BS-X, '2)- control, (3)- 10 mM NAC (4)-
5 nM H2O2 + 10 mM N AC, (5)- 10 nM H-' M 0 mM NAC, (6)- 20 nM H2O2 ^  
10 mM NAC and (7)- • •:>. respecti\ < .y 
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In addition, supernatants obtained from 14 days K4. tuberculosis cultures, treated 
with various doses of hydrogen per oxide (0-20 nM) or NAC (0- 20 mM), were subjected 
to ELISA to evaluate comparatively, the secreted M. tuberculosis antigen 85 complex. As 
evident from Fig. 11, the secretion of antigen 85 complex was found increase in a dose-
dependent manner. On the contrary, NAC decreased the levels, in the expression of 85 
complex in a dose dependent manner (0-20 mlM) (Fig. 11).Hence, this decrease and 
increase in antigen 85 complex secretion substantiates the above SDS-PAGE results. 
(d) Effect of NADPH & NAC on the expression of antigen 85 complex in H37RV 
cultures: 
After ascertaining the comparative effect of H2O2 versus NAC, an attempt was 
also made to probe the comparative effect of NADPH versus NAC on MTB 85 complex 
(30/31 k Dal) protein expression. Thus, M. tuberculosis (H37RV) was cultured in modified 
Sauton's media for 14 days with concentrations of NADPH (10 nM) & NAC (10 mM). 
Thereafter, cultures were harvested and the bacilli were subjected to sonication to liberate 
intracellular proteins. Protein content was estimated in the untreated/treated sonic extracts 
as well as culture supernatants (MTCF). As evident from our data, the proliferative effect 
of NADPH on expression of A/, tuberculosis antigen 85 complex (30/31 kDa) in M. 
tuberculosis culture filtrate (Fig. 12) and sonic extract (data not shown) as revealed by 
gradient SDS-PAGE, was found to be dose-dependent. Thus, in comparison to control 
cultures devoid of any NADPH (Lane 3). 10 nmol of N.ADPH proved to be a potent 
enhancer of antigen 85 complex (30/31 kDa) protein expression. However after addition 
of NAC (10 niM) in 10 nM of NADPH, the expression level decreased upto considerabi} 
(Fig. 12). 
In addition, supernatants obtained from 14 da\s M. tuberculosis cultures, treated 
with various doses of NADPH and NAC. v\ere subjected to ELISA to evaluate secreted 
M tuberculosis antigen 85 complex. As evident from Fig. 13. the secretion of antigen 85 
complex was found to be dose-dependent and increased b\ an appreciable amount of 
NADPH (0-20 nM) whereas it decreased with addition of NAC (0-10 mM). Hence, this 
decrease and increase in antigen 85 complex secretions by NADPH and NAC 
respectiveh' substantiates the above SDS-PAGE results. 
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Fig. 11: Dose response effect of Hydrogen peroxide (0-20 nM) (Black bar) and 
NAC (0-10 mM) (empty bar) on the secreted Ag 85B protein in 14 days culture 
supernatants of Mycobacterium tuberculosis (H37RV). The results are mean of 3 
experiments (p<0.001). 
79 
205 KD WHWR ^% 
97.4 KO 
66 KD 
43 KD 
30 KD 
29 KD 
Fig. 12: SDS-PAGE of Mycobacterial Protein. MTB (HT;RV) was gniwn m 
modified Sauton's Media with NADPH & NAC. Midlogarithmic Mycobactena! 
cultures (14 days) were harvested and mycobacterial culture filtrate (MTCP) protein 
of 15 ng of each sample were resolved by 6-15% gel SDS-'^AGE under reducing 
condition. The gel v/as visualized h\ silver staining. Lanes (1)- Marker (2)-control, 
(3)-10 nM N,\DPH, (4)- 10 rtlVl .. .o?{ i +10 mM NAC respectively. 
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Fig. 13: Dose response effect of NADPH (0- 20 nM) (Black bar) and NAC (0- 10 
mM) (White bar) on the secreted Ag 85B protein in 14 days culture supernatants 
of Mycobacterium tuberculosis (H37RV). The results are mean of 3 experiments 
(p<0.001). 
(B) IMMUNOLOGICAL INVESTIGATION: 
Immunological characterization of sera and monocytes from patients with 
TB and MDR-TB: 
Prior to any in-depth study, an attempt was made to characterize the 
monocyles and sera from patients with active tuberculosis and MDR-TB as follows: 
(a) ELISA for Mycobacterial intracellular and secreted protein antigens: 
Before any in-depth investigations, the reactivity of sera from patients with TB 
(n=10) and MDR-TB (n=10) were probed against M. tuberculosis antigens secreted in 
M. tuberculosis (H37RV) culture filtrate (MTCF) as well as against intracellular protein 
antigens in bacilli sonic extract (MTSE). This was done so in order to ensure that our 
laboratory grown causative organism of MTB (H37RV) was in order or not. 
Direct binding ELISA on microtitre plates coated with total protein antigens of MTCF 
showed remarkable reactivity against antibodies found in sera of tuberculosis and MDR-
TB patients (Fig. 14). Most of the sera exhibited an antibody titre of greater than 1:12800. 
No binding was observed with negative control i. e. normal human sera (NHS). Similar 
binding were also observed on plates coated with total sonicate proteins (MTSE) (Fig. 
15). On the contrary, when MTCF and MTSE of i\4ycohaclerium tuberculosis (H37RV) 
co-cultured with neem extract as described in methods were used as coating antigen in 
direct binding ELISA. then an appreciably reduced antibody titre to the order of only 
1:400 were recorded with sera of patients with TB and MDR-TB (Fig. 16. 17). Thus, the 
direct binding results show that all the patients selected in this study had a high degree of 
active tuberculosis, and that, neem extract - a natural antioxidant / herbal component, 
reduced the immunobinding capability.Thereafter, the specificity of tuberculosis sera 
used in this stud} against M. tuberculosis antigens was probed by employing inhibition 
ELIS.A. The data obtained from inhibition ELISA exhibited high magnitude inhibition in 
tuberculosis sera antibody activity with MTSE and MTCF protein antigens. A maximum 
of 81.23% inhibition in antibody activity was achieved at a maximum inhibitor 
concentration of 10 |.ig/ml of MTSE protein antigens (Fig. 18). 50% inhibition was 
recorded at an inhibitor concentration of 0.9 )ig/ml. Similarly, with MTCF proteins as an 
inhibitor, a maximum of 73.11% inhibition in the antibody activitv was observed at a 
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maximum inhibitor concentration of 10 |ug/ml (Fig. 18), where 50% inhibition was 
achieved a: an inhibitor concentration of 1.7 |.ig/ml. Thus, inhibition data depicted in Fig. 
18 showed that the intracellular protein antigens, liberated from bacilli by sonication, as 
well as secretory MTCF protein antigens have high magnitude of specificity for 
tuberculosis antibody. Interestingly, co-culturing of H37RV with 1000 )ig/ml of neem 
extract reduced the immuno-binding against MTCF to insignificant levels (Fig. 18). 
Similarly, a high magnitude inhibition in MDR-TB sera antibody activity was 
recorded with MTSE and MTCF protein antigens. A maximum of 84.27% inhibition in 
MDR-TB antibody activity was recorded at a maximum inhibitor (MTSE) concentration 
of 10 |ig/ml (Fig. 19). Here, 50%) inhibition was achieved at an inhibitor concentration of 
0.09 (ig/ml. With MTCF, a maximum of 77.92% inhibition was recorded with 50%) 
inhibition in antibody activity being achieved at 0.2 |Lig/ml (Fig. 19). Thus, in comparison 
to antibody from sera of patients with TB, the results show 50%) inhibition was 
accomplished at a much lower inhibitor concentration in patients with MDR-TB. Similar 
to the observations made in Fig. 18, here again, we observed that co-culturing of MTCF 
with 1000 i-ig/ml of neem extract reduced the immuno-binding of antibodies in MDR-TB 
patients to insignificant levels (Fig. 19). 
(b) [nhibition ELISA for dsDNA and total protein lysates isolated from in vitro 
MTB-infected monocytes tiiat were either untreated or treated with neem 
extract: 
Next, an attempt was made to probe the specificity of antibodies in sera of 
patients with TB and MDR-TB against DNA isolated from human monocyte cultures that 
were either untreated or treated with neem extract (NE) as described in methods. The 
inhibition ELISA data exhibited high magnitude inhibition in antibody activity in sera of 
patients with tuberculosis and MDR-TB against dsDNA isolated from MTB-infected 
monocytes. A maximum of 78.32% and 83.89% inhibitions in anti-TB and anti-MDR-TB 
sera antibody activities respectively were achieved at a maximum inhibitor concentration 
of 10^g/mlofdsDNA(Fig. 20). 
83 
c: 
o 
T -
Tt 
4-' 
ni 
Q], 
0 
c n X3 
w. 0 
<n Si 
< 
1.8 
1.6 
1.4 
1 2 
1 
0.8 
0.6 
0.4 
0.2 
0 
Q 
TB Sera 
1:100 S 1:200 
1:3200 m 1:6400 
MDR-TB Sera 
MTCF 
0 1:400 m 1:800 
• 1:12800 
NHS 
BD 1:1600 
Fig. 14: Direct binding ELISA: Microtiter plates were separately coated with 
total protein l^sates (100 |al / well from 30 |Lig/ml stock) from MTCF 
(Mycobacterial Culture Filtrate). The binding was checked against antibodies 
present in sera from patients with acti\e tuberculosis and MDR- TB as well as 
norm.il healtln individual. Normal healthy human sera served as negative control. 
Data are means (+ SF| often experiments (p<0.001). 
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Fig. 15: Direct binding ELISA: Microtiter plates were separately coated with 
total protein lysates (100 |al / well from 30 [ig/ml stock) from MTSE 
(Mycobacterial Sonic Extract). The binding was checked against antibodies 
present in sera from patients with active tuberculosis and MDR TB. Normal 
healtliy human sera ser\ed as negative control. Data are means (+ SE) of ten 
experiments (p<0.001). 
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Fig. 16: Direct binding ELISA: Microtiter plates were separately coated with 
total protein lysates (100 |il / vvell from 30 jig/ml stock) from MTCF 
(Mycobacterial Culture Filtrate) of H37RV co-cultured with Neem Extract. The 
binding was checked against antibodies present in sera from patients with active 
tuberculosis and MDR TB. Normal healthy human sera served as negative 
control. Data are means (+ SE) often experiments (p<0.00l). 
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Fig. 117: Direct binding ELISA: Microliter plates were separately coated with 
ttual protein 1} sales (100 |.il / well from 30 ng/'nil stock) from MTSE 
(Mycobacterial Sonic Extract) co-cultured with Neem Extract. The binding was 
checked against antibodies present in sera from patients with active tuberculosis 
and MDR-TB. Normal health} human sera served as negative control. Data are 
means (z ^t^l often experiments (pO.OOl). 
87 
>. 
* J 
> 
+ J 
o TO 
^ 
< 
m 1-1 
'<M 
c 
TO 
_C 
c 
o 
* J 
!a 
!c 
_c 
•»-> 
c 
o 
^ 0) 
Q. 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
MTCF MTSE NE1000ug/ml 
Inhibitor concentration in ug/ml 
• 0 S0.1 01 S2 115 010 
Fig. 18: Inliibition ELJSA: Microtiter plates were coated with total protein (100 
|.il ' well from 30 |ag'ml stock) from MTCF and MTSE obtained from 24 hr 
cultures of H;,7Rv that were either untreated or co-cultured with 1000 |ig/ml Neem 
Extract. The coating antigen as well as the inhibitor emplo\'ed here were the 
same. The concentration of inhibitor used in this study was 0, 0.1, 1, 2, 5 and 10 
Ligml. The inhibition in the binding was checked against antibodies present in 
sera from patients with actixe tuberculosis. Data are means (+ SE) of ten 
experiments (p<0.00l). 
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P"ig. 19: Inhibition ELISA: Microtiter plates were coated with total protein 
lysates (100 f.il / well from 30 |ig/ml stock) from MTCF and MTSE obtained from 
24 hr cultures of H y^Rv that were either untreated or co-cultured with 1000 |ig/ml 
Neem Extract. The coating antigen as well as the inhibitor employed here were 
the same. The concentration of inhibitor used in this study was 0, 0.1, 1, 2, 5 and 
10 (igml. The inhibition in the binding was checked against antibodies present in 
sera from patients with MDR- IB. Data are means (+ SE) of ten experiments 
(p<0.00i). 
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Fig. 20: Inhibition ELISA: Microtiter plates were coated with DNA isolated from 
monocyte infected with M tuberculosis H37RV (1:1 bacterial/cell) cultures treated 
without supplements. The coating antigen as well as the inhibitor employed here 
were the same. The concentration of inhibitor used in this study was 0, 0.1, 1, 2, 5 
and 10 |ig/ml. The inhibition in the binding was checked against antibodies 
present in sera from patients with active tuberculosis and MDR-TB. Data are 
means (+ SE) often experiments (p<0.001). 
90 
50% inhibitions were recorded at inhibitor concentrations of 0.9 (ag/ml and 0.6 ^g/ml 
against anti-TB and anti-MDR-TB antibody respectively (Fig. 20). 
Interestingly. dsDNA isolated from MTB-infected monocytes that were co-
cultured with neem extract (NE) failed to show any appreciable inhibition in anti-TB 
(maximum inhibition 25.11 %) and anti-MDR-TB (maximum inhibition 31.06 %) 
antibody activities, and none of them showed any 50% inhibition values (Fig. 21). Next, 
an attempt was also made to probe the specificity of anti-TB and anti-MDR-TB 
antibodies against total protein lysates of infected monocytes that were either untreated or 
treated with neem extracts. Similar to the DNA data as described above, here also the 
inhibition ELISA results exhibited high magnitude inhibition in anti- tuberculosis and 
anti- MDR-TB antibody activities against total protein lysates obtained from MTB-
infected monocytes. A maximum of 74.77% and 83.99% inhibitions in anti-TB and anti-
MDR-TB sera antibod}' activities respectively were achieved at a maximum inhibitor 
concentrations of 10 i^g/ml of total protein lysates (Fig. 22). 50%o inhibitions were 
recorded at inhibitor concentrations of 1 ^ g/ml and 0.2 jag/ml against anti-TB and anti-
MDR-TB antibody respectively (Fig. 22). 
Interestingly, total protein lysates isolated from MTB-infected monocytes that 
were co-cultured with neem extract (NE) did not show any appreciable inhibition in anti-
TB (maximum inhibiiion 26.98 %) and anti-MDR-TB (maximum inhibition 33.01 %) 
antibody activities, and none of them showed any 50%) inhibition values (Fig. 23). 
(c) Inhibition ELISA for total protein lysates isolated from MTB-infected 
monocytes that nere either untreated or treated with NAC, SN50 or SN50M: 
Next, an attempt was also made to probe the specificity of antibodies in sera of 
patients with TB and MDR-TB against total protein lysates isolated from human 
monocNte cultures infected with MTB. and were either untreated or treated with NAC (10 
mM). SN50 (100 (ig/ml) and SN50M (100 |ig/ml) respectively as described in methods. 
The results depicted in Fig. 24, exhibited that total protein lysates isolated from MTB-
infected monocytes that were co-cultured with NAC (10 mM) did not show any 
appreciable inhibi.ion in anti-TB (maximum inhibition 23.17 %) and anti-MDR-TB 
(maximum inhibition 30.12 %) antibod) activities, and none of them showed any 50% 
inhibition values (Fig. 24). Thus, like neem extract. NAC also reduced the specificity of 
the above said antibodies. 
Similarly, total protein iysates isolated from MTB-infected monocytes that were 
co-cultured with SN50 - a peptide inhibitor of NF-kB (100 ^ig/ml) also did not show any 
appreciable inhibition in anti-TB (maximum inhibition 23.17 %) and anti-MDR-TB 
(maximum inhibition 30.12 %) antibody activities, and none of them showed any 50% 
inhibition values (Fig. 25). Thus, like neem extract and NAC, the above employed 
inhibitor of NF-kB i. e. SN50 also reduced the immuno-recognition of the above said 
antibodies. It is to be pointed out that the rationale for employing NF-kB inhibitor is best 
explained in the studies carried out at the gene level However, the control peptide of NF-
kB inhibitor i. e. SN501VI showed high binding (Fig. 25) as were observed in Fig. 22. 
(d) Inhibition ELISA for total protein Iysates isolated from in vitro MTB-infected 
monocytes that were either untreated or treated with monoclonal anti-TNF-alpha 
antibody: 
Next, an attempt was also made to probe the specificity of antibodies in sera of 
patients with TB and MDR-TB against total protein Iysates isolated from human MTB-
infected monocNte cultures that were either untreated or treated with monoclonal anti-
TNF-alpha antibody (10 ng/ml). Inhibition ELISA results exhibited low magnitude 
inhibition in antibody activity in tuberculosis sera and intermediate to somewhat 
appreciable degree of inhibition of MDR-TB sera against total protein Iysates isolated of 
MTB-infected monocxtes co-cultured with 10 ng/ml of monoclonal anti-TNF-alpha 
antibod_\. A n-aximum of 40.23% and 68.89%) inhibitions in anti-TB and anti-MDR-TB 
sera antibody activities respectively was achieved at a maximum inhibitor concentration 
of 10 fig/ml of total protein Iysates (Fig. 26). 50% inhibitions were recorded onl\ in 
samples of MDR-TB at relativel)' high inhibitor concentrations of 3.2 f.ig/ml against anti-
MDR-TB antibod) (Fig. 26). Thus, although the maximum inhibition in antibod}' 
activit) in MDR-TB sera was some what appreciable, but the high inhibitor concentration 
(3.2 i-ig/ml) at which this inhibition was achieved reflects upon the low' specificity of the 
said antibodies against TNF-u treated MTB infected monocvtes. 
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Fig. 21: Inhibition ELISA: Microliter plates were coated with DNA isolated from 
mcinocyte, infected with M. tuberculosis H37RV (1:1 bacterial/cell) cultures treated 
with supplements (1000 |ag/ml Neem Extract). The coating antigen as well as the 
inhibitor employed here were the same. The concentration of inhibitor used in this 
study was 0, 0.1, 1, 2, 5 and 10 |ig/ml. The inhibition in the binding was checked 
against antibodies present in sera from patients with active tuberculosis and 
MDR- TB. Data are means (+ SE) often experiments (p<0.001). 
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Fig. 2.2: Inhibition ELISA: Miciotiter plates were coated with total protein lysates 
(100 111 well from 30 |.ig'ml stock) from MTB-infected monocytes (24 hrs 
culture) treated without supplement. The coating antigen as well as the inhibitor 
enipkvyed here were the same. The concentration of inhibitor used in this stud\ 
was 0. 0.1. 1.2. 5 and 10 iig'ml. The inhibition in the binding was checked 
against antibodies present in sera from patients with active tuberculosis as well as 
MDR- IB. Data are means (+ SE) often experiments (p<0.00r) 
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Fig. 23: Inhibition ELISA: Microtiter plates were coated with total protein lysates 
(100 |ul / well from 30 |ig/ml stock) from MTB-infected monocytes (24 hrs 
culture) treated with supplement (1000 i^ g/ml Neem Extract). The coating antigen 
as well as the inhibitor employed here were the same. The concentration of 
inhibitor used in this study was 0, 0.1, 1, 2, 5 and 10 ^g/ml. The inhibition in the 
binding was checked against antibodies present in sera from patients with active 
tuberculosis as well as MDR-TB. Data are means (+ SB) of ten experiments 
(pO.OOl). 
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Fig. 24: Inhibition ELISA: Microliter plates were coated with total protein 
lysEites (100 i^l / well from 30 |Lig/ml stock) from MTB-infected monocytes (1:1 
bacterial/cell; 24 hrs culture) co-cultured with 10 mM NAC. The coating antigen 
as well as the inhibitor employed were the same. The concentration of inhibitor 
used were 0, 0.1, 1, 2, 5 and 10 |ag/ml. The inhibition in the binding was checked 
against antibodies present in sera from patients with active tuberculosis as well as 
MDR -TB. Data are means (+ SE) often experiments (p<0.001). 
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Fig. 25: Inhibition ELISA: Microtiter plates were coated witli total protein lysate 
isolated from NIN's infected 1:1 with H^^ Rv and co-cultured with 100 |Ug/ml 
SN50 or SN50N4. The coating antigen as well as the inhibitor employed here 
were the same. The concentration of inhibitor used in this study was 0, 0.1, 1, 2. 5 
and 10 ug ml. The inhibition in the binding was checked against antibodies 
present in sera from patients with acti\e tuberculosis as well as MDR-TB. Data 
are means (* SE) often experiments (pO.OOl). 
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Fig. 2(»: Inhibition ELISA: Microtiter plates were coated with total protein lysates 
(100 |.il / well from 30 |ag/ml stock) from anti-TNF-a antibody treated MTB-
infected monocytes (24 hrs culture). The concentration of monoclonal anti-TNF-a 
Ab used for co-culturing was 10 ng/ml. The coating antigen as well as the 
inhibitor employed here were the same. The concentration of inhibitors used in 
this slud\ was 0. 0.1. 1. 2. 5 and 10 |.igml. The inhibition in the binding was 
checked against antibodies present in sera from patients with active tuberculosis 
as well as MDR-TB. Data are means (+ SE) often experiments (p<0.001). 
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(e) Inhibition ELISA for total protein lysates isolated from MTB-infected monocytes 
that were either untreated or treated with varying doses of streptomycin, rifampicin 
and isoniazid: 
Next, an attempt was made to probe the specificity of antibodies in sera of 
patients with TB and MDR-TB against total protein lysates isolated from human MTB-
infected monocyte cultures that were either untreated or treated with known TB 
antibiotics like streptomycin (100 (ag/ml), rifampicin (100 fig/ml) and isoniazid (100 
Mg/ml). 
As evident from the data depicted in Figs. 27-29, inhibition ELISA results 
exhibited low magnitude inhibition of tuberculosis sera antibody activities with total 
protein lysates isolated of MTB-infected monocytes co-cultured with the above-
mentioned antibiotics. A maximum of 38.44%, 39.43 and 30.94 % inhibitions in anti-
sera antibody activities respectively was achieved with streptomycin (Fig. 27), rifampicin 
(Fig. 28) and isoniazid (Fig. 29) respectively at a maximum inhibitor concentration of 10 
).ig/ml of total protein lysates. 50% inhibitions could not be achieved. 
On the contrary, no suppressive effects were observed with antibodies from 
MDR-TB patients against streptomycin, rifampicin and isoniazid. This is evident from 
high inhibition values obtained to the order of 80.67% (streptomycin) (Fig. 27). 79.93%) 
(rifampicin) and 74.11% (Fig. 28) (isoniazid) (Fig. 29). Thus, as expected, antibiotics 
failed to exert any effect in case of MDR-TB patients. 
(f) Inhibition ELISA for total protein lysates isolated from monocytes of TB and 
MDR-patients that were either untreated or treated "ith vaoing doses of 
stroptom\cin, rifampicin and isoniazid: 
Next, after immunological analysis of in vitro MTB-infected monocytes, an 
attempt was made to probe the specificity of antibodies in sera of patients with TB and 
MDR-TB against total protein l\sates isolated from human monocytes of TB and MDR-
TB patients, whose cultures were either untreated or treated with streptomycin (100 
fjg/ml). ri1am:Ticin (100 pg/ml) and isoniazid (100 fig/ml). 
As evident from the data depicted in Figs. 30-32, inhibition ELISA results 
exhibited low magnitude inhibition of tuberculosis sera antibody activities with total 
protein lysates isolated from monoc\'tcs ofTB patients and co-cultured with the above-
99 
mentioned antiDiotics. A maximum of 35.91%, 37.98% and 28.94 % inhibitions in anti-
TB sera antibody activities respectively was achieved with streptomycin (Fig. 30), 
rifampicin (Fig. 31) and isoniazid (Fig. 32) respectively at a ma.ximum inhibitor 
concentration of 10 i^ g/ml of total protein lysates. 50% inhibitions could not be achieved. 
No suppressive effects in anti-MDR-TB antibody (sera) activity were observed 
with protein lysates obtained from monocytes of patients with MDR-TB that were co-
cultured with either with streptomycin, rifampicin or isoniazid. This is evident from high 
inhibition values obtained to the order of 84.12%) (streptomycin) (Fig. 30), 81.09% 
(rifampicin) and 71.31% (Fig. 31) (isoniazid) (Fig. 32). Thus, antibiotics failed to exert 
any effect in case of MDR-TB patients. 
(g) Inhibition ELISA for total protein lysates isolated from monocytes of TB and 
MDR-patients that were either untreated or treated with neem extract or NAC: 
Next, after immunological analysis of in vitro MTB-infected monocytes, an 
attempt v\as made to probe the specificity of antibodies in sera of patients with TB and 
MDR-TB against total protein lysates isolated from human monoc}tes of TB and MDR-
TB patients, w hose cultures were either untreated or treated with neem extract and NAC 
(10 mM). Similar to the in vitro infected monocytes, total protein lysates isolated from 
TB and MDR-TB patient's monocytes that were co-cultured with neem extract (NE) did 
not show any appreciable inhibition in anti-TB (maximum inhibition 20.56 %) and anti-
MDR-TB (m£,ximum inhibition 37.98 %) antibody activities, and none of them showed 
any 50% inhibition values (Fig. 33). Similar observations were made with NAC (Fig, 34). 
Thus, the inhioition results indicate the neem extract as well as NAC-induced suppression 
in MTB Ag 8;> in monocytes of both TB and MDR-TB patients. 
[C] Preliminary Studies Probing the Identification of a Natural 
Antagonist of M tuberculosis 85B: 
,'\fter ensuring that our laboratory protocols )'ield established results with minor 
variation, and prior to any further in-deplh studies, we undertook preliminary studies to 
identif} a natural antagonist of M iiiherculosis 85B. The objeclive of these experiments 
was to explore an economical and cost-ltiendl_\ option towards combating tuberculosis. 
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Fig. 27: Inhibition ELISA (modulation with Streptomycin): Microtiter plates 
were C(3ated with total protein lysates (100 [i[ I well from 30 i^ g/ml stock) from 
streptomycin treated MTB-infected monocytes (24 hrs culture). The concentration 
of streptomycin used for co-culturing was 100 f,ig/ml. The coating antigen as well 
as the inhibitor employed here were the same. The concentration of inhibitor used 
in this stud} v\as 0. 0.1. 1. 2, 5 and 10 |ig/ml. The inhibition in the binding was 
checke(i against antibodies present in sera from patients with active tuberculosis 
as well as MDR-TB patients. Data are means (2 STi) of ten experiments 
(p<0.0(i|). 
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Fig. 28: Inhibition ELISA (modulation with Rifampicin): Microtiter plates were 
coated with total protein lysates (100 ^1 / well from 30 ^g/ml stock) from 
rifam])icin treated MTB-infected monocytes (24 hrs culture). The concentration of 
rifamjjicin used for co-culturing was 100 [ig/ml. The coating antigen as well as the 
inhibitor employed here were the same. The concentration of inhibitor used in this 
study was 0, 0.1, 1, 2, 5 and 10 [ig/ml. The inhibition in the binding was checked 
against antibodies present in sera from patients with active tuberculosis as well as 
MDR-TB. Data are means (+ SE) often experiments (p<0.001). 
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Fig. 29: Inhibition ELISA (modulation with isoniazid): Microtiter plates were 
coated with total protein lysates (100 )al / well from 30 ^ g/ml stock) from isoniazid 
treated MTB-infected monocytes (24 hrs culture). The concentration of isoniazid 
used for co-culturing was 100 |ig/ml. The coating antigen as well as the inhibitor 
employed here were the same. The concentration of inhibitor used in this study was 
0, 0.01, 0.1, 1, 10 and 20 ^g/ml. The inhibition in the binding was checked against 
antibodies present in sera from patients with active tuberculosis as well as MDR-
TE5. Data are means (+ SE) often experiments (p<0.001). 
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Fig. 30: Inhibition ELISA: Microtiter plates were coated with total protein lysates 
isolated from monocytes of TB and MDR-TB patients (100 fil/well from 30 (jg/ml 
stock) that were co-cultured for 24 hrs with streptomycin (100 )ig/ml). The coating 
antigen as well as the inhibitor employed here were the same. The concentration of 
inhibitor used in this study was 0, 0.1, 1, 2, 5 and 10 ug/ml. The inhibition in the 
binding was checked against antibodies present in sera from patients with active 
tuberculosis as well as MDR-TB patients. Data are means (± SE) often experiments 
(p<0.001). 
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Fig. 31: Inhibition ELISA: Microtiter plates were coated with total protein 
1> sates isolated from monocytes of TB and MDR-TB patients (100 |il/well from 
30 pg/ml stock) that were co-cultured for 24 hrs with rifampicin (100 |Lig/ml). The 
coating antigen as well as the inhibitor employed here were the same. The 
concentration of inhibitor used in this study was 0, O.l, 1, 2, 5 and 10 fig/ml. The 
inhibition in the binding was checked against antibodies present in sera from 
patients with active tuberculosis as well as MDR-TB patients. Data are means 
(+ SB) of ten experiments (p<0.001). 
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Fig. 32: Inliibition ELISA; Microtiter plates were coated with total protein 
lysates isolated from monocytes of TB and MDR-TB patients (100 [il/well from 
30 i-ig'ml stock) that were co-cultured for 24 hrs with isoniazid (100 |.tg/ml). The 
coating antigen as well as the inhibitor employed here were the same. The 
concentration of inhibitor used in this stud}' was 0. 0.1, 1, 2, 5 and 10 |ig/ml. The 
inhibition in the binding was checked against antibodies present in sera from 
patients with active tuberculosis as well as K4DR-TB patients. Data are means 
(:i SH) often experiments (p<0.001). 
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Fig 33: Inhibition ELISA: Microliter plates were coated with Neem Extract in-
\itro treated monocvtes isolated from TB and MDR-TB patients. The 
concentration of neem extract used for co-culturing was 1000 |.ig/ml. The coating 
antigen as well as the inhibitor employed here were the same. The concentration 
of inhibii.or used in this study was 0. 0.1, 1. 2, 5 and 10 |Lig/ml. The inhibition in 
the binding was checked against antibodies present in sera from patients with 
acti\e tuberculosis as well as MDR-TB patients. Data are means (+ SE) often 
experiments (pO.OOI). 
107 
50 
40 
> 
•D 
O 
JD 
c 
< 
~ ^ 30 
o > 
i < 2 0 
c o o 
Q. 
10 
TB MDR-TB 
Inhibitor Concentration, ug/ml (NAC) 
HO Q0.1 031 112 as QIO 
Fig. 34: Inhibition ELISA: K4icrotiter plates were coated with NAC in-vitro 
treated inonoc}'tes isolated from TB and MDR-TB patients. The concentration of 
NAC used for co-culturing was 100 pg/ml. The coating antigen as well as the 
inhibitor eniploNed here were the same. The concentration of inhibitor used in this 
stud} was 0. 0.1, L 2. 5 and 10 |.ig/ml. The inhibition in the binding was checked 
against antibodies present in sera from patients with acti\e tuberculosis as well as 
MDR-TB patients. Data are means (z SE) of ten experiments (p<O.OOI). 
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Taking into considfralion the role of neem extract in alternative medicine since ancient 
times, we opted to study its role in MTB. 
(a) Dose-response effect of neem extract on M. tuberculosis 85B niRNA 
expression in HjvRv cultures: 
H37RV strain of M. tuberculosis was co-cultured with varying concentrations of 
neem extract (100, 200, 400, 600, 800 and 1000 ftgs/ml), as well as culture devoid of 
neem extract which served as the corresponding control, were grown in Middlebrook 
7H9 broth for 14 days at 37"C in 5% COo. After lysis of bacilli, RNA was extracted and 
assessed for 16S rRNA and 85B mRNA. None of the concentrations of neem extract had 
any significant effect on the expression of the housekeeping gene of M tuberculosis, i.e., 
I6S rRNA (Fig. 35), thereby indicating that neem extract did not non-specifically affect 
M tuberculosis transcription. In contrast, the data showed appreciable effects of neem 
extract on the expression of vV/. tuberculosis 85B mRNA. As is evident from Fig. 36. 
cultures of Hj7Rv. receiving 200 pg/ml of neem extract exhibited negligible changes in 
858 mRN.-\ level in comparison to control cultures de\oid of neem extract. A low 
magnitude decrease to the order of 1 logs (f<0.05) in M. tuberculosis 858 mRNA 
expression was recorded with 400 pg/ml neem extract. Further increase in neem extract 
concentrations to 600, 800 and 1000 |ug/ml in HjyRv cultures exhibited an appreciable 
suppression in M tuberculosis 85B mRNA by -1.7, 2.4 and 3 logs {P<0.00\ for all), 
respectivel). in comparison to control cultures (Fig. 36). The decrease in the 858:16S 
ratio (Fig. 37) to the extent of 91% and 92% observed for cultures challenged with 800 
and 1000 pg/ml of neem extract, respectively, in comparison to control cultures devoid of 
neem extract, supports the above data. Although, low concentrations of neem extract do 
not affect the .'/. luberculosi.s growth, it appreciably downregulates the M. tuberculosis 
858 gene expression. 
(b) Effect of Neem Extract on the expression of secreted antigen 85 complex 
protein in H3 R\ cultures supernatants: 
In addition, supernatants obtained from 14 days M. tuberculosis cultures, treated with 
various doses of neem extact were subjected to ELISA to evaluate secreted A/. 
tuberculosis antigen 85 complex. As evident from Fig. 38. the secretion of antigen 85 
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complex was found to be dose-dependent and decreased by an appreciable amount with 
600, 800 and and 1)00 |.ig/ml neem extract. Hence, this decrease in antigen 85 complex 
secretion is indicati\e of anti-TB properties of neem extract, 
[DJ Studies at the gene expression knel on Monocytes Infected //; Vifro with 
M. tuberculosis: 
(a) Time-dependent effect of M. tuberculosis infection on the expression of 
human housekeeping genes and on the expression of TNF-a mRNA: 
An attempt was made to probe the effect of M. tuberculosis (H37RV) infection, if 
any, on the human housekeeping genes. It was observed that M. tuberculosis infection had 
no effect at any time intervals (0-120 hours) of culturing of infected monocytes on the host 
housekeeping genes like RI8 gene (18S rRNA) as revealed by quantitative real-time RT-
PCR(Fig. 39). 
Thereafter we investigated the kinetics (0-120 hours) of expression of TNF-a 
mRNA in A/. /z//)erc?//(9.s'/.S'-infected monocytes. TNF-a mRNA was corrected to host 
internal control, i e.. 18S rRNA. in the same sample. .As evident from Fig. 40. the effect 
of 3/ liiherculosis infection on TNF-a mRN.A was found to be time-dependent. The 
levels of TNF-a mRNA copy numbers in infected monocytes at various time intervals 
were recorded as 2.1 logs. 6.3 logs (P<0.00l). 10.3 logs (/'<0.001). 4.6 logs (y<0.00l) 
and 1.9 logs (/'<0.05). after 0, 4, 24, 72 and 120 hours of M. mbercidusis infection, 
respectively. Thus, the expression of TNF-a was maximal at 24 hours, which decreased 
considerably the.'-eafter. This is in accordance to the results published earlier from our 
laborator) (fiasan et al.. 2006). 
Thereafter, we further probed the effect of .\/. luhcrcidosis infection on secreted 
TNF-a protein in culture supernatants that were harvested at various time intervals (0-
120 hours). .As evident from Fig. 41, the effect of hd. tuberculosis infection on secreted 
TNF-a was found to be time-dependent. The concentration of soluble TNF-a secreted in 
supernatants of infected monocyte cultures at various time intervals were observed as 
28.44. 59.68 (7'<0,00l), 96.78 [P<OM\). 188.23 (/'<0.00l). 105.78 {P<0.00]). 60.^5 
{P<0.00\) and 11.23 (/^<0.00l) pg/ml after 0. 4. 12, 24. 48. 72 and 120 hours of M 
tuberculosis infection, respectively. 
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Thus, the maximum secretion of TNF-a in culture supernatants was observed after 24 
hours of M tuberculosis infection, followed by a substantial decrease at the remaining 
time intervals of culture. Again our results are in accordance to the results published 
earlier from our laborator)' (Hasan et al., 2006). 
(b) Time-dependent effect of M. tuberculosis (HjyRv) infection in healthy 
monocytes on M tuberculosis 85B and 16S genes as well as on secreted antigen 
85 complex: 
An attempt was also made to investigate the kinetics (0-120 hours) of expression 
of M tuberculosis I6S rRNA and 85B mRNA in M tuberculosis-infected monocytes. As 
evident from Fig. 42, I6S rRNA expression was observed to linearly increase with time. 
Also, the expression of 85B mRNA continued to increase up to 120 hours (Fig. 43). The 
ratio of 85B:16S was found to increase with increasing time periods of infection. The 
85B:16S ratio recorded at various time intervals were 0.0013, 0.0018 (P<0.05), 0.0822 
(P<0.00\). 0.3234 {P<0.00\) and 0.7866 (/'<0.001), after 0. 4, 24, 72 and 120 hours of 
infection, respeciively (Fig. 44). Furthermore, between 4 and 24 hours, M. tuberculosis 
85B:16S increased significantly (?<0.001). This increase in 85B:16S ratio with time 
correlates with 85B mRNA levels at various time periods observed in Fig. 43. 
[EJ Modulation Studies in in-vitro MTB infected monocytes at the gene 
expression levels: 
(a) Dose-response effect of neem extract on host TNF-a and M. tuberculosis 85B 
gene expression in M. tuberculosis-infected monocytes: 
Prior to any study on effects of neem extract on MTB-infected monocytes with 
regards to TNF-alpha and MTB 85B gene expressions, an attempt was made to ensure 
that the doses selected in this study for neem extract were non-toxic to human monocytes. 
Thus, effects of varying doses of neem extract on human house-keeping gene R18 rRNA 
was probed by RT-PCR. As evident from Fig. 45, none of the doses of neem extract 
showed any toxic or adverse effect on RI8 rRNA expression.The role for endogenous 
TNF-a in auto-induction and in the induction of M tuberculosis 85B gene expression is 
well established. Thus, to assess the regulation of TNF-a, and in turn MTB 85B, in other 
experiments, va.''ying doses of neem extract as described in methods (0- 1000 |ug/ml) was 
added to M. tuberculosis-'mfecied monocytes, 
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and then TNF-a and 85B mRNA were assessed. Evaluation of cultures harvested after 24 
hours of infection revealed high magnitude expression of endogenous TNF-a mRNA as a 
result of M tuberculosis infection in monocytes devoid of exogenous any neem extract 
(Fig. 46). In comparison to control infected monocytes, an appreciable decrease in 
endogenous T7MF-a mRNA was recorded by around 0.4 logs, 0.9 logs, 1.7 logs, 2.4 logs, 
3.8 logs and 4.8 logs (P<0.001 for all) with treatments of 100, 200, 400, 600, 800 and 
1000 (jgs/ml of neem extract respectively (Fig. 46). 
Next, an attempt was made to assess the effect of varying doses of neem extract 
on the expression of mycobacterial house keeping gene 16S rRNA in in vitro MTB-
infected monocytes. As evident from Fig. 47, none of the doses of neem extract sdecled 
in the study showed any effect on the expression of I6S rRNA. On the contrary, 
significant suppressions were observed in MTB 858 mRNA expression as a consequence 
of neem extract treatment. Real time RT-PCR data showed that the neem extract-induced 
down-regulation of MTB 85B mRNA in MTB-infected monocytes was dose-dependent 
(Fig. 48). 
(b)NF-KB playing an important role in M. tuberculosis-infected monocytes: 
Induction of TNF-a by cellular activation is known to be mediated via NF-KB (Toossi et 
al., 1997; Fan et al., 2002, Hasan et al., 2006). It has been well documented that TNF-a 
induced nuclear translocation of NF-KB was inhibited in SN50 peptide-treated human 
monocytic cell lines as demonstrated in EMSA (Lin et al., 1995). Thus, we employed 
SN50, an inhibitor of NF-KB, to assess the role of NF-KB in activation of gene expression 
in M. luberculosis'-lnkctQd monocytes. SN50 (100 x^g/ml) was added to monocytes 3 
minutes prior to M. tuberculosis infection. Control cultures did not receive SN50. At 24 
hours. SN50 suppressed endogenous TNF-a mRNA expression in M. tuberculosis-Infected 
monocytes by around 5.0 logs (P<0.001) in comparison to control cultures devoid of SN50 
pre-treatment (Fig. 49). To ensure that cellular inhibition was specific, we compared the 
effect of SN50 with its inactive analogue, SN50/N4 at the same concentration. As expected, 
SN50/M failed to show any effect on TNF-a mRNA expression (P<0.05) (Fig. 49). 
Similarly, SN50 was found to decrease the ratio of 85B:16S in M. tuberculosis-infected 
monocytes. This can be best viewed from the data depicted in Fig. 50, where M 
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tuberculosis 85B:16S ratio was found to be 0.08, 0.0004 (P<0.001) and 0.092 {P>0.05) for 
control infected monocytes, infected monocytes challenged with SN50. and infected 
monocytes challenged with SN50/M, respectively (Fig. 50). Therefore, it can be 
concluded that the increased expression of TNF-a and 85B mRNA in M. tuherculosis-
infected monocytes is mediated mainly via NF-KB. 
[F] Modulation Studies in in-vitro MTB infected monocytes at the protein 
expression levels: 
(a) Quantification of soluble TNF-a in supernatants of monocyte cultures of 
tuberculosis patients: 
Adherent monocytes from PBMC's of tuberculosis patients were cultured for 24 
hours. Supernatants were then subjected to evaluation of soluble TNF-a as by ELISA. 
The levels of solub'e TNF-a was found to be to the order of 192 ± 28 pg/ml (mean ± 
SEM; /'<0.001) (Fig. 51). On the contrary, negligible and insignificant amounts of 
soluble TNF-a were observed in supernatants of normal healthy monocyte cultures. 
Interestingly, co-culturing of MTB-infected monocytes with varying doses of neem 
extract for 24 hrs exhibited a dose-dependent down-regulation in soluble TNF-a protein 
expression. The results show 191 pg/ml, 165 pg/ml, 122 pg/ml, 98 pg/ml. 66 pg/ml, 51 
pg/ml and 39 pg/ml of soluble TNF-a protein expressions with 0, 100, 200, 400, 600, 800 
and 1000 |igs/ml neem extract respectively (Fig. 51 ). 
(b) Dose-dependent effect of neem extract in M. tuberculosis infection of 
monocytes on glutathione peroxidase (GPx) activity: 
GPx activity with respect to varying doses of neem extract was determined in M. 
tuberculosis-lnfecitd monocytes. Uninfected monocytes served as controls. At dose 0 
(ig/ml, GPx activity in uninfected control exhibited high GPx activity (79 U/mg protein) 
in comparison to M. luberculosis-infected monocytes which showed a much suppressed 
GPx activity (33 U/mg protein). However, M tuberculosis-infected monocytes co-
cultured with varying doses of neem extract (0 - 1000 ^g/ml) exhibited a linear 
increase/amelioration in GPx activity with dose. GPx activity in M luherculosis-inftcted 
monocytes was recorded as 33. 39, 43, 50, 60, 68 and 71 U/mg protein with 0, 100, 200, 
400, 600, 800 and 1000 ^gs/ml neem extract respectively (Fig, 52). 
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expression of TNF-alpha mRNA: Human monocytes were infected with M. 
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Fig. 52: Modulation of glutathione peroxidase (GPx) activity: Human monocytes 
were infected with M. tuberculosis H37RV (1:1 bacterial/cell). Uninfected 
monocyte cultures served as controls (empty bars). Cultures then received 
different doses (0-1000 fJg/ml) of neem extract, GPx activity was determined in 
culture supernatants at 24 hours. Data represent mean ± SEM of eight 
experiments (P<0.001 for all). 
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(c) Regulation of Glutathione peroxidase (GPx) activity in MTB-infected monocytes: 
Next, an attempt was made to probe the comparative regulatory effects of neem 
extract, with l<.novvn antioxidant NAC as well as SN50 and its control SN50M on the GPx 
activity in MTB-infected monocytes. MTB-infected cultures were co-cultured for 24 hrs 
either with neem extract (1000 ng/ml), NAC (10 mM), SN50 (100 Mg/ml) or SN50M (100 
Hg/ml), and thereafter harvested. Uninfected monocyte cultures served as controls. As 
evident from Fig. 53, uninfected cells showed a GPx activity to the order of 79 U/mg 
protein whereas when the same cells were infected with 1:1 MTB, then the GPx activity 
was found to be down-regulated to 33 U/mg protein (Fig. 53). Interestingly, when infected 
cells were separately co-cultured with neem extract, NAC and SN50, then the results 
showed amelioration in the GPx activities to the order of 72 U/mg protein, 63 U/mg protein 
and 70 U/mg protein respectively (Fig. 53). On the other hand, SN50M failed to exert any 
amelioration effect (Fig. 53). 
(d) Evaluation of MDA levels in monocytes of healthy uninfected, in vitro MTB-
infected, TB patients and MDR-TB patients: 
Next, an attempt was also made to determine the levels of MDA in monocytes of 
healthy uninfected controls, in vitro MTB-infected, TB patients and MDR-TB patients. 
As evident from Fig. 49, MDA levels were computed out to be 8 ng/ml, 18 ng/ml 22 
ng/ml and 29 ng/ml in monocytes of healthy uninfected controls, in vitro MTB-infected, 
TB patients and MDR-TB patients respectively (Fig. 54). Thus, the increase in MDA 
levels as a consequence of MTB infection either in vitro or in TB and MDR-TB patients, 
reflects upon the MTB-infection-induced generation of free radicals (ROS). 
(c) Modulation of MDA levels by NAC and Neem Extract: 
Next, an attempt was made to modulate the levels of MDA in monocytes of 
healthy uninfected controls, in vitro MTB-infected, TB patients and MDR-TB patients by 
NAC (10 mM) and neem extract (1000 jig/ml). As evident from Fig. 55), MDA levels 
were computed out to be 8 ng/ml, 18 ng/ml 22 ng/ml and 29 ng/ml in monocytes of 
healthy uninfected controls, in vitro MTB-infected, TB patients and MDR-TB patients 
respectively. On the contrary, co-culturing with 10 mM NAC exhibited an appreciable 
suppression in MDA levels, which were of the order of 10 ng/ml, 12 ng/ml and 15 ng/ml 
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in in vitro MTEMnfected, TB patients and MDR-TB patients respectively (Fig. 55). In 
comparison to NAC. co-culturing the above-mentioned cells with 1000 pg/ml of neem 
extract showed a little improved inhibitory effect on MDA levels. As evident from (Fig. 
56). neem extract suppressed the MDA levels, which were found to be of the order of 8 
ng/ml, 10 ng/ml and 12 ng/ml in in vitro MTB-infected, TB patients and MDR-TB 
patients respectively (Fig. 56). Thus, Neem extract, followed by NAC were potent 
suppressors of MTB-induced augmented MDA levels. 
(1) Modulatorj effects of NADPH on the expression of soluble TNF-alpha in 24 hr 
cultures and MTB Ag 85 complex in 72 hr cultures of MTB-infected monocytes: 
As a matter of fact, reactive oxygen species (ROS) plays an important role 
augmenting TNF-alpha, and in turn, MTB 85B, thus an attempt was also made to probe 
the effects of NADPH, a known positive modulator of ROS, on sTNF-alpha secretion in 
infected monocytes. As evident from Fig. 57, uninfected healthy control monocyte 
cultures showed negligible expression of secreted TNF-alpha, whereas 24 hr MTB-
infected monocyte cultures showed high expression of secreted TNF-alpha (188.69 
pg/ml; P<O.OOI). Co-culturing of MTB-infected monocytes with varying doses of 
NADPH (0, 2, 4, 6, 8 and 10 nM) exhibited a dose-dependent augmentation in secreted 
TNF-alpha expression. The results show that from 188.69 pg/ml (0 nM NADPH), the 
secreted TNF-a expression was up-regulated to 201.22 pg/ml, 222.34 pg/ml, 289.45 
pg/ml, 344.21 Dg/ml and 371.39 pg/ml with 2 nM, 4 nM, 6 nM, 8 nM and 10 nM of 
NADPH respectively Fig. 57. 
Thereafter, an attempt was also made to evaluate the expression of secreted MTB 
Ag 85 complex in 72 hr cultures of MTB-infected monocytes. As evident from Fig. 58, 
uninfected healthy control monocyte cultures showed no expression of secreted MTB Ag 
85 complex, whereas MTB-infected monocyte cultures showed high expression of 
secreted MTB Ag 85 complex (130.22 pg/ml; P<0.001). As expected, co-culturing of 
MTB-infected monocytes with varying doses of NADPH (0, 2, 4, 6, 8 and 10 nM) 
exhibited a dose-dependent augmentation in secreted MTB Ag 85 complex expression. 
The results show that from 130.22 pg/ml (0 nM NADPH), the secreted MTB Ag 85 
complex expression was up-regulated to 135.77 pg/ml, 148.78 pg/ml, 171.23 pg/ml, 
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(Empt\ ha:) onh and MN+1:1 MTB (black bar) as well as doses of NADPH (0 -
10 nM) in different bar diagram. Expression of sTNF-(x was determined in 
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196.32 pg/ml and 224.55 pg/mi with 2 nM 4 nM. 6 nM. 8 nM and 10 nM of NADPH 
respective!} Fig. 58. 
(g) Dose-res|)onse effect of NADPH on the GPx activity in MTB-infectcd monocytes: 
GP.x activit} with respect to varxing doses of NADPH was determined in M. 
tuberculosis-'mkcted monocytes. Uninfected monocytes served as controls. At dose 0 
|ig/ml, GPx activity in uninfected control exhibited high GPx activity (81.32 U/mg 
protein) in comparison to M. tuberculosis-'mfected monocytes which showed a much 
suppressed GPx activity (23.87 U/mg protein). However, M. tuberculosis-'mfecied 
monocytes co-cultured with varying doses of NADPH ( 0 - 1 0 nM) exhibited a linear 
decrease in GPx activity with dose. GPx activity in M. tuberculosis-Infected monocytes 
was recorded as 23.87, 18.44, 14.98, 9.22 and 7.18 U/mg protein with 0, 2, 4, 6, 8 and 10 
nM of NADPH respectively (Fig. 59). 
[G] Dose-dependent effect of Antibiotics like Streptomycin, Rifampicin and 
Isoniazid on GPx activit}', secreted TNF-a and secreted MTB 85B protein 
expressions in monocytes infected with MTB: 
The effects of streptomycin, rifampicin and isoniazid (all 0-100 fig/ml) on the 
expression of GPx activity, secreted TNF-a (24 hr cultures) and secreted N4TB 858 
protein expressions (72 hr cultures) in monocytes infected with NfFB-in cultures were 
found to be dose-dependent. The results are depicted below. 
(i) Effect of Streptomycin on GPx activit}', secreted TNF-alpha and secreted MTB 
85B protein: 
GPx activity with respect to varving doses of streptomycin v\as determined in M 
tuberculosis-infected monocytes. Uninfected monoc\'tes served as controls. .At dose 0 
pg/mL as described previously, GPx activity in uninfected control exhibited high GPx 
activity (81.32 Ll/mg protein) in comparison to M. tuberculosis-infected monoc\tes. 
which showed a :nuch-suppressed GPx activit} (23.87 U/mg protein). On the contrary, 
M. tuberculosis-infected monocytes co-cultured with varying doses of strepiomycin (0. 
20. 40, 60, 80 and 100 |.igs/ml) exhibited increase / up-regulaiion i,i GI'x ;icii\'it}' with 
dose. GPx acti\'it\' in iVl. tuberculosis-infected monocvtes was recorded as 23.S7. 29.66. 
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33.56, 41.22. 46.76 and 53.43 U/mg protein with 0. 20. 40. 60. 80 and 100 Mgs/ml of 
streptomycin respectivel)' (Fig. 60). 
Ne.xt. a dose-dependent effect of streplom} cin w as probed on the expression of 
secreted TNF-alpha in MTB-infected monoc>te cukures. Uninfected monocxtes ser\ed as 
controls. At dose 0 (ig/ml, no or negligible secreted TNF-alpha was observed in 
uninfected control. On the contrary, M. tuberculosis-infected monocytes showed an 
appreciably augrnented expression of secreted TNF-alpha (197.55 pg/ml). However, M 
tuberculosis-'mkcted monocytes co-cultured with varying doses of streptomycin (0, 20, 
40, 60, 80 and 100 fxgs/ml) exhibited a linear decrease/ down-regulation in secreted TNF-
alpha expression with dose. It was recorded as 154.32, 121.76, 102.37, 96.34 and 84.33 
pgs/ml with 20, 40, 60, 80 and 100 |igs/ml of streptomycin respectively (Fig. 61). 
Thereafter, a dose-dependent effect of streptomycin was probed on the expression 
of secreted MTB 85B protein expressions in MTB-infected monocyte cultures. 
Uninfected monocytes served as controls. .At dose 0 Mg/ml, no secreted MTB 85B protein 
was observed in uninfected control. On the contrary, M tuberculosis-'mfected monocytes 
showed an appreciably augmented expression of secreted MTB 85B protein (128.56 
pg/ml). However. A/. /z//)£'rc;//o5/.v-infected monocytes co-cultured with varying doses of 
streptomycin (0, 20. 40, 60, 80 and 100 ngs/mi) exhibited a linear decrease/ down-
regulation in secreted MTB 85B protein expression with dose. It was recorded as 101.23. 
89.34, 69.34. 55.39 and 48.92 pgs/ml with 20, 40. 60. 80 and 100 pgs/ml of streptomycin 
respectively (Fig. 62). 
(ii) Effect of Rifampicin on GPx activity, secreted TNF-alpha and secreted MTB 
85B protein: 
Next. GPx activil} with respect to var}ing doses of rifampicin was delcrmincd in 
M /;//7e/T///as7.v-infected monocytes. Uninfected monocytes served as controls. .At dose 0 
Lig/'ml. GPx activity in uninfected control exhibited hiL'h Gl'x ;::i!viiy (82.44 (.'.''mg 
protein) in comparison to M luberadosis-'mkcied monocytes, which showed a much-
suppressed GPx activity (23.44 U/mg protein). Ho\\e\er. 1/. suhjrai'-'sis-'v^i'ccicd 
monocytes co-cultured with \arying doses of rifampicin (0, 20. -iCi. •';'). N'' ;::i:J iO') 
ugs'mi) exhibited increase / up-regulation in GPx activity with dose. 
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Fig. 59: ELISA for modulation of GPx activity: Human monocytes were infected 
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diagram. GPx acti\'it}' was determined in culture supernatants at 24 hrs .Data 
represent m.^ an n- SEM offne experiments (p< 0.001). 
142 
90 
c 
'5 
*-> 
o 
1 . 
a 
O) 
E 
D^ >. 
*^ 
• > 
+3 
U 
< 
X 
Q. O 
60 
30 
1 
^ 
^ 
MN MN+1:1 MTB MN+1:1 WITB 
+Strepto. 
Streptomycin (ug/ml) 
DO 020 340 11160 080 0100 
Fig. 60: liLISA for modulation of GPx acti\ ity with streptomycin: Human 
monocytes were infected with Xf.tuberculosis H^TRN' (1:1 bacterial/cell). Some 
cultures were not infected (K'fN only; empt}' bar) and ser\ed as control. MN+1:1 
MTB (black bar) as well as doses (0 - 100 fig/ml) of Streptomycin showed in 
different bar diagram. GPx activity was determined in culture supernatants at 24 
hrs. Data represent mean = SbM of six experiments (p< 0.001). 
143 
300 
E 
(TJ 
sz 
I 
u. 
z 
\-
V) 
200 
100 
MN MN+1:1MTB 
Streptomycin (ug/ml) 
MN+1:1 MTB 
+Strepto. 
DO 020 g40 iiaeo S80 0100 
Fig. 61: ELISA for Expression of sTNF-a: Human monocytes were infected with 
M. iiiherctilosis H;,-R\ (1:1 bacterial'cell). Some cultures were not infected (MN 
onl}-; empty bar) and served as control. N4N+1:1 MTB (black bar) as well as doses 
(0 - 100 i-ig-'ml) of Streptomycin showed in different bar diagram. Expression of 
sTNF-a was determined in culture supernatants at 24 hrs .Data represent mean ^ 
SFM of six experiments (p< 0.001). 
144 
£ 
B) Q.
nf 
lO 
00 
0) 
< 
m 
T3 
O 
*-• 0) 
O 
a (J) 
140 
120 
100 
80 
60 
40 
20 
0 
MN MN+1:1MTB MN+1:1 MTB 
+Strepto. 
Streptomycin (ug/ml) 
EUO 0 20 iJ40 0 60 E3 80 a lOO 
Fig. 62: ELISA for modulation of Expression of secreted MTB antigen 85B: 
Human monoc\tes were infected with M. tuberculosis H;,-7R\- (1:1 bacterial/cell). 
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bar diagram. Expression of secreted MTB antigen 85B was determined in culture 
supernatr.nts at 24 hrs. Data represent mean ± SEM of six experiments (p< 0.001). 
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GPx activi;} in M. tuberculosis-Infected monocytes was recorded as 27.43. 31.98. 
37,67. 43.66 and 48.39 U/mg proteins with 20. 40. 60. 80 and 100 ^gs/ml of rifampicin 
respecti\cl> (Fig. 63). 
N'e.xl. a dose-dependent effect of rifampicin was probed on the expression of 
secreted TNF-alpha in MTB-infected monocyte cultures. Uninfected monocytes served as 
controls. At dose 0 fig/ml, no or negligible secreted TNF-alpha was observed in 
uninfected control. On the contrary, M. tuberculosis-infecied monocytes showed an 
appreciably augmented expression of secreted TNF-alpha (197.55 pg/ml). However, M. 
tuberciilosis-mfei'^ed monocytes co-cultured with varying doses of rifampicin (0, 20, 40, 
60, 80 and 100 |igs/ml) exhibited a decrease/ down-regulation in secreted TNF-alpha 
expression with dose. It w-as recorded as 150.43, 126.89, 109.95, 94.32 and 87.99 pgs/ml 
with 20, 40, 60, 80 and 100 (igs/ml of rifampicin respectively (Fig. 64). 
Thereafter, a dose-dependent effect of rifampicin was probed on the expression of 
secreted MTB 85B protein expressions in MTB-infected monocyte cultures. Uninfected 
monocytes served as controls. At dose 0 ^g/ml, no or negligible secreted MTB 85B 
protein was obser\ed in uninfected control. On the contrar); M. luberculosis-mkcied 
monocytes showed an appreciably augmented expression of secreted MTB 85B protein 
(128.56 pg/ml). However. M. tuberculosis-infected monocytes co-cultured with varying 
doses of rifampicin (0, 20, 40, 60, 80 and 100 |igs/ml) exhibited a decrease/ down-
regulation in secreted MTB 85B protein expression with dose. It was recorded as 98.34, 
84.56, 63.98, 51.23 and 47.12 pgs/ml with 20, 40, 60, 80 and 100 ^gs/ml of rifampicin 
respectively (Fig. 65). 
(iii) Effect of I.soniazid on GPx acti\itA, secreted TNF-aiplui and secreted MTB 85B 
protein: 
.'\fler probing the effects of streptomycin and rifampicin. attempts were made to 
determine the CPx acti\'it\' with respect to \'ar\'ing doses of isoniazid in .\/. tuberculosis-
infected monocytes. Uninfected monocytes served as controls. .At do^^ 0 [ig/ml, GPx 
activiiv in uninfected control exhibited high GPx acti\ii\ (80.58 I i'lrg protein) in 
comparison to M. luberculosis-'mfecied monocytes, which sliowec! a iiiiivh-suppresscd 
GPx activity (24.05 U/mg protein). However. M lubcrrtilosis-inl'cacd ni'UiOCNtes co-
cultured with \ar\'ing doses of isoniazid (0, 20. 40. 60, Sti .;;;.;' 1('\) ,u-s;:.\) cxIiHiiu-J 
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increase / up-regulation in GPx activity with dose. GPx acti\'ity in M. tubercidosis-
infected monoc\tes was recorded as 29.04. 35.76. 43.76. 48.97 and 55.32 U/mg proteins 
with 20. 40. 60. 80 and 100 ugs/ml of isoniazid respective!) (Fig. 66). 
\e.\l. a dose-dependent effect of isoniazid was probed on the expression of 
secreted TNF-alpha in MTB-infected monocyte cultures. Uninfected monocytes served as 
controls. At dose 0 |ig/ml, no or negligible secreted TNF-alpha was observed in 
uninfected control. On the contrary, M. tuberculosis-'mfected monocytes showed an 
appreciably augmented expression of secreted TNF-alpha (192.44 pg/ml). However, M. 
tuberculosis-infectsd monocytes co-cultured with varying doses of isoniazid (0, 20, 40, 
60, 80 and 100 |igs/ml) exhibited a decrease/ down-regulation in secreted TNF-alpha 
expression with dose. It was recorded as 163.44, 131.38, 99.43, 83.56 and 79.51 pgs/ml 
with 20, 40, 60, 8C and 100 |ags/ml of isoniazid respectively (Fig. 67). 
Thereafter, a dose-dependent effect of isoniazid was probed on the expression of 
secreted MTB 85B protein expressions in MTB-infected monocyte cultures. Uninfected 
monocytes served as controls. At dose 0 ng/ml, no or negligible secreted N4TB 85B 
protein was obserxed in uninfected control. On the contran, .1/ litherculosis-lnfected 
monoc\tes showed an appreciably augmented expression of secreted MTB 85B protein 
(128.56 pg/ml). Flowever, M. tuberculosis-Infected monoc)tes co-cultured with varying 
doses of isoniazid (0. 20, 40, 60, 80 and 100 |Ligs/ml) exhibited a decrease/ down-
regulation in secreted V1TB 85B protein expression with dose. It was recorded as 105.66. 
80.23. 59.49, 48.12 and 42.11 pgs/ml with 20, 40, 60, 80 and 100 ^gs/ml of isoniazid 
respectively (Fig. 68). 
[H] Regulator) effect of neem extract on the expression of sfFN-y in MTK-
infected human monocytes: 
Next, an attempt was also made to probe the modulator) effect of neem extract 
(NF) on sIFN-y in 24 hr culture supernatants of MTB- infected monoc)ies. As evident 
from Fig. 69. supernatants of uninfected healthy monocytes which ser\ed as control, 
exhibited a high magnitude of slFN-y proteins (~ 275 pg/ml. p<0.00l). On the contrary, 
in vitro infection of monocytes with 1:1 MTB resulted in an appreciai^le su'^p-'ssion in 
sIFN-y levels (~ 150 pg/ml. p<0.00l) (Fig. 69). Interesting!), a linear anieJioration in 
sIFN-y leves were observed in MTB- infected monocytes tiia: were co-ctiluired with 
varxing doses o;~ neem extract (0-1000 |ag/in!) (Fig. 69). Fin-.iijr. l!ic dai;*. dopicied in 
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Fig. 70. reveals neem extract to be a better ameliorator of slFN-y levels than known 
antioxidants, namel} NAC (Fig. 70). 
|I] Preliminary Studies on the Role of Reacti\e Nitrogen Intermediates (RNI) in 
.MTB-infected liuman monocytes: 
Intea^stingl; . like TNF-alph:! (De C(>ck et al., 1^ )'>0)^  both beneficial and 
deleterious effects of ilMOS producing NO to host, and in turn, contributing to the 
pathophysiology of tuberculosis have been observed (Barnes and Cave, (2003). hi view 
of the above, understanding the mechanisms that are involved in regulating INOS 
expression is important in achieving a harmonious balance between the outcome of both 
its beneficial and pathologic effects. It may be worth mentioning that studies indicate NO 
to be detectable in peripheral blood monocytes derived macrophages infected with M tb. 
(Corbett et al., 20C2). Interestingly, it has been established that cultured peripheral blood 
monocyte isolated from patients with active TB not only had increased iNOS expression 
compared with cells from normal subjects, but also had increased spontaneously released 
N02 in culture iredium (Shaferand Edlin, 1996). 
Thus, in the present study, an attempt was made to e\'aluate the levels of iNOS 
mRNA. modulation b\' Sodium nitroprusside (SNP) as well as its regulation by neem 
extract in 24 hr cultures of human monocytes infected in vitro with 1:1 MTB. As evident 
from Fig. 71. dose dependent neem extract-induced suppressions in iNOS expressions 
were observed in 24 hr MTB-infected monocyte cultures. 'Real time' data exhibited a 
suppression of iNOS mRNA expressions respectively by 0.4 logs (P<O.OOI), 1.2 logs 
(P<O.OOI), 2.3 logs (P<0.001). 2.8 logs (P<0.001), 4.2 logs (P<0.001) and 7.3 logs with 
100, 200, 400, 600, 800 and 1000 ^g/ml of ne«m extract (NF) respectixely (Fig. 71). 
Thus, the results mdicate neem extract to suppress iNOS gene. Furthermore, in the same 
sample, a suppression in .MTB 85B mRNA by -~ 0.2 logs (P<0.00l). 1.2 logs (P<0.001). 
1.8 logs (P<O.O0.j. 2.2 logs (P<0.00l), 2.8 logs (P<0.00i) and 3.1 logs iP<0.00i) were 
recorded with 100. 200. 400. 600. 800 and 1000 ^g,ml of neem extract (NF) respective!} 
(Fig. 71). Co-culturing of MTB-infected cells with 5u.\'l S.NP for 24 hr showed 
augmented expression in iNOS expression (Fig. 72). Interesting!}, co-culuiiir.g of MTB-
infected cells with a mixture of 5 uM SNP and 1000 pgnu neem (.-XLiaci exhibited 
suppression in iNOS expression by an appreciable magniiuue (iig. 72). i lius, neem 
extract was elTective in neutralizing RNI effect. 
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Fig. 63: IrXISA for modulation of GPx activity: Human monocytes were infected 
with M.tuberculosis H37RV (1:1 bacterial/cell). MN only (empty bar) and ser\ed 
as control. Cultures then received MN+1:1 MTB (black bar) as well as doses 
(0 -100 ug/ml) of Rifampicin showed in different bar diagram. GPx activity was 
determined in culture supernatants at 24 hrs .Data represent mean ± SEM of six 
experiments (p< 0.001). 
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Fig. 64: l-LISA for Expression of sTNF-a: Human monocytes were infected with 
M.luhercvlosis WyKx (1:1 bacterial/cell). MN only (empty bar) and served as 
control. Cultures then received MN+1:1 MTB (black bar) as well as doses (0-
100 lag'ml) of Rifampicin showed in different bar diagram. E.xpression of sTNF-a 
was determined in culture supernatants at 24 hrs. Data represent mean ± SEM of 
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Fig. 65: ELISA for modulation of Expression of secreted MTB antigen 85B: 
Human monocvtes were infected with A/, tiihercidosis H -^Rv (1:1 bacterial/cell). 
NTN on!) (empty bar) and served as control. Cultures then received MN+1:1 MTB 
(black bar) as well as doses (0 - 100 }ig/ml) of Rifampicin showed in different bar 
diagram. Expression of secreted MTB antigen 85B was determined in culture 
supernatants ai 24 hrs. Data represent mean ± SEM of six experiments (p< 0.001). 
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100 |ag/ml) of Isoniazid showed in different bar diagram. Expression of sTNF-a 
was determined in culture supernatants at 24 hrs .Data represent mean ± SEM of 
six experiments (p< 0.001). 
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Fig. 68: I^ 'LISA for modulation of Expression of secreted MTB antigen 85B: 
Human monocytes were infected with M tuberculosis H37RV (1:1 bacterial/cell). 
Some cultures were not infected (MN onl\; empt}' bar) and served as control. 
Cultures then received MN+1:1 MTB (black bar) as well as doses (0 - 100 )-ig/ml) 
of Isoniazid showed in different bar diagram. Expression of secreted MTB antigen 
85B was determined in culture supernatants at 24 hrs. Data represents mean .::: 
SEM of six experiments (p< 0.001). 
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Fig. 69: Dose respose effect of neem extract (0-1000 |iig/ml) on the expression of 
sIFN-y proteins in 24 hr culture supernatants of in vitro MTB- infected monocytes 
(Black bar). Uninfected monocytes (white bar) served as control in comparison to 
infected monocytes that were devoid of any neem extract. The data represents mean 
± SEM of three experiments (p< O.OOl). 
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Fig. 70: Modulatory effects of neem extract (1000 |Lig/ml) versus .NAC (10 mM) on 
the expression of sIFN-y proteins in 24 hr culture supernatants of in vitro TB-infected 
human monocytes. Data represents mean ± SEIVI of three experiments (p< 0.001). 
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Fig. 71: Dose response effect of Neem extract (0-1000 |ig/ml) on the expression 
of iNOS mRNA and MTB 85B mRNA in MTB-infected monocytes. Data 
represents mean ± SEM of three experiments (p< O.OOI). 
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Fig. 72: Viodulation of iNOS mRNA in \4TB-infected monocytes with SNP 
(5|iM) and a mixture of 5 uM SNP + 1000 ug/ml of Neem extract. Data 
represents mean ± SEM of three experiments (p< 0.001). 
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Tuberculosis caused by H37RV strain of Mycobacterium tuberculosis is most 
common among the clderK', poor, malnourished, or immuno-compromiscd, cspeciallx 
persons infected with human immunodeficiencN virus (HIV). Persistent infection ma_\' 
reactivate after decades owing to deterioration of immune status; exogenous re-infection 
also occurs. Only around 5-10% of infected normal individuals develop active disease. 
Tuberculosis primarily affects the lower respiratory system. Chronic productive cough, 
low-grade fever, night sweats, and weight loss are the main characteristics of this 
infectious disease. 
Among the most troublesome world health problems, tuberculosis occupies the 
front row. Around 2-3 million fatalities are reported annually due to infection by the 
exclusively hurrian pathogen, Mycobacterium tuberculosis. Tuberculosis resurgence is 
assuming threatening proportions, and hence, it has been declared a global health 
emergency more than a decade ago (WHO. 2002). Among the important rea.sons for the 
causative killer parasite spiralling out of control at an alarming rate is attributed to the 
emergence of multidrug-resistant (MDR) strains and the AIDS epidemic (Islam et al., 
2004; Hasan et al., 2006; Toossi et al., 2004). Despite current treatment regimens, which 
include streptomycin, rifampicin, isoniazid, etc., tuberculosis continues to evade control, 
thereby fuelling an urgent need for developing novel therapeutic strategies. Furthermore, 
even TB patients showing effective response against antibiotics, have reported side 
effects of antibiotics, especially on hepatics cells. Hence, the need of alternative 
therapeutic strategies for the management of TB is the need of the present day. 
The initial interaction (both, phagocytic and non-phagocytic) of M. tuberculosis 
with mononuclear phagocytes gives rise to a cytokine profile that is dominated by f'Nl-'-
a, a pro-inflammator} cytokine (Hirsch et al.. 1994; Means el al., 1999). TNF-a is present 
at the site of active M. tuberculosis infection in humans, regardless of the stage of 
mycobacterial infection (Schwander et al., 2000; Hirsch et al., 2001). TNF-a is a 
pleiotropic cytokine, and its role in harmful or beneficial inflammator}' processes is 
complex (Keane, 2005j. Although this cytokine is involved in multiple cell regulator) 
and differentiation processes leading to immunity in tuberculous infection, however. 
TNF-u also mediates effects deleterious to the host contributing to the pathophysiology 
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of tuberculosis. High levels of the cytokine at the site of infection induce an excessive 
damaging inflammatory response that overwhelms its beneficial effects (Bekker et al., 
2000). 
Out of a wide spectrum of M tuberculosis genes shown to be upregulated after M 
tuberculosis infection of human mononuclear cells, the 85B gene was expressed most 
frequently (Graham and Clark-Curtiss, 1999). M. tuberculosis 85B is a predominant 
protein produced during human M. tuberculosis infection (Salata et al., 1991); however its 
role in tuberculosis pathogenesis is not clear and warrants further investigation. At least 
with regard to mycolyl transferase activity, which underlies cell-wall biosynthesis, it 
appears that both M tuberculosis 85A and 85B are redundant (Puech et al., 2002). In 
sputum from patients with tuberculosis, levels of M. tuberculosis 85B protein and mRNA 
correlate with M. tuberculosis growth, and maintenance of 85B levels correlates with a lack 
of response to therapy (Wallis et al., 1998; Wilkinson et al., 2001). The expression of 
antigen 85B in M. tuberculosis-infected monocytes correlates positively with both the 
amount of secreted TNF-a and subsequent intracellular mycobacterial growth (Wilkinson 
et al., 2001). Interestingly, although many mycobacterial components induce TNF-a in 
mononuclear phagocyte (Islam et al., 2004; Hasan et al., 2006; Wallis et al., 1993), only 
the members of 85 complex interact with host fibronectin (Abou-Zeid et al., 1988). 
Moreover, binding of 85B to fibronectin enhances the expression of TNF-a in monocytes 
(Aung et al., 1996). Therefore, the role of M tuberculosis 85B in intracellular infection 
may be the maintenance of an inflammatory response. In addition, M. tuberculosis 85 
complex may act as an intermediary to synthesis of trehalose dimycolate, which enhances 
the host inflammatory response (Lima et al., 2001). 
Previous studies show that infection of human alveolar macrophages with M. 
tuberculosis induce M tuberculosis 85B and, TNF-a, both at mRNA and protein levels, 
which may be important to the immunopathogensis of disease (Islam et al., 2004). The 
rationale for the use of monocytes in this study is based on the fact that in vivo, the initial 
interaction of M. tuberculosis is with residential alveolar macrophages. If initial 
pulmonary defenses are overcome, successful control of the infection depends upon 
recruitment of blood monocytes," which are activated by cytokines, and form a granuloma 
restricting the growth and spread of this pathogen. Whereas the interaction of M. 
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tuberculosis with more mature alveolar macrophages occurs at the very initiation and all 
through M. tuberculosis infection, the continuous recruitment of monocytes (Hirsch et al., 
2001; Peters et al., 2001) to sites of M tuberculosis infection ascertains that this less 
mature cell type interacts with M tuberculosis intensely also. Thus, the cytokines and 
activation profile of both cell types need to be considered to develop a better 
understanding of host-M tuberculosis interactions in situ. As mononuclear cells are 
recruited to sites of M tuberculosis infection, their in vitro functional capacities may 
reflect in situ immune responsiveness (Islam et al., 2004; Toossi et al., 2004). 
It's worth pointing out here that, although attenuation of the biological activity of 
TNF-a has lately become an important therapeutic intervention in the management of a 
wide variety of chronic inflammatory diseases (Shanahan and Clair, 2002), a growing 
body of clinical evidence indicates that neutralization of TNF-a is associated with an 
increased risk of opportunistic infections, including mycobacterial diseases (Dinarello, 
2003). In vievv' of this, modulation of TNF-a release is being proposed as the basis for 
novel therapeutic approaches (Warwick-Davies et al., 2001). Focus has now shifted to 
development of corfipounds from natural sources that have anti-oxidant and anti-
mycobacterial activity. By boosting host immunologic responsiveness, these compounds 
may be particularly useful in the treatment of drug-resistant tuberculosis. Our study 
involves the incorporation of such a compound, namely, neem extract, as the natural 
herbal component for tuberculosis management. 
Azadirachta indica, commonly known as neem, is well known in India and its 
neighboring countries for more than 2000 years as one of the most versatile medicinal 
plants (Biswas et al., 2002). Although the range of uses for Azadirachta indica, is 
amazingly diverse, interestingly, the intense scientific scrutiny paid to this ultimate herb 
has led to medical validation for many of these applications. Azadirachta indica has 
attracted worldwide prominence in recent years, owing to its wide range of medicinal 
properties (Subapriya and Nagini, 2005). The neem tree is considered as the panacea for 
all diseases and has also been hailed as 'heal all', 'divine tree', 'village dispensary' and 
'nature's drugstore' (Puri, 1999). 
Neem has been extensively used in Ayurveda, Unani and Homoeopathic medicine 
and has become a cynosure of modern medicine. Neem elaborates a vast array of 
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biologically active compounds that are chemically diverse and structurally complex. 
More than 140 compounds have been isolated from different parts of neem. All parts of 
the neem tree- leaves, flowers, seeds, fruits, roots and bark have been used traditionally 
for the treatment of inflammation, infections, fever, skin diseases and dental disorders 
(Subapriya and Nagini, 2005). 
The oil from the neem leaves is recognized to possess antibacterial activity 
against a wide spectrum of Gram-negative and Gram-positive microorganisms, including 
M. tuberculosis and Streptomycin-resistant strains (Chopra et al., 1952). 
Neem leaf is known to inhibit M tuberculosis and M. pyogenes in vitro (Satyavati et a!., 
1976). Mahmoodin, a limonoid isolated from A. indica showed significant antibacterial 
activity (Siddique et al., 1992). Neem leaves may affect spermatogenesis through 
antispermatogenic and antiandrogenic properties (Kasturi et al., 2002). Aqueous extracts 
of old and tender neem leaves were shown to completely immobilize and kill human 
spermatozoa within 20 seconds (Khillare and Shrivastav, 2003). The water-soluble 
portion of 70 per cent ethanolic neem leaf extract was found to possess anti-
inflammatory activity in rats (Chattopadhyay, 1998). A 75 per cent ethanolic extract of 
neem leaves in doses of 400 to 800 mg/kg had pronounced anti-inflammatory effect on 
carrageenin-induced oedema in rats (Okpanyi and Ezeukwu, 1981). The medicinal 
utilities have been described especially for neem leaf, its constituents have been 
demonstrated to exhibit immunomodulatory, anti-inflammatory, antihyperglycaemic, 
antiulcer, antiraalarial, antifungal, antibacterial, antiviral, antioxidant, antimutagenic and 
anticarcinogenic properties (Subapriya and Nagini, 2005). The aqueous extract of neem 
leaf exerts its immunostimulant activity by enhancing both humoral and cell mediated 
responses (Sen et al., 1992; Ray et al., 1996). Selective activation of the TH-I component 
of lymphocyte population by neem leaf is believed to elicit and enhance cell-mediated 
immune response. Radical scavenging properties of neem leaf has reported 
(Chattopadhya}', 1998). Neem leaf has been documented to decrease the extent of lipid 
peroxidation. Experiments from this laboratory have shown that both aqueous as well as 
70 percent ethanolic neem leaf extracts significantly reduce Nmethyl-N'-nitro-N-
nitrosoguanidine (MNNG)-induced lipid peroxidation, by enhancing the activities of 
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glutathione dependent antioxidants as well as superoxide dismutase (SOD) and catalase 
(CAT) (Ari\ azhagan et al., 2000; Subapriya et al., 2003). 
Azadirachta indica, is a common plant with rich medicinal attributes. The 
aqueous ext'act is reported to contain several active substances and is known to posses 
anti-inflammatory, and immunomodulatory activities (Van Der Nat, 1987). The 
immunomod ulatory activity of the neem-bark extract has also been reported (Van Der 
Nat, 1987). Anti-inflammatory, immunostimulant and antiulcerogenic actions have also 
been reported in the extracts of A. indica (Sen et al., 1992; Ray et al., 1996; Pillai et al., 
1978; Balakrishnan et al., 1985). Anti-inflammatory action of Azadirachta indica show 
different types of activity against acute and chronic inflammation. Azadirachta indica 
shows strong inhibition of immediate or acute inflammation suggests it prevents the 
release of inflammation-inducing neurochemicals including prostaglandins. In fact, one 
1977 study showed neem extract to be more effective than aspirin in inhibiting 
prostaglandins (Journal of the West African Science Association, 1977, vol. 22). There 
have been attributed by several researchers to a strong Thl cytokine response, 
particularly IFN-gamma and TNF (Talwar et al; 1997). Increases in CDS cells have been 
reported (Talwar et al., 1997). Talwar also reports that Neem has "inhibitory action on a 
wide spectram of micro-organisms, including Candida albicans, C. tropicalis, 
gonorrhoeae, the multidrug-resistant Staphylococcus aureus and urinary tract Escherichia 
coli, Herpes simplex-2 and HlV-1." (Talwar et al., 1997). 
Furthermore, a neem compound azadirachtin also has great application in herbal 
medicine/healthcare products, especially for major skin diseases, anti-malarial, anti-
tuberculosis, anti-viral, anti-bacterial etc (National Research Council 1992). Oil from the 
leaves, seeds and bark possesses a wide spectrum of antibacterial action against different 
micro-organisms, including M. tuberculosis and streptomycin-resistant strains (Chopra et 
al., 1952). In vitro, it inhibits M. tuberculosis andM. pyogenes (Satyavati, et al., 1976). 
Nimbidin, a major crude extracted from neem oil, has been identified as the active 
constituent of the oil (Pillai and Santhakumari, 1981; Biswas et al., 2002). It is a mixture 
of tetranortriterpenes and possesses potent anti-inflammatory, antiarthritic and antiulcer 
activities (Pillai and Santhakumari, 1981; Siddiqui and Mitra, 1945). Nimbidin also 
inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) production in 
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lipopolysaccharide (LPS) stimulated macrophages following in vitro exposure (Kaur et 
al., 2004). Inducible nitric oxide synthase (iNOS) activity measured in the presence or 
absence of nimbidin in cytosolic preparation of macrophages cultured with 
lipopolysaccharide (LPS) for 24 h but the concentration, 100 pg/ml was not determined 
due to cytotoxicity of nimbidin (Kaur et ai., 2004). Nimbidin is, as such, a general anti-
inflammator)' drug and is effective in both acute and chronic states of inflammation. 
However, the mechanism of its action is ambiguous. Therefore, the present investigation 
probed into the mechanism of anti-inflammatory action of nimbidin and found it to 
significantly suppress some of the functions of macrophages and neutrophils relevant to 
inflammation (Kaur et al., 2004). Nimbidin is a major active principle of Azadirachta 
indica that helps in inflammation. Neem leaves and their constituents exhibit 
immunomodulatory, anti-inflammatory, antibacterial, antioxidant, and anticarcinogenic 
effects (Subapriya and Nagini, 2005). These properties are of immense value in skin 
conditions like acne and pimples, eczema, and dermatitis. It is also useful in preventing 
free radical-induced skin damage. 
Several workers studied the medicinal properties of the plant Azadirchata indica. 
The antipyretic effect (Okpanyi and Ezeukwk,l981) anti-malarial effect, (Khattak et al., 
1985; Telia, 1977) anti-tumour effect, (Rochankij et al., 1985) anti-ulcer effect, 
(Fujiwara et al., 1982) anti-diabetic effect, (Pillai and Santhakumari, 1984), anti-fertility 
effect, (Shukla et al.,1973) effect on the central nervous system, (Sinha et al., 1984; Pillai 
and Shanthakumari, 1984) and cardiovascular effect (Singh et al., 1987) were some of 
the studies of tie earlier workers. 
In 1992, US National Academy of Science published a report entitled, Neem—a 
tree for solving global problems (N.R.C., 1992). Immunomodulatory properties of 
different neem preparations (Biswas et. al. 2002) such as, activation of B cells, T cells 
and macrophages (Ray et al., 1996) have been reported earlier. Neem kernel oil induces 
secretion of ga'Tima interferon (Upadhyay et al., 1992) and tumor necrotic factor-alpha 
(Thatte et al., 1997). 
Prior to any investigations, we first probed the reactivity of sera from tuberculosis 
and MDR-TB patients against both, sonic extracts as well as MTCF protein antigens of 
cultured H37RV and found a remarkably high magnitude of immuno-binding of both, 
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intracellular protein antigens as well as secretory MTCF protein antigens, with 
tuberculosis sera. Further characterization of tuberculosis and MDR-TB sera used in our 
study revealed elevated basal levels of TNF-a and circulating M tuberculosis antigen 85 
complex, which was consistent with earlier studies. Monocytes from patients with active 
tuberculosis were also characterized similarly. Real-time RT-PCR was employed to 
evaluate TNF-a mRNA expression, and our results demonstrated that they were elevated 
appreciably. Furthermore, supernatants of monocyte cultures from tuberculosis patients 
also exhibited appreciable levels of soluble TNF-a and secreted antigen 85 complex 
proteins. 
After establishing the virulence of the pathogenic M. tuberculosis strain used in 
our laboratory, we examined the effectiveness of neem extract as a natural antioxidant 
and antimycobacterial compound, focussing on its role as an antagonist of M. 
tuberculosis J15B, in H37RV cultures. The selected neem extract concentrations in our 
study was non-toxic and failed to show any affect on M. tuberculosis growth, as revealed 
by an insignificant effect on the expression of M tuberculosis housekeeping gene (16S 
rRNA). The dose-response studies clearly demonstrated downregulation of M. 
tuberculosis 85B mRNA expression in H37RV cultures. 
The observations of electrophoresed gel clearly indicate the decreased expression 
of antigen 85 complex (30/31 kDa) in M. tuberculosis cultures treated with varying doses 
of neem extract. On the contrary, co-culturing of causative organisms with NADPH and 
hydrogen peroxide augmented the protein expression of antigen 85 complex (30/31 kDa). 
Thus, electrophoresis data are indicative of scavenging of reactive oxygen species (ROS) 
by neem extracts, which in turn resulted in down-regulation of antigen 85 complex (30/31 
kDa) expression. ELISA results for secreted antigen 85 complex in M tuberculosis 
culture supernatants also indicate the decreased secretion of antigen 85 complex when co-
cultured with varying doses of neem extract. To have further insight, we further designed 
immunoassays to study the effect of neem extracts on the immuno-interaction of 
antibodies present in sera of patients with tuberculosis against protein antigens in M. 
tuberculosis sonic extract as well as in MTCF. A concentration of 1000 \igl\x\\ of total 
neem extract proved to be a potent inhibitor of M tuberculosis 858 mRNA as well as 
antigen 858 protein expression in M. tuberculosis cultures. 
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Next, an attempt was made to examine the interaction of M tuberculosis with 
human monocytes, focussing on the relationship between expression of TNF-a and M. 
tuberculosis 85B mRNA, with or without modulators. It's well known that M. 
tuberculosis induces high amounts of TNF-a (Hirsch et al., 1994), and the success of 
intracellular growth of virulent M. tuberculosis has been in part attributed to the capacity 
to induce TNF-a. In agreement with previous findings, our data also revealed a time-
dependent increase in TNF-a mRNA expression and protein production, reaching a 
maximum 24 hours post-infection. Interestingly, M. tuberculosis 85B mRNA expression 
and protein production were increased well beyond 24 hours of infection. Our results 
demonstrate that the induction of TNF-a and M. tuberculosis 85B mRNA expression 
mutually corresponded at to and 24 hours. Thus, stronger cell activation, as has been 
reflected by induction of TNF-a, seems to be associated with increased expression of 85B 
gene. In support of this finding, exogenous TNF-a was also found to significantly induce 
the expression of both TNF-a and M. tuberculosis 85B, in parallel. These results are 
suggestive of a modulatory role being exerted by M. tuberculosisAwdnctdi TNF-a, in 
monocyte cultures, over the expression of M tuberculosis 85B during the initial 24 hours 
of infection. 
It may be worth in pointing out that TNF-a may not be involved in sustaining the 
continued expression of M tuberculosis 85B with time. The maintenance of 85B 
expression at time points beyond 24 hours, when TNF-a activity is reduced, suggests the 
involvement of alternative mechanisms as has been previously observed in macrophages 
(Islam et al., 2004; Hasan et al., 2006). The expression of the TNF-a gene and production 
of its protein are under strong intracellular control mechanisms. The TNF-a mRNA 
expression at 24 hours showed a positive linear correlation with the secretion of antigen 
85B into parallel cultures. An effect of cytokines released by M. tuberculosis-infected 
monocytes on intracellular expression of M. tuberculosis gene throughout infection of 
mononuclear phagocytes needs to be considered. The 85B:16S ratio at 24 hours showed a 
positive linear correlation with the secretion of TNF-a into parallel cultures. 
Furthermore, cellular signaling by TNF-a is mediated mainly through activation 
of NF-KB (Islam et al., 2004; Hasan et al., 2006). In turn, activation of NF-KB and other 
pathways sustain TNF-a activity (Hillas et al., 2000). Thus, in order to probe the role of 
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NF-KB in the expression of TNF-a in M tuberculosis-'mfecttd monocytes, SN50, an 
inhibitor of NF-KB was employed in our study. It was apparent from our results that the 
induction of INF-a and M. tuberculosis 85B expression in M. tuberculosis-'mfQCted 
monocytes was mediated through activation of NF-KB, because both mRNAs were 
suppressed in cultures receiving SN50. On the contrary, the inactive analogue of SN50 
failed to show any effect. Thus, our results show that cellular activation is associated with 
augmentation of expression of both TNF-a and M. tuberculosis 85B in M tuberculosis-
infected monocytes, and that, it is in agreement with the previously reported data on 
macrophages (Islam et al., 2004; Hasan et al., 2006). 
It's an established fact that effective host defense mechanisms by innate immune 
cells to M. tuberculosis within the phagolysosomes of activated macrophages is known to 
include the production of reactive oxygen (ROI) and reactive nitrogen intermediates 
(RNI). Phagoc;/tosis of microbes as well as cellular activation activates ROIs (Ropert et 
al., 2001), and H2O2, a product of the ROI pathway activates the expression of iNOS and 
production of NO (Takao et al., 1996). Reactive oxygen intermediates (ROI) and 
reactive nitrogen intermediates (RNI) are both downstream mediators of macrophage-
activating cytokines and are considered to be microbicidal. Activation of iNOS and 
production of NO may be important in the final containment of M. tuberculosis by 
macrophages (Han et al., 2001). However, M. tuberculosis has evolved resistance 
mechanisms against both, ROI (MacMicking et al., 1997) and RNI (Hillas et al., 2000). 
Regarding antioxidant studies, here, when the activation of reactive oxygen species 
(ROS) was inhibited by NAC, then the expression of both TNF-a and M tuberculosis 
85B was significantly downregulated in monocytes infected with M. tuberculosis. Our 
results have substantiated these observations by using agents that release oxygen radicals 
(NADPH) or H2O2. In M /w/jercw/o /^^ -infected monocytes, these reagents increased 
expression of both TNF-a and M tuberculosis 85B. Thus, both RNI and ROI, induced 
early after M. tuberculosis infection of monocytes, activate expression of M tuberculosis 
gene. 
In view of the above, our study demonstrates that M. tuberculosis-mfectlon of 
monocytes leads to a concomitant induction of TNF-a, and expression of the M. 
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tuberculosis 85B gene. Based on these findings, we probed here the regulation of TNF-a 
and 853 activation in M. tuberculosis-'mfected human monocytes, by neem extracts. 
In the present study, an attempt was also made to probe the cell viability and 
potential cytotoxicity of varying concentrations of neem extract which were employed in 
this study using trypan blue and MTT assays, where viability of-98-99% was observed. 
Interestingly, all the concentrations of neem extract employed in the study failed to show 
any type of adverse / toxic effect on human housekeeping genes like R18, thereby 
demonstrating that the effect of neem extract was not mediated by cellular death, but 
rather by specific inhibition of expression as well as secretion of TNF-a and M 
tuberculosis 85B. Furthermore, it is to be mentioned out here that neem extract failed to 
show any effect on the intracellular growth of M. tuberculosis as inferred by the data 
obtained exhibiting insignificant effect of neem extract on 16S rRNA expression. 
To the best of our understanding, we show for the first time that neem extract 
exerts potent anti-inflammatory effects on host mononuclear cells infected with M 
tuberculosis as evidenced by a strong inhibition of the pro-inflammatory cytokine TNF-a 
and in turn, of M tuberculosis 85B. The results indicate an appreciably high magnitude 
suppression in soluble TNF-a secretion as well as endogenous TNF-a mRNA expressions 
with 600, 800 and 1000 ^gs/ml of neem extract in M. tuberculosis-'mfQCted monocytes. A 
parallel dose-response effect of neem extract was found on M. tuberculosis 858 protein 
secretion as well as on 858 mRNA expression in M. tuberculosis-'mkcted monocytes. 
The production of autocrine cytokine TNF-a in monocytes is regulated at multiple 
intracellular levels, beginning with transcription (Islam et al., 2004). Elevated expression 
of TNF-a mRNA and activation of a relevant transcription factor, NF-K8 (Islam et al., 
2004; Toossi et al., 1997) have been reported in monocytic cells infected with M. 
tuberculosis. Induction of TNF-a expression was mediated through activation of NF-KB, 
as evidenced by the suppression of TNF-a mRNA in the presence of SN50, an inhibitor 
of NF-KB. On the contrary, SN50/M, an inactive analogue of SN50, failed to show any 
such effect. It has been well established that TNF-a induced nuclear translocation of NF-
KB is inhibited by SN50 peptide as demonstrated in EMSA (Lin et al., 1995). In light of 
the above viev/, it seems from our results obtained that this effect involved inhibition of 
the NF-KB pathway induced by neem extract, probably by inhibiting the degradation of 
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kBa. The NF-KB heterodimer is retained in the cytoplasm in an inactive form through 
association with one of the IKBS inhibitory proteins. IKBO is phosphorylated by a specific 
icinase complex (IKK) leading to its ubiquitination and subsequent proteolysis by the 28S 
proteosome due to stimulation by TNF-a (St John et al., 2001). The degradation of IKB 
releases active NF-KB, which translocates to the nucleus and regulates gene expression 
by binding to KB binding sites or by interacting with other transcriptional factors (Ladel 
et al., 1997b). Since a number of genes involved in inflammatory responses are regulated 
by NF-KB pathway, thus a high magnitude downregulation of the NF-KB pathway by 
neem extract, would predictably reduce the elaboration of NF-KB-mediated TNF-a 
mRNA expression and thereby, 85B mRNA expression. In addition, neem extract exerted 
a higher degree of neutralizing effects than NAC on TNF-a-induced actions in M. 
tuberculosis-'mkcted human monocytes. 
The exact mechanism underlying the antioxidant activity of neem extract in 
MTB-infected monocytes still remains poorly understood. Anti-oxidant-induced 
enhancement of glutathione peroxidase activity has been reported (Brown et al., 1995; 
Perchellet et el., 1986). Furthermore, a role for the antioxidant enzyme glutathione 
peroxidase (GPx) in infected mononuclear cells was investigated with respect to various 
modulators employed in this study. Glutathione directly reacts with ROS, and GPx 
catalyzes the removal of hydrogen peroxide (Bryk et al., 2002). Decrease in GPx activity 
indicates impairment of hydrogen peroxide-neutralizing mechanisms (Mesiter and 
Anderson, 1983; Rukmini et al., 2004). Here, we observed a decline in GPx activity in M. 
tuberculosis-inkcted monocytes that were untreated or treated either with H2O2, SN50/M 
or H2O2+SN5O/M, thereby concurring with earlier reports that substantial amounts of 
ROS are being generated in cells infected with M. tuberculosis due to cellular activation 
(Islam et al., 2004). Enhancement of GPx activity in M. tuberculosis-infected monocj'te 
cultures after addition of NAC, a precursor of the in vivo antioxidant glutathione, 
indicates reversal of impaired neutralizing mechanisms. Interestingly, the GPx activity 
was found to be further enhanced / augmented when various concentrations of neem 
extracts were co-cultured instead of NAC, thereby inferring neem extract to be an 
effective natural antioxidant combating ROS which was generated due to stimulation by 
TNF-a of cellular activation in M. tuberculosis-infected mononuclear phagocytes. In 
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continuation to tiie above, the neem extract-induced up-regulation of soluble IFN-y in 
culture supernatants coupled with simultaneous down-regulation of TNF-a at both the 
gene and protein levels is indicative for the anti-inflammatory and elicitation of 
protective immune response properties of neem extract. 
Furthermore, it is to be pointed out here that, our 'real time' data revealed neem 
extract to be even better antagonist of MTB 85B than antibiotics like isoniazid, 
rifampicin and streptomycin. The suppression of 85B by antibiotics showed IC-50 values 
of the order of ~50fig/ml, ~60|ig/ml and ~70fig/ml for isoniazid, rifampicin and 
streptomycin, respectively. On the contrary suppression of 858 by Neem extract showed 
IC-50 values of the order of ~500 |ag/ml. 
The present study in summary shows that in human monocytes early after 
infection with M tuberculosis, a vicious circle may exist in which expression of host 
inflammation and mycobacterial products amplify one another. Our study also shows 
enhancement of GPx activity by neem extract, which correlated inversely with the 
downregulation of TNF-a and M. tuberculosis 853 mRNA expression as well as TNF-a 
and M tuberculosis 858 protein expression in monocytes infected with M tuberculosis. 
The up-regulation of soluble IFN-y in culture supernatants coupled with simultaneous 
down-regulation of TNF-a at both the gene and protein levels by neem extract is 
indicative for the anti-inflammatory and elicitation of protective immune responses 
properties of neem extract. 
Moreover, based on the IC50 of values, neem extract proved to be even a better 
inhibitor of MTB 85B and TNF-a gene expressions than antibiotics like isoniazid, 
rifampicin and streptomycin. Thus the antimicrobial effects of neem extract investigated 
earlier in other systems (Zhao et al., 2001; Clisa et al., 1992) as well as the data generated 
in the present study involving infected human monocytes, appears to strongly indicate 
neem extract to be potential adjunct in the treatment of tuberculosis. 
In conclusion, the following can be inferred from the present study: 
1. Neem extract suppresses the expression of M tuberculosis 858 mRNA and the 
secretion of M tuberculosis 858 protein in M. tuberculosis (H37RV) cultures. 
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2. Activation of monocytes by M tuberculosis induces the expression of both TNF-a 
and M. tuberculosis 85B mRNA. 
3. Reactive oxygen species (ROS), induced early after M. tuberculosis infection of 
monocytes, increase expression of both TNF-a and M tuberculosis 85B mRNA. 
4. Activation of monocytes by M. tuberculosis initiates a cascade of events whereby a 
vicious circle may exist in which expression of host inflammation and mycobacterial 
products amplify one another. 
5. Neem extract (0-1000 [ig/ml) exhibited no toxic effect on the viability of human 
monocytes. Mctreover, this concentration failed to show any inhibitory effect on the 
growth of M tuberculosis. 
6. Neem extract inhibits the expression of TNF-a mRNA and its protein production in a 
dose-dependent manner in M. tuberculosis infected monocyte cultures after 24 hours of 
infection. 
7. Post 24 hours of M tuberculosis infection, neem extract was found to down-regulate 
the expression of M tuberculosis 85B mRNA as well as its protein secretion in monocyte 
cuhures. 
8. Suppressior of TNF-a and M. tuberculosis 858 by neem extract in M. tuberculosis-
infected monocytes is mediated mainly via NF-KB. 
9. Neem extract enhances the glutathione peroxidase activity in M. tuberculosis-infected 
monocytes. 
10. The up-regulation of soluble IFN-y in culture supernatants coupled with simultaneous 
down-regulation of TNF-a at both the gene and protein levels by neem extract is 
indicative for the anti-inflammatory and elicitation of protective immune response 
properties of neem extract. 
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